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This thesis is a distillation of work carried out by the author and others between 1999
and 2010. The overarching objective was to achieve a better understanding of the
epidemiology and prevalence of ovine caseous lymphadenitis within the UK sheep
industry. Using that knowledge, means by which the disease could be controlled were
then evaluated. Throughout this process the existing knowledge of Corynebacterium
pseudotuberculosis and the diseases that it causes, provided a foundation on which these
further developments were built.
Although C. pseudotuberculosis infection has been recognised in the UK for a
comparatively short period, it has been a cause of significant disease in various animal
species around the globe for many decades. A comprehensive review of C.
pseudotuberculosis disease and related research was therefore an essential starting point
for consideration of the infection in this country.
The use of phospholipase D ELISA tests has been an established tool ofCLA research in
other countries. Using a recently developed ELISA assay and blood samples collected
from around GB for the Sheep Health Scheme, the prevalence of CLA within the
terminal sire sector of the British sheep industry was assessed. Seropositive animals
were detected in 18% of the 745 flocks tested, with the Charollais breed showing the
highest apparent prevalence.
In response to concerns within the dairy goat sector regarding milk hygiene in CLA
affected herds, the ability of normal commercial pasteurisation techniques to kill C.
pseudotuberculosis organisms in milk was established.
The potential of using CLA ELISA and Western blot assays to control and eradicate the
disease was studied: first in a number of lowground terminal sire flocks and then in a
vii
large upland commercial flock. In both situations a policy of test and cull was shown to
be effective in substantially reducing clinical manifestations of disease. Complete
eradication was found to be achievable under certain circumstances. In a lowground
flock where initial seroprevalence was greater than 60%, a complete absence of clinical
disease and a seronegative status was achieved. In a large upland flock, seroprevalence
was reduced from 10% to 0.4%. More significantly, the incidence of clinical CLA in
this flock, which in 2007 was approximately 5% amongst the adult animals, was reduced
to zero for a period of two years from June 2008.
Vaccination, which forms the mainstay of CLA control efforts in many parts of the
world, was assessed for its potential for disease control in the UK. The market-leading
proprietary vaccine was compared with three experimental vaccines in its ability to
confer protection against bacterial challenge. A recombinant PLD and bacterin
combined vaccine was shown to confer the most effective protection.
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Chapter 1: INTRODUCTION TO THIS THESIS
When the Corynebacterium pseudotuberculosis bacterium was identified in a laboratory
at the Cambridge University Veterinary School in January 1990, it was the first time that
the organism had been isolated from a clinically diseased animal from the UK (Lloyd
and others 1990b). While the detection of the organism was noteworthy as a
bacteriological finding, it also represented the first case in this country of a disease,
caseous lymphadenitis, which has troubled sheep producers in the rest of the world for
more than a century. During the subsequent twenty years the condition has spread
steadily within the country and at different times has become a cause for concern for
producers in different sectors of the sheep industry.
This thesis presents the main areas of work carried out by the author on ovine caseous
lymphadenitis. In each phase of research the work has been progressed in close
collaboration with colleagues from other scientific institutes. The contribution of these
colleagues is fully described in the Acknowledgement section of this thesis. Where the
results of the research have been published, this too is acknowledged.
With no previous experience of CLA in the UK, a close examination of the existing
scientific literature on the disease forms the starting point for any study of the disease.
While this review of current literature is done principally in Chapter 2, further papers of
relevance are cited in subsequent chapters.
Chapters 3 to 7 describe the research work pursued by the author. Chapter 3 describes
an early study of CLA seroprevalence within Great Britain. Chapter 4 records research
on the protective effects of pasteurisation in relation to the potential contamination of
milk by C. pseudotuberculosis, a concern at the time amongst dairy goat producers.
Chapters 5 and 6 review the development of a CLA control programme based on
serological testing and clinical examination. This model was applied in two distinct
sectors of the sheep industry: intensive low ground systems for the production of
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terminal sire rams and an extensive upland commercial flock, where the sale of store
lambs and female replacement stock forms the principal source of income. Chapter 7
describes a series of experiments where an artificial infection model was used to
compare the protective effects of a proprietary CLA vaccine with a series of
experimental vaccines developed employing a UK strain of the organism. Finally,
Chapter 8 is a discussion section, where the preceding chapters are set in the context of
current disease trends and the author seeks to establish the lessons gained from the last
twenty years.
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Chapter 2: THE VETERINARY SIGNIFICANCE OF
COR YNEBA CTERIUMPSEUDOTUBERCULOSIS
The perceived importance of caseous lymphadenitis (CLA) as a disease of sheep varies
greatly around the world. In the UK, where this disease appeared for the first time in the
early 1990's, the steady and apparently relentless spread of infection in sheep and goats
has prompted considerable concern amongst farmers and veterinary surgeons. However,
in the sheep industries of Australia and New Zealand, CLA is regarded as relatively
minor infection, albeit one that is very widespread. The roots of these contrasting
attitudes lie in differences in disease prevalence, available means of control and meat
inspection practices.
To the veterinary pathologist, the causative organism of caseous lymphadenitis,
Corynebacterium pseudotuberculosis, has a valid claim to being the "perfect parasite".
Once successfully established within the host, this pathogen can evade the immune
system with apparent ease. As a result, chronic infections tend to last for most or all of
an animal's life, although they are rarely fatal (Valli 2007). If left unchecked, the
disease may infect the majority of sheep in a flock. Even away from its mammalian
host, the organism is well equipped for long-term survival in the environment. As a
result of these formidable characteristics, flock infections by C. pseudotuberculosis are
generally "managed" rather than eradicated.
History
In 1888, the French bacteriologist Edward Nocard isolated an unusual organism from a
case of lymphangitis in a cow (Nocard 1896). Some three years later, the Bulgarian
bacteriologist Hugo von Prei'sz identified a similar bacterium in cultures from a renal
abscess in a ewe (Pre'isz and Guinard 1891). Two years later Nocard isolated the same
organism from a horse thought to be suffering from glanders. As a consequence of these
related discoveries, the organism in question became known as the "Pre'isz-Nocard"
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bacillus, a vernacular name with which it was linked for decades thereafter. Towards
the end of the century caseous lymphadenitis was described for the first time in the
United States (Norgaard and Mohler 1899).
Towards the end of the 19th Century the bacterium was described by the German
bacteriologists Lehmann and Neumann in the first edition of their bacteriological atlas
(Lehmann and Neumann 1896). In that publication, the Prei'sz-Nocard bacillus was
renamed Bacillus pseudotuberculosis - a derivation of the Greek pseudes tuberculosis or
"false tuberculosis" and a reference to the supposed clinical similarity of the lesions to
caseous nodules ofmycobacterial tuberculosis. In the First Edition of Bergey's Manual
of Determinative Bacteriology, published in 1923, the organism was placed in the
Corynebacterium genus, which had originally been created as a category for the human
pathogen Corynebacterium diphtheriae (Benham and others 1962). This edition of the
Manual referred to work showing that B. pseudotuberculosis resembled C. diphtheriae
in morphology and cell wall composition, leading to a further change of name to
Corynebacterium ovis. Subsequently however, the organism was isolated from purulent
infections and ulcerative lymphangitis in other mammalian species, including goats,
horses and human beings (Daines and Austin 1934; Merchant 1935). In recognition of
this, by the time the Sixth Edition of Bergey's Manual was published in 1948, the
species name had been changed back from ovis to the earlier designation of
pseudotuberculosis (Benham and others 1962). Since that point in time, the officially
recognized designation of C. pseudotuberculosis has remained consistent (Euzeby
2010); notwithstanding the fact that several authors continued to refer to the organism as
C. ovis until the 1980s (Carne and Onon 1978; Burrell 1980; Nain and others 1984;
Shnawa and others 1988).
Geographical Distribution
The global range of C. pseudotuberculosis reflects that of farmed small ruminants, the
bacterium having been identified in Europe, Australasia, North and South America,
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Africa and the Middle East (Robins 1991; Paton and others 2005). In many countries,
CLA has for decades been an established and economically important infection of
livestock, and particularly sheep (Merchant 1935). As early as the 1930s it was
acknowledged that the disease "very extensively affected" the flocks of most mutton
exporting countries of the southern hemisphere (Cesari 1930). It is surprising therefore,
that the first diagnosed case in an animal originating from the UK was not confirmed
until as recently as 1990, and even then one of those reports concerned goats (Lloyd and
others 1990a), whilst the other was in sheep (Meldrum 1990).
Some suggestions have been made that the origins of the infection may lie in Europe,
and that spread of C. pseudotuberculosis around the world followed the exportation of
sheep, by the 18th Century colonial powers (Paton 2000). The Merino breed, which
originated in Spain, was widely valued as a dual meat and wool animal and was
exported extensively, first to South Africa and subsequently to Australia and the
Americas. This early exportation may, at the very least, have assisted in the spread of C.
pseudotuberculosis infection, a condition to which the Merino as a breed is particularly
prone (Paton 2000; West and others 2002). Such a theory is difficult to prove, but
supporting evidence is provided by the highly conserved nature of the C.
pseudotuberculosis genome, irrespective of the country from which the strain originates
(Connor and others 2007). Certainly, it is interesting to speculate that the absence of the
Merino as a commercial breed in the British Isles may have gone some way to protecting
this country from the infection.
Equine C. pseudotuberculosis infections became a serious problem for military planners
during the First World War, when widespread infection caused the debilitation of
hundreds of horses used on the battlefields of Europe (Mitchell and Walker 1944).
Ovine CLA later sparked controversy in Britain during the 1920s, when mutton carcases
imported from a number of different countries were found to be affected by the disease.
It was noted at the time that evidence of infection would often remain unobserved at
import meat inspection "only to be revealed when the roast leg ofmutton appears on the
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table and is cut through" (Rolleston and Wooldridge 1926). Mutton from Argentina was
particularly badly affected, forcing the British government of the time to take action in
relation to consignments of carcases from that country (Anon 1929). The extent of the
problem was demonstrated by a report that in just one season, 9,770 mutton carcases
(representing 27% of the total throughput) were rejected at a single Patagonian meat
plant because of CLA (Mills 1928). Other mutton exporting countries took heed of the
concerns in Britain and it was soon acknowledged that "Argentina, Uruguay, Chili (sic),
Australia and New Zealand are actively occupied...in a struggle against this tenacious
chronic disease which, completely neglected up to now, is very extensively affecting the
flocks of those countries" (Cesari 1930). These concerns also stimulated veterinary
research into the disease, principally in Australia, leading to important early discoveries
on pathogenesis, bacterial survival and risk factors (Seddon and others 1929; Bull and
Dickinson 1935). As early as the 1920s a "preventative vaccine" was said to be used in
France to protect sheep from CLA infection (Howarth and Young 1926)
Research interest in CLA was renewed in the 1970s, when the authorities in the USA,
Canada and Japan applied strict regulations relating to the presence of lesions in
imported sheep carcases. A further series of studies into disease pathogenesis and
epidemiology was then initiated in Australia (Nairn and Robertson 1974; Burrell 1978a;
Batey 1986b, Batey 1986c), which, as a major exporter of sheep, with a high CLA
prevalence within its national flock, had much to lose from the stricter regulatory
regime. This in turn led to the formulation of control strategies aimed at reducing
disease prevalence (Nairn and others 1977; Ellis and others 1987; Paton and others
1988a) and provided a catalyst for developments in the field of vaccination (Nairn and
others 1977; Eggleton and others 1991a; Eggleton and others 1991b; Eggleton and
others 1991c; Paton and others 1995).
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Global Prevalence of CLA
While C. pseudotuberculosis is recognized as having a worldwide distribution, farm and
abattoir-based research aimed at establishing disease prevalence rates, has been limited
to relatively few countries. The average prevalence of CLA amongst adult sheep in
Western Australia was recorded as 58% in 1973, and as 53% in 1984 (Batey 1986a). In
an Australian abattoir survey, 54% of adult ewes and 3.4% of lambs showed evidence of
infection at meat inspection (Batey 1986b). In another abattoir survey, individual flocks
in Tasmania and Western Australia demonstrated prevalence levels within the adult
population as high as 61% (Middleton and others 1991). Subsequent surveys tended to
identify steadily decreasing prevalence rates, this generally being attributed to the
introduction of a CLA vaccine in 1983 and its increasing acceptance within the farming
community (Paton and others 2003). A field study of 412 sheep flocks, once again
conducted in Western Australia, recorded an average prevalence of 45% (Pepin and
others 1994a). A combined abattoir and postal survey of farmers carried out in 2002,
suggested that the average prevalence had fallen to 20% in Western Australia, 23% in
Victoria and 29% in New South Wales (Paton and others 2003).
A survey conducted in 1986/87 by meat inspectors in New Zealand identified lesions of
CLA in 7.1% of the adult sheep slaughtered and 0.64% of lambs (Nuttall 1988). CLA
was also identified as the leading cause of sheep carcase condemnation in South African
abattoirs (Collett and others 1994) where losses of between 0.24 and 0.3% of all sheep
carcases were attributed to CLA and substantial additional losses were incurred due to
carcase trimming (Paton and others 1995). In the western USA, average disease
prevalence amongst adult ewes was estimated to be as great as 42.5% (Stoops and others
1984). Similar studies have been conducted in the Canadian province of Quebec, where
the prevalence of clinical CLA was found to range from 21 to 36% amongst culled adult
sheep (Arsenault and others 2003). Abattoir statistics from Alberta indicated that up to
5% of mutton carcases and 0.03% of lamb carcases were condemned due to CLA, and
7
that a further 8% of all carcases were trimmed to remove CLA lesions (Stanford and
others 1998). Unfortunately, similar published statistics do not exist in respect of
Europe. In the UK, where small abattoir surveys of CLA prevalence have been carried
out, the results to date have been of limited scope and significance (Mechie 1998).
Bacterial Characteristics
Classification
The Corynebacteriaceae are now considered to belong to the Corynebacterineae, a
suborder ofActinomycetales. The Corynebacterineae also includes most of the acid-fast
bacteria, including the Mycobacterium and Nocardia genera (Clarridge and Spiegel
1995) characterised by the high mycolic acid content of the cell wall. Corynebacterium
pseudotuberculosis possesses many of the classical features of its genus (Collins and
Cummins 1986). It consists ofnon-motile pleomorphic rods (0.5-0.6 pm by 1.0-3.0 pm)
which are Gram-positive, although staining may sometimes be irregular. Groups of the
bacteria tend to show a characteristic palisade or "Chinese letter" arrangement in smears
(Figure 1.1).
Figure 1.1 Gram-stained smear of C. pseudotuberculosis organisms showing irregular
staining and formation of palisades (picture supplied by Kathleen Connor).
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At a temperature of 37°C, C. pseudotuberculosis will grow under aerobic or anaerobic
conditions. On solid media, the bacterial colonies are pale in colour, dry and friable in
consistency, and may be moved freely over the surface of the agar with the point of a
probe (Quinn and others 1994a). After incubation for 24 hours small yellowish colonies
will appear, increasing to a diameter of 1 to 2 mm after 48 hours (Coyle and others
1985). Bacterial growth benefits from the addition of serum or whole blood to nutrient
media. When whole blood is used, a narrow band of P-haemolysis is seen around each
colony, although it may appear only after incubation for 48-72 hours.
When grown in liquid media or when in aqueous suspension, C. pseudotuberculosis has
a tendency to form clumps. This has been related to the presence of long-chain 2-
branched 3-hydroxy fatty acids, or mycolic acids, on the outside of the cell wall (Carne
and others 1956). Mycolic acids were first identified in 1939, in the tubercle bacillus
(Asselineau and Laneelle 1998) and were subsequently found to be a feature common to
the actinomycete family as a whole. Mycolic acids may be solvent-extracted from C.
pseudotuberculosis without impairing the viability of the organism (Carne and others
1956).
The so-called chemotaxonomic approach has been used widely as a means of
classification of bacteria, based upon an analysis of the chemical composition of the cell
wall. Analysis of cell wall mycolic acids greatly aided clarification of the taxonomy of
actinomycetes, especially those of the genera Corynebacterium, Mycobacterium,
Rhodococcus and Nocardia (Minnikin and others 1975; Goodfellow and others 1976;
Keddie and Cure 1977; Minnikin and Goodfellow 1980; Collins and others 1982). In
these studies, thin-layer (pyrolysis) chromatographic analysis of mycolic acid revealed
that fatty acid chain length varied according to the genus and to a lesser extent the
bacterial species. It was shown that mycobacterial mycolic acids normally consist of
chain lengths of between 60 and 90 carbon atoms, and may possess a number of distinct
functional groups (Minnikin and others 1978). In contrast, nocardiae and rhodococci
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were shown to possess shorter mycolic acids, consisting of between 36 and 66 carbon
atoms, and with fewer functional groups (Minnikin and Goodfellow 1976). The mycolic
acids of corynebacteria were found to be even smaller, being between 20 and 36 carbon
atoms in length, and usually saturated or containing a single double bond (Minnikin and
others 1978). Collins and others (1982) reported that, consistent with the mycolic acid
classification of corynebacteria, strains of C. pseudotuberculosis possessed mycolic
acids with carbon chain lengths of between 26 and 36 carbon atoms, which contained
predominantly saturated side-chains of 14 carbon atoms length.
There are few published data on the resistance of C. pseudotuberculosis to chemical
disinfectants. However, most common disinfectants, including calcium hypochlorite,
formalin and cresol solution, appear to be effective in killing the organism, but the
presence of organic material necessitates increased exposure time (Ismail and Hamid
1972). This protective effect is clearly significant for a pathogen commonly found
within a thick matrix of purulent debris. The organism is capable of surviving in
commercial sheep dip solutions for 24 hours or more, a point of relevance in disease
control (Nairn and Robertson 1974).
Early reports showed that C. pseudotuberculosis isolates from different mammalian
species shared identical biochemical characteristics, with the exception of nitrate
reduction. It was found that the majority of isolates from horses and cattle reduced
nitrate to nitrite, while those from sheep and goats did not (Knight 1969). This led to the
proposal of two distinct biotypes or subspecies (Biberstein and others 1971), organisms
responsible for disease in sheep being consistently nitrate-negative (Sutherland and
others 1996). Based on this property of nitrate reduction, Songer and others (1988)
proposed the designations C. pseudotuberculosis biovar ovis (biotype 1) and C.
pseudotuberculosis biovar equi (biotype 2). However, the isolation in recent years of
nitrate-negative strains of C. pseudotuberculosis from cattle in Israel (Yeruham and
others 1997) and from horses in the UK (Connor and others 2000), suggests that such a
form of categorization may be unsatisfactory.
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A further minor difference between certain isolates lies in the area of antibiotic
sensitivity. In a comparison of susceptibility to 17 different antimicrobial agents, the
minimum inhibitory concentration of the aminoglycoside antibiotic amikacin was higher
for nitrate-negative sheep and goat isolates than for nitrate-positive equine and bovine
isolates (Costa and others 1998); however, the significance of this finding is not clear.
Virulence factors
No avirulent strain of C. pseudotuberculosis has yet been described; however, the
organism's virulence mechanisms remain poorly understood. Since no plasmids have
been identified in isolates of C. pseudotuberculosis, the absence of plasmid-encoded
virulence determinants must be assumed. To date, research has focussed mainly on two
known virulence factors identified as phospholipase D (PLD) and mycolic acids. The
genome of C. pseudotuberculosis, unlike that of a number of other bacterial pathogens,
has yet to be fully sequenced; as a result, there is at present no opportunity to identify
novel gene sequences that may encode other virulence factors.
Phospholipase D
The designation "phospholipase" is used to describe a varied group of enzymes able to
hydrolyse one or more ester linkages in glycerophospholipids; the letters A-D are used
to distinguish between phospholipases and to denote the specific phospholipid ester
bond that is cleaved (Ansell and Hawthorne 1964). In eukaryotic cells, phospholipase
enzymes play a role in signal transduction and normal membrane maintenance. Some
mammalian cells also produce phospholipases as part of the cellular inflammatory
response (Schmiel and Miller 1999). Eukaryotic cell membranes are composed of
proteins and lipids, which constitute a significant target of attack during microbial
invasion of host tissues. As part of their invasive arsenal, many microbes have
developed their own phospholipase enzymes, which may be used to hydrolyse phosphate
bonds within membrane phospholipids (Ghannoum 2000). The result of this is the
damage or destruction of host cell membranes, which in turn may lead to their
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dysfunction or disruption, or both (Salyers and Witt 1994). Various bacterial genera are
known to secrete phospholipase enzymes, and in some cases these have been shown to
play a role in virulence (Schmiel and Miller 1999). In C. pseudotuberculosis, PLD has
been identified as a potent exotoxin and a key virulence factor in the development of
CLA (Carne and Onon 1978).
PLD in this organism was first characterized by (Carne 1940) and has since been
detected in every isolate of C. pseudotuberculosis that has been studied; including
isolates of both of the suggested biotypes, and all known strains of the organism
recovered from infected mammalian species (Songer and others 1988). The contention
that PLD represents a significant virulence factor is supported by much experimental
evidence. Isolates of C. pseudotuberculosis in which the pld gene, encoding PLD, has
been deleted from the chromosome or rendered inactive by mutation, are incapable of
causing the classic lymph node abscesses of CLA in sheep (Hodgson and others 1992;
McNamara and others 1994). Similarly, the presence of specific antibody to PLD
greatly limits the progress of the clinical disease (Brown and others 1986).
PLD is defined as a sphingomyelin-specific phospholipase that catalyses the dissociation
of sphingomyelin into ceramide phosphate and choline (Bernheimer and others 1980;
Pepin and others 1994a). The C. pseudotuberculosis pld gene has been cloned and
sequenced, and analysis reveals that it encodes a protein of some 31.4 kDa, preceded by
a probable secretory signal sequence of 2.7 kDa (Hodgson and others 1990). The
relatively large size of the protein molecule assists in its purification in the laboratory
and enables large quantities to be collected (Egen and others 1989).
Several biological activities have been reported for PLD including dermonecrosis (Carne
1940; Muckle and Gyles 1986), lethality (Brogden and Engen 1990), synergistic lysis of
erythrocytes in the presence of an extracellular Rhodococcus equi factor (Fraser 1961),
and inhibition of staphylococcal lysin-induced lysis of erythrocytes (Zaki 1976); the two
latter activities are employed as laboratory tests for the identification of C.
12
pseudotuberculosis. PLD also interferes with ovine neutrophil chemotaxis and is lethal
to the cells themselves (Yozwiak and Songer 1993). In terms of the significance ofPLD
as a virulence factor, the activity that has been the focus of most interest is the increase
in vascular endothelial membrane permeability engendered by the hydrolysis of
sphingomyelin. This increased permeability leads to the leakage of plasma from blood
vessels and into the surrounding tissues, and from there into the lymphatic drainage
(Jolly 1965; Carne and Onon 1978). This effect may assist pathogenesis by favouring
the lymphatic drainage of C. pseudotuberculosis in tissue fluid (Batey 1986c).
PLD may assist the organism at the site of initial infection in other ways. It is known to
activate the complementary pathway of the innate immune system, thereby depleting
complement in the region surrounding the invading bacteria and protecting them from
opsonization (Yozwiak and Songer 1993). The same paper indicates that it may also
impair the chemotaxis of neutrophils and, as a consequence, decrease the likelihood of
phagocytosis early in infection. In some respects this suggestion is at odds with other
theories of pathogenesis, which propose that in the early stages of disease the organism
parasitizes phagocytic cells and multiplies within them. Indeed, other authors have
indicated that PLD may play a role in the escape of the bacterium from within
macrophages (Pepin and others 1994a). It is possible that this role is related to the
action of PLD on the inner phospholipids layers of the macrophage cell membrane, as
indicated by the comparable observations on other bacterial infections (Titball 1993).
Exotoxins with similarities to the PLD of C. pseudotuberculosis are known to be
important virulence factors for other bacterial pathogens. For example, there is 97%
homology between C. pseudotuberculosis PLD and the active exotoxin of C. ulcerans, a
rare cause of human diphtheria (McNamara and others 1995). A PLD-like exotoxin is
also considered to be an important virulence factor in Pseudomonas aeruginosa
(Wilderman and others 2001). Likewise, the gene coding for C. pseudotuberculosis
PLD (pld) shows homology to the ymt gene from the plague-causing organism Yersinia
pestis (Hinnesbusch 2000). PLD also demonstrates an intriguing similarity in structure
13
and biological activity to an enzyme toxin produced by the venomous North American
brown recluse spider, Loxosceles reclusa (Bernheimer and others 1985). This toxin
induces dermonecrosis, haemolysis, platelet-aggregation and, on rare occasions, fatal
renal failure (Lee and Lynch 2005). Similarly, it has been shown that severe haemolytic
crises may result from the injection of C. pseudotuberculosis culture supernates or
crudely purified exotoxin preparations into small ruminants (Hsu and others 1985).
Mycotic acid
C. pseudotuberculosis does not produce a protective capsule but has instead a waxy
mycolic acid coat on the cell wall surface. Observations on the growth of virulent and
attenuated strains of C. pseudotuberculosis, together with quantitative differences in the
amount of extractable mycolic acid from two of these strains, led to the hypothesis that
these surface lipids were concerned with pathogenicity and virulence (Jolly 1966).
Later work established the cytotoxic properties of this lipid coat, which was shown to
play a major role in pathogenicity (Hard 1972; Muckle and Gyles 1983; Tashjian and
Campbell 1983). The subcutaneous injection into mice of mycolic acid extracted from
C. pseudotuberculosis results in localized swelling, with congestion and a central area of
haemorrhagic necrosis (Muckle and Gyles 1983). Similarly, when guinea pigs are
injected the inoculated area of skin becomes blanched, although surrounded by a zone of
erythema. This is then followed by local necrosis and tissue sloughing (Hard 1975). In
addition, mycolic acid induces degenerative changes and death in phagocytising
leucocytes (Carne and others 1956). However, unlike the lethal effect of injection of
similar molecules extracted from mycobacteria, the cytotoxic effect of C.
pseudotuberculosis mycolic acid is confined to the site of injection (Carne and others
1956; Hard 1975).
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Some authors have suggested that the mycolic acid coat enables C. pseudotuberculosis
to survive for extended periods within the environment, a feature common to other
members of the actinomycete family. C. pseudotuberculosis is indeed relatively
resistant to environmental conditions (West and others 2002). Low ambient
temperatures and mixing with particulate fomites enhance survival of the organism in
discharged pus, viable bacteria being recoverable from inanimate surfaces for up to 55
days after contamination (Augustine and Renshaw 1986). Batey (1986c) reported that
under cold and damp conditions, the organism may remain viable in a farm environment
for six months or more. Soil experimentally contaminated with pus still contained
viable bacteria eight months later (Brown and Olander 1987). Thus the environment
may remain infectious for a significant period after contamination by an affected sheep.
In natural infections, the waxy mycolic acid coat of C. pseudotuberculosis provides the
organism with mechanical, and possibly biochemical, protection from the hydrolytic
enzymes present within lysosomes. This in turn enables the bacterium to survive
phagocytosis and to exist within the host as a facultative intracellular parasite
(Williamson 2001). This capacity is likely to be essential for the migration of the
organism from the point of initial entry to the eventual site of lesion development. In
addition, the toxic nature ofmycolic acid seems to contribute to abscess formation. In
artificial infections ofmice, a direct relationship was demonstrated between the quantity
of cell wall lipid produced by different isolates of C. pseudotuberculosis and their ability
to produce chronic abscessation (Muckle and Gyles 1983).
Other secondaryfactors involved in infection
Undetermined differences in virulence factors have been suggested to account for the
specific "ovine/caprine" and "equine/bovine" strains of C. pseudotuberculosis, which
are in other respects (cultural, antigenic and toxigenic) equivalent (Valli 2007). The fact
that the equine disease syndromes associated with the organism appear to be absent from
large parts of the world in which the ovine infection is endemic, supports the existence
of such differences. As discussed later, the probable importance of secondary factors,
15
such as insect vectors in C. pseudotuberculosis infections of horses (Miers and Ley
1980; Spier and others 2004), may go some way to explaining this. However, in order to
clarify the matter fully, experimental infections with ovine and equine strains in parallel
would be required. A previously unreported 40 kDa protein antigen of C.
pseudotuberculosis, suggested to be a virulence factor (Wilson and others 1995) has yet
to receive detailed study.
Clinical and Pathological Features of Caseous Lymphadenitis
in Sheep
C. pseudotuberculosis infections in sheep are classically associated with the formation
of pyogranulomas (Valli 2007), and this accounts for the name "caseous lymphadenitis".
The lesions occur in two main forms, namely external (also known as superficial or
cutaneous) and internal (or visceral), which may co-exist within the same animal.
The external form is characterized by abscessation of those lymph nodes that may be
seen or palpated externally (Figure 2.2). Any of the superficial lymph nodes of the body
may be affected, dependent upon the original point of entry of the organism. Less
commonly, localized purulent lesions not directly associated with the superficial lymph
nodes may occur within the subcutaneous tissues. Such lesions may appear as organized
abscesses, with swelling, fibrous encapsulation, loss of overlying hair and eventual
rupture, resulting in the discharge of pus (Radostits and others 2000a).
The visceral form is associated with abscesses in the internal lymph nodes and other
organs. In sheep, the principal locations for these internal CLA lesions are the lung
parenchyma and mediastinal lymph nodes. Lesions may also be found in the liver,
kidneys or udder, and more rarely the heart, testis, scrotum, uterus, joints, brain or spinal
cord (Valli 2007).
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Figure 2.2 A typical external CLA lesion in the parotid lymph node of an adult Friesland
ewe which is yet to discharge its purulent contents (picture taken by author).
Pathogenesis in sheep
There is a general consensus among recent reviewers regarding the stages through which
C. pseudotuberculosis infection progresses (Batey 1986c; Pepin and others 1994a; Paton
and others 2005). After initial entry, the organism spreads rapidly to the local drainage
lymph node. Here, multiple microscopic pyogranulomas develop, growing in size and
coalescing to form larger abscesses. This is sometimes followed by a further extension
of infection via the blood or the lymphatic system, leading to similar lesions in other
organs. The nature of these slowly developing CLA lesions means that chronic, and
frequently lifelong, disease is the rule rather than the exception (Valli 2007). Viable
bacteria may be recovered from abscesses several years after initial infection
(Williamson 2001). Reactivation of disease may also occur, with the growth of lesions
recommencing after a period of apparent quiescence (Brown and Olander 1987; Pepin
and others 1994a).
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Figure 2.3 CLA abscesses within the lung parenchyma. Note the close proximity of the
lesions to the small airways (picture taken by author).
Numerous routes of inoculation have been used to induce experimental CLA in sheep;
intradermal, subcutaneous, intravenous, intratracheal, intravaginal, and intralymphatic
inoculation have all proved successful in establishing disease (Nagy 1976; Burrell
1978a; Pepin and others 1994b; Fontaine and others 2006). In natural infections
however, the principal route of entry is believed to be through the skin (Batey 1986c;
Brown and Olander 1987; Davis 1990; Collett and others 1994). This initial infection is
facilitated by minor cutaneous wounds and abrasions, especially those caused by
shearing (Paton and others 1988a). Wounds caused during castration or docking have
also been suggested as an occasional route of entry, as has the umbilicus in neonatal
animals (Valli 2007). Entry via the oral cavity has been postulated to account for the
small number of head and neck lesions seen in sheep from the Antipodes and North
America, and similar, more common lesions in goats (Ashfaq and Campbell 1979). In
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contrast, the more distal parts of the intestinal tract are not believed to provide a portal of
entry for the organism, even following parasitic damage (Valli 2007).
A respiratory route of CLA infection has been postulated (Stoops and others 1984) and
has been widely quoted in subsequent reviews (Batey 1986c; Brown and Olander 1987).
This theory was based on the observations that some naturally infected sheep show only
pulmonary lesions, and that a small number of these lesions are located within the walls
of airways (Figure 2.3). Moreover, the production of disseminated pulmonary abscesses
has been reported to occur following the intratracheal injection of a broth culture of
C. pseudotuberculosis (Brown and Olander 1987). However, other studies have
indicated that such pulmonary lesions may develop as part of a systemic infection
initiated elsewhere in the body. Thus, after the intravenous inoculation of lambs with C.
pseudotuberculosis, the majority of internal lesions appeared in the lungs and associated
thoracic lymph nodes (Brogden and others 1984b). It has also been noted that in natural
ovine CLA infections, the patterns of distribution of pulmonary lesions are consistent
with haematogenous or lymphogenous spread rather than with aerogenous spread (Nairn
and Robertson 1974). It would therefore appear that entry of infection via the
respiratory tract, although a theoretical risk, is ofminor importance.
As already described, purulent cutaneous or subcutaneous lesions from which
C. pseudotuberculosis may be isolated, occur infrequently in sheep, even in flocks in
which the incidence of classic lymph node lesions is high. It therefore follows that, on
infecting the host via the skin, the organism is poorly suited to establishing persistent
infections at the site of entry and on most occasions must progress to the local drainage
lymph node and beyond if infection is to be sustained (Valli 2007). The means by which
the organism spreads from the initial point of entry, eventually to form the classic lesion
of CLA, has received close examination (Brogden and others 1984b; Holstad and Teige
1988; Pepin and others 1991a; Pepin and others 1991b). Of crucial importance is the
survival and replication of C. pseudotuberculosis in macrophages, which then carry the
organism to the site of the eventual CLA lesion.
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The use of radioisotopically labelled inflammatory cells and scintigraphic imagery
demonstrated that within a few hours of subcutaneous inoculation with bacteria, huge
numbers of neutrophils were recruited to the injection site and by 24 hours post-
inoculation, these neutrophils began to appear in the local drainage lymph node
(Guilloteau and others 1990). The relative number of neutrophils decreased from day
three, while the relative numbers of macrophages at the site of inoculation rose
dramatically. As suggested above, the ability of C. pseudotuberculosis to survive
phagocytosis by such cells and to exist as a facultatively intracellular parasite, enables
the organism to be carried within these cells via the lymphatic drainage to the local
lymph node (Pepin and others 1994a). Thus, it is thought that phagocytic cells recruited
to the area in response to infection become the very means by which further colonization
of the body is achieved.
Once a lymph node has been colonized by C. pseudotuberculosis it undergoes a short
period of generalized inflammation. PLD produced by the C. pseudotuberculosis
organisms is the probable initiator of this lymphadenitis. It has been reported that within
24 hours of the subcutaneous inoculation of lambs a number of micro-abscesses
occurred within the cortical region of the lymph node draining the site of inoculation
(Pepin and others 1991b). By day six post-inoculation, these micro-abscesses had
become more numerous and began to expand and coalesce to form larger purulent foci.
The early pyogranulomas contained clumps of bacteria and cellular debris, with a
relatively high proportion of eosinophils giving the purulent core a slightly green hue
macroscopically. At the same time, and in parallel with the cellular events at the point
of entry, the infiltration of neutrophils diminished and monocytes/macrophages became
the predominant cell type within the lesion (Pepin and others 1994b). A process during
which the lesion became encapsulated followed shortly thereafter, leading to a
diminution of the inflammatory reaction in the parenchyma of the node. Continued slow
expansion of the lesion sometimes then occurred, depending on the location of the node
and whether or not it ruptured to discharge its contents. Such enlargement progressed
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through a repeated cycle of necrosis and refonnation of the outer capsule. In the early
stages, the purulent contents of the abscess were soft and semi-fluid; however, as time
progressed, the pus within the lesion took on a more plastic or solid form, in which
scattered clumps of bacteria were sometimes noted. Small nodules of mineralization
formed within the purulent material, causing it to become progressively paler in colour.
These calcified foci tended to be laid down in concentric layers reminiscent of the cross-
sectional view of an onion.
The classic "onion ring" presentation (Figure 2.4) is regarded as virtually
pathognomonic for CLA in countries such as Australia and New Zealand, but is rarely
reported in the UK. This probably reflects the relatively small number of chronic
infections amongst sheep in Britain, where C. pseudotuberculosis is still regarded as a
new and emerging disease and infected animals are still likely to be culled after
diagnosis (Baird 2003). Superficial lymph node abscesses may expand to reach a
diameter of as much as 15 cm, but 3-5 cm is a more common size (Valli 2007).
The majority of reviews of ovine CLA have been written from a North American or
Australian perspective. These describe the external form of CLA as most commonly
affecting the superficial lymph nodes of the torso (Nagy 1971; Stoops and others 1984;
Brown and Olander 1987; Williamson 2001). A review of the disease in US sheep,
reported that the precrural node was most commonly affected, followed by the
prescapular and then by other superficial lymph nodes with equal frequency (Ayers
1977). The author regarded the occurrence of lesions in the head and neck as relatively
rare in sheep, but more common in goats. A similar statement is made by an Australian
author describing the usual presentation of the disease in that country (Batey 1986b).
Authors from New Zealand (Nuttall 1988), South Africa (Collett and others 1994) and
Canada (Muckle and Menzies 1993) all describe a similar tendency for superficial
lesions to develop particularly in the lymph nodes of the torso. This therefore implies,
for the above countries, that the skin of the torso is a frequent site of entry for the
pathogen.
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Figure 2.4 Superficial CLA lymph node abscess in an aged ewe in Perth, WA. Note the
typical onion ring appearance as recognised commonly in Australia (picture taken by
author).
It is likely that the infected superficial lymph node represents a staging post for the
further colonization of internal lymph nodes and viscera. At which stage in the course
of the infection such colonization occurs, is the subject of some speculation. It seems
probable that purulent emboli detach from pyogranulomas within the affected nodes,
pass into the efferent lymphatic flow and are then delivered into the bloodstream
(Radostits and others 2000a). However, once encapsulation of a lymph node abscess has
taken place, the escape of such infectious emboli seems likely to occur infrequently, if at
all. Consequently, it has been argued that in most cases, any colonization of organs
beyond the local drainage lymph node must occur relatively quickly after initial
infection, and that phagocytic cells may once again be the vehicles for this further
movement (Pepin and others 1994a).
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Other than the lymph nodes, the lung is the most frequent site of CLA lesions (Stoops
and others 1984; Brown and Olander 1987; Pekelder 2000; Paton and others 2005). As
already noted, the generally random distribution of lesions within the parenchyma is
consistent with haematogenous or lymphogenous spread, with seeded lesions developing
from within the alveolar vasculature (Batey 1986c). These pulmonary lesions most
commonly take the form of encapsulated abscesses similar to those seen in the lymph
nodes (Figure 2.5), although occasionally a more extensive bronchopneumonia is also
recorded (Valli 2007). The latter may lead to areas of pleuritis, resulting in the
development of fibrinous or fibrous adhesions to the chest wall, pericardium or
diaphragm (Renshaw and others 1979; Stoops and others 1984). In animals with
pulmonary abscesses, CLA lesions are commonly encountered in the associated
mediastinal and bronchial lymph nodes, implying an additional step in the transit of the
organism from the lung parenchyma. Abscesses within the mediastinal lymph nodes
may become so large as to put pressure on the adjacent oesophagus, interfering with
normal swallowing and rumination, and leading to chronic ill-thrift (Valli 2007).
Mastitis due to C. pseudotuberculosis is encountered occasionally in sheep and is most
likely to represent an extension of infection from the adjacent supra-mammary lymph
node (Radostits and others 2000a). It may take the form of an acute suppurative
mastitis, or appear as chronic encapsulated abscesses within the mammary gland (see
Figure 4.1). Lesions in other organs such as the liver, kidneys and scrotum also tend to
be encapsulated abscesses containing a thick caseous material, which may again take on
a lamellated form in chronic cases (Valli 2007). On rare occasions, the organism has
also been isolated from the stomach contents and tissues of ovine foetuses, consistent
with a role in abortion (Dennis and Bamford 1966).
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Figure 2.5 Multiple encapsulated CLA abscesses within the lung of an adult ram
examined at SAC Centre St Boswells (picture taken by author).
Economic significance ofthe disease in sheep
CLA is recognized as a significant cause of financial loss to the sheep industry in a
number of countries where the disease is endemic. The major cause of these economic
losses lies in the condemnation and downgrading of affected carcases at slaughter and
meat-inspection. In Australia, where CLA-related losses have been extensively studied,
it was estimated that in the early 2000s the disease costs the meat industry $A12 to $A15
million per annum (Paton and others 2003). This was due both to carcase losses and to
the requirement for additional staff in abattoirs to carry out meat inspection and carcase
trimming.
Systemic infection by C. pseudotuberculosis is acknowledged to be detrimental to the
productivity of the infected animal, but to what extent is unclear. Studies of Merino
sheep in Australia failed to show a relation between carcase conformation and weight,
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and the occurrence or extent of CLA lesions (Batey 1986b). However, workers in that
country established that CLA infection had a detrimental effect on wool production. In a
comparison between CLA-affected and unaffected Merino sheep in three Australian
flocks, the loss of total clean wool production in the infected animals was assessed as 4.1
to 6.6% during the year of initial infection (Paton and others 1988b). Based on disease
surveillance and wool production data from 1992, it was estimated that CLA infection
cost the Australian sheep industry approximately $A17 million per annum in lost wool
production (Paton and others 1994). However, the same field workers were unable to
confirm that CLA infection had any detrimental effects on the live weight gain of young
sheep (Paton and others 1988b).
In contrast to much of the Southern Hemisphere, where the systemic effects of CLA on
the individual sheep are regarded as marginal, in North America the disease is
considered to be much more significant clinically. There, the visceral form of infection
with C. pseudotuberculosis has been associated with so-called "thin-ewe syndrome", a
chronic emaciation of ewes, occurring despite good appetite and in the absence of
significant parasitic infestation or specific clinical signs (Paton and others 2005). Two
studies conducted in the US concluded that CLA infection had an economically
significant effect on culling rates and reproductive efficiency in ewes (Gates and others
1977; Renshaw and others 1979), although these studies have been criticised for a lack
of experimental controls (Arsenault and others 2003). Certainly, the diagnostic criteria
of "thin-ewe syndrome" are vague, and although C. pseudotuberculosis is the principal
bacterial causative agent, other organisms such as species of Moraxella,
Arcanobacterium and Staphylococcus may also be isolated from lung lesions in mixed
culture (Renshaw and others 1979). On occasion, Moraxella species may be present in
the absence of C. pseudotuberculosis. More significantly, there would appear to be
some evidence of a statistically significant association between the presence of CLA
thoracic lesions and maedi visna-induced pneumonia in culled sheep in Canada
(Arsenault and others 2003).
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In the Middle East, considerable economic losses arise through the condemnation of
lamb carcases with CLA lesions, most commonly in the submandibular lymph nodes.
Prevalence rates of 20-40% have been reported amongst lambs from intensively reared
flocks of Najdi sheep (Pepin and others 1994a). CLA lesions in lambs destined for
slaughter as part of religious festivals may render the carcass virtually worthless -
equivalent to a loss of $200 per head.
Epidemiology of Infection in Sheep
Much CLA research has focussed on how C. pseudotuberculosis cells, commonly
contained within thick-walled abscesses, are transferred from one animal to another.
Several possible routes have been suggested. The numbers of viable bacteria in purulent
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discharge from a CLA lesion have been estimated as between 10 and 5x10 /g (Brown
and Olander 1987). The rupture of superficial abscesses therefore releases huge
numbers of viable bacteria on to the adjacent skin and fleece, and may readily
contaminate the immediate environment. Other animals may then be exposed, either by
direct physical contact with the affected animal, or indirectly via contaminated fomites.
In addition, given the ability of C. pseudotuberculosis to survive within the environment
for a number of weeks or months, the potential period for infection may extend well
beyond the point of initial rupture and discharge.
The recovery of organisms from the faeces of infected animals was reported from the
earliest days ofCLA research (Seddon and others 1929) and its potential significance for
disease transmission has been noted in subsequent reviews (Henton 2001; Paton and
others 2005). However, in the absence of CLA lesions in the intestinal tract, the
organisms probably originate from the respiratory tract, or represent bacteria that have
traversed the gut, having been ingested. The fact that bacteria have also been isolated
from the faeces of uninfected sheep would tend to support the latter hypothesis (Benham
and others 1962). Despite the ability of C. pseudotuberculosis to survive in the
environment for protracted periods of time, attempts to isolate the organism from the
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soil in areas of endemic infection have been unsuccessful (Knight 1969). Therefore the
presence of C. pseudotuberculosis organisms in faeces, and the consequent risk to other
animals are likely to be ofminor importance.
In CLA-infected sheep flocks, animals with lung lesions are thought to represent the
principal source of infection for other animals (Pepin and others 1994a; Williamson
2001). These conclusions are based principally on epidemiological observations
recorded in Australia, in which the seroprevalence of CLA increased rapidly in groups
of sheep, despite the absence of superficial CLA lesions (Ellis and others 1987; Paton
and others 1988a). In addition, C. pseudotuberculosis has been isolated from the
tracheae of sheep with pulmonary abscesses, confirming that discharge from lung
lesions into the airways does indeed occur (Stoops and others 1984; Pepin and others
1994a). The assumption is made that even a relatively small number of animals with
lung abscesses can create an aerosol of infectious organisms. Under conditions of close
contact and reduced airflow, as in a covered shed for example, such an aerosol might be
capable of infecting a large number of animals in a short period of time (Paton and
others 1996).
The usual means of entry of a new infection into a naive flock is via the introduction of a
clinically or sub-clinically infected carrier animal (Ayers 1977). A role for transmission
of the bacterium by farm workers and their equipment between animals within the same
flock has been established (Nagy 1976) and it has also been suggested that human
activity may, on rare occasions, be responsible for introducing infection to previously
disease-free flocks. In flocks with a high prevalence of CLA, shearers and their
equipment are inevitably exposed to the purulent discharges of superficial CLA lesions.
If subsequent decontamination measures are inadequate, it is possible that shearing gear,
clothing and mobile handling equipment may act as a mechanical vector of infection to
other flocks. A circumstantial link between new disease outbreaks in previously
unaffected closed sheep flocks, and visits by contract shearers has been suggested in
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Western Australia (Paton 2000) and Canada (P. I. Menzies, personal communication);
such reports, however, remain anecdotal.
Other mechanical vectors of infection have been suggested. The investigation of an
outbreak of CLA in a closed and accredited disease-free goat herd in The Netherlands
identified the most likely source of infection as bales of hay purchased from another
farm. This second farm was known to have a herd of goats in which CLA was highly
prevalent, and infected goats had been housed in the hay shed (Dercksen and others
1996).
A number of risk factors have been suggested for the spread of C. pseudotuberculosis
infection amongst sheep. These include the breed (West and others 2002), increasing age
of animals (Pepin and others 1994a; Paton and others 1995) and a dusty farm
environment (West and others 2002). However, the principal risk factor identified in
Australia and other parts of the world is the minor skin damage caused during shearing
of the fleece (Nagy 1976; Paton and others 1988a; Serikawa and others 1993; Paton and
others 1996; A1 Rawashdeh and A1 Qudah 2000). In Australia, sheep are frequently
housed or yarded together for a period immediately after shearing, before being returned
to their grazings. This spell of close confinement is regarded as the period of greatest
risk, during which the organism may pass via an infectious aerosol from one animal to
another (Paton and others 1996). The risks inherent in shearing may be increased if a
plunge or shower dipping is applied within a few days of shearing (Nairn and Robertson
1974; Augustine and Renshaw 1986; Ayers 1986; Paton and others 1996), the
suggestion here being that organisms from affected animals persist in the dip solution for
a period of time.
Comparison with infection in goats
Natural CLA infections in goats demonstrate a number of similarities with the disease in
sheep, not least that the same biotype of C. pseudotuberculosis is responsible. However,
consideration of the differences in clinical presentation between sheep and goats may be
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instructive in respect of pathogenesis and specific risk factors. This is of particular
interest in the UK, where the clinical presentation of ovine CLA is closely similar to that
of the caprine infection in other parts of the world (Baird 2003).
In goats the major sites of infection are the superficial lymph nodes, visceral lesions
being encountered in only a minority of animals. In sheep, however, visceral lesions,
and especially lung lesions, occur more frequently and in greater numbers than in goats
(Renshaw and others 1979; Hein and Cargill 1981; Ayers 1986; Muckle and Menzies
1993). In caprine CLA, the principal sites of superficial lesions are the nodes of the
head and neck (Ayers 1977; Burrell 1981; Batey 1986c; Batey and others 1986; Brown
and Olander 1987; Williamson 2001). As already noted, most reports of ovine CLA
from other countries indicate that head and neck lesions are uncommon, the more
frequent site of abscessation being the superficial lymph nodes of the torso. These
observations are consistent with the notion that the main routes of infection in goats are
via the oral cavity or via skin of the face and head. If bacteria are present on the skin or
in the immediate environment, certain behavioural traits shown by goats, such as mutual
grooming, head butting, and an inquisitive attitude (including browsing and mouthing
behaviour), would increase the risk of exposure to infection. In contrast, such
behavioural traits are less frequently observed in sheep. In addition most goats are
neither shorn nor subjected to plunge or shower dipping.
Corynebacterium pseudotuberculosis infections in other animal
species
C. pseudotuberculosis is pathogenic for a variety of mammalian species. Although a
wide range of warm-blooded creatures are susceptible to the infection, specific disease
syndromes are recognized in a smaller subset. In addition to the globally important




In horses, C. pseudotuberculosis is the cause of three recognized disease syndromes:
ulcerative lymphangitis, contagious folliculitis and fiirunculosis, and deep-seated
subcutaneous abscessation (Miers and Ley 1980). In the US, C. pseudotuberculosis has
also been recorded as a rare cause of abortion (Poonacha and Donahue 1995) and
mastitis in mares (Addo and others 1974), and with generalized visceral abscessation
(Paton and others 2005). The three main equine syndromes tend to have a distinct
geographical distribution, suggesting the importance of secondary disease factors.
Indeed, the western areas of Canada and the US represent the only regions in which all
three syndromes have been recorded (Aleman and others 1996). In a study employing a
real-time PCR assay for the PLD-encoding gene of C. pseudotuberculosis, evidence of
bacterial carriage was detected in a significant proportion of flies collected around
horses with infections. In total, three fly species were identified as potential vectors for
transmission of disease with C. pseudotuberculosis identified in up to 20% of the
houseflies (Musca domestica) examined (Spier and others 2004).
Ulcerative lymphangitis first gained prominence during World War I when outbreaks
occurred amongst the large numbers of horses used by allied forces in continental
Europe (Mitchell and Walker 1944). In clinical cases, infection appears to enter via
wounds, generally those of the lower limbs. This is followed by extension to the
afferent lymphatic vessels and the formation of abscesses along their course. These
abscesses appear as subcutaneous nodular lesions, which rupture to discharge pus and
form necrotic ulcers (Radostits and others 2000c). Such infections may persist for many
months, as successive crops of ulcers develop and then resolve. Transmission
commonly occurs by direct contact between horses, although an arthropod vector has
also been suggested to be of importance in Africa (Addo 1983).
Equine folliculitis and furunculosis (also referred to as equine contagious acne,
Canadian horsepox and equine contagious pustular dermatitis) is a much less clinically
important form of disease, which probably represents a secondary infection by C.
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pseudotuberculosis of a pre-existing seborrhoea or dermatitis (Radostits and others
2000b). The lesions tend to develop at points of contact with harnesses and other tack,
and spread may occur through the use of contaminated grooming equipment. Again, the
characteristic lesion is a small nodule that develops into a pustule, before rupturing to
discharge purulent material. These lesions usually resolve spontaneously but may
occasionally result in an ulcer at the site of infection.
Deep-seated C. pseudotuberculosis abscessation (pigeon fever, Wyoming strangles, false
strangles) is the most serious manifestation of the infection in horses. It is usually seen
as abscesses in the musculature of the chest and shoulder, and is of economic
significance in much of the western US (Hughes and Biberstein 1959; Miers and Ley
1980), the incidence being greatest in the months of September to November (Aleman
and others 1996; Doherr and others 1998). This probably reflects the seasonal incidence
of various species of biting arthropod that act as mechanical vectors (Doherr and others
1999).
The recognized equine syndromes have not been described in the UK in recent years,
despite the isolation of C. pseudotuberculosis from horses on a number of occasions
(Connor and others 2000). The apparent significance of seasonality, environmental
conditions and arthropod vectors in C. pseudotuberculosis infections of horses has been
emphasized by a number of authors (Hughes and Biberstein 1959; Miers and Ley 1980;
Welsh 1990). It would therefore appear that, although equine pathogenic strains exist in
the UK, essential contributory risk factors do not. It is noteworthy that ulcerative
lymphangitis was not uncommon in the UK during World War I, but this probably
resulted from the introduction of infected horses from Russia and the Balkans where the
condition was present (Petrie and McClean 1934; Benham and others 1962).
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Bovine disease
In recent years infections of dairy cattle have been recorded in Israel, commonly in the
form of deep subcutaneous abscesses that develop into granulating and discharging
ulcers that respond poorly to systemic antibiotic treatment. The disease is sporadic but
may sometimes occur in an epidemic form (Yeruham and others 2003a). Morbidity
rates of up to 35% have been recorded in some Israeli dairy herds (Yeruham and others
1997). A less common mastitic form of disease is also recognized. This may be mild,
the only sign being the appearance of clots in the milk, or severe with a greatly enlarged
and tender mammary gland and complete cessation ofmilk production. The severe form
often necessitates premature culling, as the response to antibiotic therapy is poor
(Shpigel and others 1993). In a rare visceral form of disease, widespread abscessation
occurs in lymph nodes associated with the upper and lower respiratory tract (Yeruham
and others 2003a) and in severe cases this may lead to swelling and obstruction of
airways. Finally, the organism has also been associated with a necrotic and ulcerative
dermatitis of the heel in heifers, a morbidity rate of 91% having been reported in one
outbreak (Yeruham and others 2003b). C. pseudotuberculosis has been recorded as a
cause of an ulcerative lymphangitis and mastitis of cattle in countries other than Israel,
albeit rarely (Purchase 1944; Adekeye and others 1980; Kariuki and Poulton 1982;
Anderson and others 1990).
C. pseudotuberculosis was isolated from houseflies collected over an ulcerative
lymphangitis lesion in a cow (Yeruham and others 1996). A significant proportion of
flies that have fed on superficial C. pseudotuberculosis lesions in cattle, or on
contaminated milk from animals with C. pseudotuberculosis mastitis have been found to
harbour the organism either on their body surfaces or in their intestines, the bacterium
being present in the faeces (Braverman and others 1999). It was concluded that this
species of fly had a predilection for feeding on milk residues of cow teats, and therefore
played an important role in harbouring and disseminating C. pseudotuberculosis
infections in dairy herds in Israel.
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Disease in other animal species
C. pseudotuberculosis is commonly identified as the cause of a purulent
lymphadenopathy affecting large numbers of farmed llamas and alpacas in Chile and
other South American countries (Braga and others 2006). It is also encountered
sporadically as the cause of abscesses in companion camelids in North America
(Anderson and others 2004). In parts of the Middle East C. pseudotuberculosis has been
isolated from lymph node abscesses of buffaloes (Ali and Zaitoun 1999) and from
similar lesions in camels (Esterabadi and others 1975; Nashed and Mahmoud 1987;
Abubakr and others 1999). Sporadic natural infections have been recorded in deer
(Hammersland and Joneschild 1937; Eghetti and Mc Kenney 1941), pigs (Zhao and
others 1993), coypus, primates and ducks (Benham and others 1962) and a hedgehog
(McAllister and Keahey 1971). Experimental infections are readily induced in
laboratory species such as mice, rabbits and guinea-pigs (Carne 1940; Jolly 1965).
Zoonotic Infections
Reports of human infection with C. pseudotuberculosis are relatively small in number,
the first published case appearing some 30 years ago (Lopez and others 1966). The
majority of human cases were classified as occupational infections, affecting workers
who had regular contact with sheep, such as shepherds, shearers, abattoir workers and
butchers (Henderson 1979; Richards and Hurse 1985; House and others 1986; Peel and
others 1997). Human infections tend to be chronic, presenting as a localized suppurative
granulomatous lymphadenitis, affecting the axillary, inguinal or cervical lymph nodes
(Mills and others 1997). The lymphadenitis may follow a period of influenza-like
symptoms and increasing lethargy. Treatment with systemic antibiotics is generally
unrewarding, the majority of cases requiring surgical excision of the affected lymph
node. Even then, the healing of surgical wounds and infected sinuses may be protracted,
and recurrence of the infection at the same or adjacent site is not uncommon (Peel and
others 1997). Because affected human lymph nodes are not always cultured after
excision and because unspecified axillary lymphadenitis is not uncommon in shearers, it
has been speculated that human C. pseudotuberculosis infections are under-reported in
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countries such as Australia, where ovine CLA is especially prevalent (Hamilton and
others 1968).
More serious infections in man, which extend beyond a localised lymphadenopathy,
have been recorded. On one occasion an eosinophilic pneumonia due to C.
pseudotuberculosis was diagnosed in a veterinary surgeon from the US (Keslin and
others 1979). There are however no published records of fatal infections in human
patients. One case of particular note was recorded in a city-dweller, who had no
apparent connection with a farming environment or livestock. In this instance, the only
potential cause identified was the regular consumption by the patient of unpasteurized
goat's milk (Goldberger and others 1981). No case of human infection with C.
pseudotuberculosis has yet been reported in the UK. There is however, a reference to an
isolate of C. pseudotuberculosis from a human lymph gland submitted to the UK
National Collection of Type Cultures (Hill and others 1978), although the origin of the
sample was not mentioned.
A recent report described a case of C. pseudotuberculosis necrotizing lymphadenitis in a
12-year-old girl in France (Join-Lambert and others 2006), thought to be the first
reported childhood case. The girl contracted the infection after having had contact with
sheep while on vacation in a rural part of France. The nitrate-negative organism was
susceptible in vitro to a range of common antibiotics, but treatment with amoxicillin and
clavulanic acid failed to clear the infection. A course of amoxicillin/clavulanate was
then administered again without success. After the infection had increased in severity
and spread beyond the affected inguinal lymph node, intravenous antimicrobial therapy
with imipenem/cilastatin, rifampicin and ofloxacin was administered, followed by
surgical resection of affected tissue other than lymphatic tissue (to avoid post-
lymphadenectomy oedema). Intravenous antibiotic administration was continued for a
further four months, followed by oral rifampicin and ofloxacin treatment for a further six
months. Two years after the cessation of treatment, no relapse had occurred.
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Chapter 3: SEROLOGICALLY BASED PREVALENCE
STUDY OF CASEOUS LYMPHADENITIS IN RAMS FROM
PEDIGREE TERMINAL SIRE BREEDS IN GREAT
BRITAIN.
Summary
In order to assess the likely flock prevalence of caseous lymphadenitis infection within
the GB terminal sire sector, blood samples submitted from rams as part of the Maedi
Visna Accreditation Scheme were tested using a CLA ELISA assay. The assay
employed detected antibody to PLD and has a reported sensitivity in sheep of 79% ±5%
and a specificity of 99% ± 1% when published cut-offs are applied. When blood
samples produced ELISA titres in the inconclusive range these were further tested using
a Western blot technique. A total of 2,538 serum samples from 745 different flocks
were tested in this way. A total of 250 serum samples were considered positive for PLD
antibody. This gave an overall apparent prevalence of 9.93% (with 95% confidence
interval of 8.76% - 11.1%; 99% confidence interval of 8.39% - 11.46%). One or more
seropositive animals were detected in 134 different flocks, representing almost 18% of
the total flocks sampled. These flocks were present throughout the country and animals
from all major terminal sire breeds were found to be seropositive.
Introduction
Although it is generally accepted that CLA is a relatively new arrival to the UK, there
exists a tantalising report concerning the isolation of an ''unusual diphtheroid" bacterium
from three Swaledale sheep from the same flock in southwest Cumberland (Heath and
Batty 1952). Based on colony and cell morphology and biochemical tests, these isolates
corresponded almost exactly to the previously described characteristics of
C. pseudotuberculosis (at that time C. ovis) reported a few years earlier in the US
(Morse 1949). Realizing the potential implications, Heath and Batty arranged for further
testing by other researchers in the field. The authors reported that a Dr. Lovell had
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shown that although a member of the genus Corynebacterium, the organism was not
pathogenic to guinea-pigs, did not "attack" urea and probably contained metachromatic
granules; hence it was considered not to be C. pseudotuberculosis. In addition, a Mr.
Hudson observed that the organism was not now virulent for sheep, but did otherwise
resemble C. pseudotuberculosis. In concluding their report, the authors stated that the
organism may be a different variety of the same species (i.e. C. pseudotuberculosis) and
that it was worthy of record given the extremely rare isolation of corynebacteria (other
than C. pyogenes) from British sheep (Heath and Batty 1952).
Given the inconclusive nature of the above report, and the absence of any further
literature pertaining to C. pseudotuberculosis infections in the UK, the currently
accepted first cases of infection in live animals in this country were confirmed in
January 1990 by workers at Cambridge University (Lloyd and others 1990a). The
diagnosis was made in two dairy goats from a farm in the south of England, these
animals being part of a group of 20 Boer goats originally imported from the then West
Germany in 1987 (Robins 1991).
C. pseudotuberculosis infection, although not a notifiable disease at that time, was still
of interest to the UK State Veterinary Service. The farm on which the affected goats
were kept was therefore placed under immediate movement restrictions. A subsequent
tracing exercise led to the confirmation of CLA infection in an additional five goat herds
(Meldrum 1990; Lindsay and Lloyd 1991; Robins 1991). The goats on each of these
premises were either slaughtered or placed under indefinite movement restrictions. In
addition, a group of in-contact sheep was slaughtered, but the animals showed no lesions
of CLA at necropsy.
In June 1991 C. pseudotuberculosis was identified in a sheep flock in the southwest of
England (Robins 1991). Tracings from this outbreak led to the identification of a further
six infected flocks of indigenous sheep breeds in southern England and a thorough
investigation failed to establish any links between the infected animals and any recently
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imported stock. At this point, after considering the extent of infection and the fact that
CLA was present within most countries of the European Community, UK Government
Ministers decided to deregulate the disease and all animal movement restriction orders
still in place were suspended.
Over subsequent years the condition of caseous lymphadenitis was identified in sheep
flocks and goat herds from other parts of England (Laven and others 1997; Rizvi and
others 1997; Smith and others 1997; Watson and Preece 2001), Wales (Anon 2000) and
Scotland (Anon 1996a; Scott and others 1997). The condition was then confirmed in N.
Ireland (Malone and others 2002) and the Irish Republic (O'Doherty and others 2000;
Bradshaw 2003) affecting animals recently imported from Scotland and England,
respectively.
Examination of data produced through the Veterinary Investigation Diagnosis Analysis
(VIDA) database (Anon 1996b, 2003b) gives some indication of how the disease spread
within Britain after its initial diagnosis. The VIDA database records disease incidents
on a yearly basis - an incident being defined as a single or multiple animals affected in
one flock. A specific code number for ovine and caprine caseous lymphadenitis was
provided in 1991, after which the diagnosis could be recorded by Veterinary
Investigation Officers within the VIDA system.
Examination ofVIDA records indicates that during the early part of the 1990's recorded
incidents ofCLA remained in low single figures. However the diagnostic rate began to
rise rapidly in the second half of the decade, reaching a peak of 62 outbreaks in 1998
(see Figure 3.1). There was a subsequent reduction in the number of diagnoses to a low
of 35 in 2002, partially attributable to the decline in submissions to Veterinary
Investigation Centres following the foot and mouth disease epidemic of the previous
year before rising to a figure of 68 for 2004.
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Whilst VIDA records may provide useful information on disease trends, it is generally
acknowledged that this type of passive or scanning disease surveillance is subject to
certain inherent biases (Hoinville and others 2009). An accurate assessment of disease
prevalence may therefore require more active or targeted forms of surveillance.
Several authors have identified a need to establish more robust estimates of the
prevalence of CLA infection in Great Britain and expressed concerns that the condition
may have been under-reported within VIDA (Baird 1997; Laven and others 1997; Rizvi
and others 1997; Smith and others 1997; Winter 1997). In this regard a number of small
studies of ovine CLA have been conducted in the UK in recent years. A postal survey
was organised in 2000 amongst members of the Sheep Veterinary Society and of three
unnamed terminal sire Breed Societies. Recipients were questioned about their
experiences of CLA between the years 1990 and 1999 (Binns and others 2002). In this
study 18% of the 264 veterinary surgeons that responded, had encountered the condition
in sheep at least once during the period. Approximately 45% of the sheep breeders had
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seen abscesses within their flocks. However only a relatively few farmers (14%) had
had these lesions investigated - although when this was done three quarters of cases
were confirmed as CLA. Although this postal survey was acknowledged to suffer from
a lack of statistical power (due to a low response rate), the authors did conclude that the
prevalence and incidence of the disease in the UK was increasing.
The Veterinary Laboratories Agency (VLA) conducted two bacteriologically based
surveys of CLA in sheep (Mechie 1998). In the first survey a free bacteriological
screening service was established for farmers, operated through their private veterinary
surgeons. In the second scheme, swabs from abscesses identified in sheep carcases at
meat inspection were submitted by the Meat Hygiene Service (MHS) to the VLA for
culture. In each case the number of submissions was relatively low. Although several
new flock outbreaks were identified through the farm-based survey (and recorded by
VIDA), no cases of CLA were confirmed at the small number of meat plants that
provided swabs (S. C. Mechie, personal communication).
Both "caseous lymphadenitis with emaciation'" and "caseous lymphadenitis
(generalised)'" appear on a list of specified conditions drawn up by the MHS, which
necessitate the total condemnation of an ovine or caprine carcase by meat inspectors
(HMSO 1995; Grist 2006). Among sheep of all ages slaughtered for human
consumption in Great Britain during 2004, lesions considered to be CLA were recorded
at abattoirs on 598 occasions. This represented slightly more than 0.004% of the
approximately 14.9 million sheep carcases inspected (M. Gallego, personal
communication). The condition was not identified in any of the approximately 8,000
goats slaughtered in Britain for human consumption over the same period. These figures
would seem to suggest a very low prevalence of CLA within the British sheep
population. However the majority of sheep carcases examined by meat inspectors are
prime lambs and therefore less than one-year-old at the point of slaughter. This has the
effect of skewing the MHS statistics on CLA towards prevalence at the lower end of the
age spectrum. It is recognised that younger sheep are proportionately less affected by
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the disease (Nuttall 1988; Severini and others 2003; Paton and others 2005) so it is likely
that the level of condemnation at abattoirs is not a true reflection of prevalence within
the sector as a whole.
It had been established that the introduction of clinically or sub-clinically affected
animals is the primary means by which CLA is spread between sheep flocks (Pepin and
others 1994a). Consistently, reports in the United Kingdom have indicated that a
disproportionate number of rams are affected by the disease (Rizvi and others 1997;
Scott and others 1997; Watson and Preece 2001). Disease prevalence of up to 50% has
been recorded in ram groups, whilst the disease has remained undiagnosed amongst the
breeding ewes on the same holding. Indeed, in most flock outbreaks dealt with by SAC
Veterinary Services, the first animals to be identified with CLA have been rams (Baird
2000). Since breeding rams are the animals most frequently sold or loaned between
flocks, sub-clinical or unrecognised infection of males can make them a possible vector
of disease between otherwise closed flocks. In one closely studied Scottish case, CLA
was shown to have been transferred between two flocks following the temporary loan of
one ram for a short period during the breeding season (Baird 2003).
As most lesions occur in the lymph nodes of the head and neck, the feeding of a daily
concentrate ration to rams at a common trough is a possible risk factor. Fighting
behaviour exhibited by rams might also favour the spread of infection through traumatic
injury to the skin of the poll, nose and ears (Rizvi and others 1997). This mode of
transmission is known to be important for the spread ofCLA amongst goats (Williamson
2001).
During the initial emergence of CLA within the UK sheep industry during the 1990's,
animals from the so-called terminal sire breeds formed the vast majority of reported
outbreaks. These breeds, whose primary purpose is in cross-breeding to produce
progeny with superior growth and carcase characteristics, include the main native
terminal sire breed, the Suffolk, and the two most important continental breeds, the
40
Texel and Charollais. The VLA and SAC VS monthly reports and letters published in
the Veterinary Record in the period between 1991 and 2003, confirm that the great
majority of CLA outbreaks in the UK in pedigree flocks of these three breeds (Anon
1996a, 1997; Laven and others 1997; Rizvi and others 1997; Anon 2000, 2003a). At
this time, when commercial flocks were affected by CLA, the index case was frequently
identified as being a ram from one of these breeds (Scott and others 1997; Watson and
Preece 2001). Anecdotal evidence from within the sheep industry also identified these
breeds as being the worst affected by the condition - with the Charollais regarded by
many as being the breed with the highest prevalence ofCLA.
Although VIDA data and reports from other sources indicate an increase in the incidence
of CLA, an estimate of national prevalence is difficult to reach. As an initial step to
determining the significance of CLA to the sheep industry, a prevalence study was
proposed within the terminal sire breeds. Because of the strategic position that this
sector holds at the top of the so-called "breeding pyramid", an assessment of this kind
would provide useful information on the risks facing the wider UK commercial flock.
By studying rams it was possible to further concentrate resources on the population that
was considered to suffer from CLA most commonly. Since terminal sire rams are traded
within and between different sectors of the industry they pose the greatest risk for spread
of the infection.
In the mid-1990's Workers at the Dutch Central Veterinary Laboratory (ID-DLO) and
Dutch Animal Health Service developed an enzyme-linked immunosorbent assay
(ELISA) to detect antibodies to the PLD exotoxin produced by C. pseudotuberculosis
(Laak and others 1992). The test method was later modified to further improve
specificity and sensitivity (Dercksen and others 2000). The assay is an indirect double
antibody sandwich ELISA, employing PLD exotoxin purified from the supernatant of C.
pseudotuberculosis cultures, and uses polyclonal rabbit anti-PLD serum as a capture
antibody.
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In a laboratory trial, which included sera from UK outbreaks of CLA, the calculated
sensitivity of the modified ELISA when used in sheep was 79% ± 5% and the specificity
99% ±1% (Dercksen and others 2000). The relatively low level of test sensitivity
implies a significant number of false negative results in infected sheep. However, the
high specificity of the test means that the likelihood of false positive results is low. As a
consequence of this, the test is considered to be well suited for use in a disease
prevalence study performed at a flock level.
The Maedi Visna (MV) Accreditation Scheme was originally established in the Great
Britain by the State Veterinary Service (SVS) within the Ministry of Agriculture
(Northern Ireland is designated MV free and consequently does not participate in the
Accreditation Scheme). In 1995, testing and administration of the scheme was
transferred from the SVS to the Scottish Agricultural College, under the auspices of the
Sheep and Goat Health Schemes (SGHS). The MV Accreditation Scheme certifies
qualifying sheep flocks as free from maedi visna virus infection, and goat herds as free
from caprine arthritis and encephalitis virus (CAEV) infection. Accredited status within
the Scheme is achieved and maintained on the basis of regular and targeted serological
testing of flocks and herds.
In 2000 a total of 3,185 sheep flocks and goat herds were accredited within the
MV/CAEV Accreditation Scheme - accounting for more than 180,000 individual
animals. The predominant sheep breeds within the scheme at that time are shown in
Table 3.1. The majority of member flocks are from the established terminal sire breeds.
Because MV accreditation is a membership requirement of the respective Breed
Societies, the majority of pedigree flocks in the terminal sire sector are also MV Scheme
members.
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Table 3.1 Sheep and Goat Health Scheme member flocks by breed
(Source SGHS 2001).






Rouge de l'Ouest 84
Bleu du Maine 70
Beltex 51
The basis of the MV Accreditation Scheme is the biennial testing of blood samples from
a statistically significant number of animals in the member flocks. A total of
approximately 68,000 blood samples are submitted for testing each year, from
approximately 1,600 different sheep flocks. Because breeding rams are recognised as an
important vector of infection in the epidemiology of MV, Scheme rules require that at
each flock test, all the entire male sheep of 18-months or older are blood sampled. Thus
blood samples originating from rams compose approximately 10% of the total annual
submissions within the MV Accreditation Scheme. Since the majority ofMV accredited
flocks come from the terminal sire sector, a serological survey of samples from member
flocks provides an effective cross-section of that part of the GB sheep industry. What
follows is a description of a serologically based study of CLA prevalence in Great
Britain employing blood samples taken as part of the MV accreditation scheme, which
was planned and co-ordinated by the author.
Materials and methods
Sample collection was carried out during a period of nine months between March and
November 2000. All MV Accreditation Scheme members submitting blood samples for
testing were asked if, on completion of MV testing, the submitted blood samples might
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be used for additional anonymised research purposes, to which no member objected.
Submitted blood samples were received at the SAC Veterinary Services laboratories in
Dumfries, Edinburgh, Aberdeen and Inverness. At each laboratory serum was collected
from these blood samples taken from male animals within each batch of sampled
animals and stored at -20°C. The frozen sera were sent to the Dutch Central Veterinary
Institute (ID-DLO) at Lelystad, in the Netherlands.
At the ID-DLO these sera were tested blind using the modified ELISA method described
in detail by Dercksen and others (2000). Thus, test results were expressed as net
extinction values (the extinction value with the positive antigen minus the extinction
value with the negative antigen). Values below 100 were considered negative, values of
100-200 were considered inconclusive and values above 200 were considered positive.
When sera gave an inconclusive test reaction in the ELISA, a further Western blot
technique was applied (Kamp and others 2001). The Western blot result was taken as
positive when at least two bands were clearly visible on the test membrane at 31 kDa
and 68 kDa. If the Western blot gave a negative result (no bands), or an unconvincing
result (one or two very weak bands) the sample was classified as inconclusive.
Results
A total of 2,538 serum samples from rams were tested. These samples originated from a
total of 745 different GB flocks. From the sera tested, a total of 244 samples produced
net extinction values in the ELISA test that fell above the positive threshold. In a further
six cases, the initial ELISA net extinction values fell within the inconclusive range, but
were followed by a positive result in the Western blot assay. Thus, from the 2,538
serum samples tested, a total of 250 were considered positive for PLD antibody. This
gave an overall apparent prevalence of seropositive animals within the sample group of
9.93% (with 95% confidence interval of 8.76% to 11.1%; 99% confidence interval of
8.39% to 11.46%).
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A total of 134 flocks had one or more seropositive animals, this being just under 18% of
the flocks sampled. In a total of 48 (or 36%) of these seropositive flocks, there was
more than one ELISA-positive animal. Five or more seropositive animals were detected
in the same flock submission on ten occasions.
In Figure 3.2 the geographical locations of those flocks with seropositive rams are
indicated on a county or regional basis. In Figure 3.3 the number of submitting flocks
that contained seropositive rams is related to the same geographical information. In
Figure 3.4 the proportion of submitting flocks that contain seropositive rams is indicated
for each respective region.
Figure 3.5 indicates the relative proportion of the different sheep breeds amongst the 134
flocks containing seropositive rams. Those flocks recorded in the "mixed breed"
category are composed of animals from two or more different sheep breeds. Those
flocks in the "Suff/Char/Tex" category are composed of sheep from two or more of the
Texel, Charollais and Suffolk breeds only.
45
Figure 3.2 Shaded areas indicate region or county in which flocks containing
seropositive rams are located.
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Figure 3.3 Total number of sheep flocks containing seropositive rams











Figure 3.4 Percentage of submitting sheep flocks containing seropositive rams
identified by county or region.
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Table 3.2 Single breed flocks containing CLA antibody positive rams.









Texel 29 34 31
Charollais 20 24 12
Suffolk 18 21 31
Lleyn 9 10 4
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A total of 85 flocks containing seropositive rams were composed of a single breed of
sheep. The number of positive flocks from the four breeds that gave most positive
results is recorded in Table 3.2. These figures are also given in terms of the total
number of single breed seropositive flocks. Table 3.2 also includes a figure for the
proportion that each breed constitutes within the total membership of the MV
Accreditation Scheme. Seropositive flocks from the other breeds were in such small
numbers as to make this type of calculation meaningless.
Discussion
In this study the population from which sera were collected, namely member flocks of
the MV Accreditation Scheme, represents a relatively small sector of the UK sheep
industry. In examining sera from 745 individual sheep flocks, approximately 0.95% of
the 77,900 sheep units in the UK national flock at that time (Templeton 2001) were
sampled. By the very nature of the MV Scheme, the sampled flocks are almost
exclusively purebred and predominantly from the pedigree terminal sire breeds. Further
to this, by examining only sera from rams within the member flocks, further bias has
been added to the sampling.
Whilst acknowledging the limitations of the sampling technique, the identification of
seropositive animals in some 18% of the tested flocks was greater than anticipated.
Published data from VIDA has indicated an increase in the number ofCLA outbreaks in
Britain. However, information on the particular sheep breeds affected in these outbreaks
and on their location is not easily accessible. This study confirms that at the time the
condition was both geographically widespread within Britain and present within a broad
range of strategically important sheep breeds.
The highly specific nature of the ELISA test, published as 99% +/- 1%, indicates that
few false positive results are likely within the data set. However, the more modest
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sensitivity of the assay suggests that a proportion of the negative results may in reality
come from animals infected with C. pseudotuberculosis. Based on the published
sensitivity of 79% +/- 5%, the overall flock prevalence of 18% indicated in this study
may in reality have been an underestimate of the real situation.
The findings from this study are broadly in line with the consensus of published reports
of CLA within GB and are also consistent with much of the anecdotal evidence from
veterinary practitioners and farmers. In particular the apparently higher rate of
seroprevalence amongst Charollais compared to other terminal sire flocks provides some
support for the perception within the sheep industry that this breed is badly affected by
CLA. The results are also of significance in terms of disease control. The wide
geographical distribution of the infected flocks suggests that there are few if any areas of
the country with freedom from disease.
Examination of the geographical data (Figure 3.2) indicates that infected flocks were
detected in most regions of Britain. In this study the largest numbers of seropositive
flocks were found in the Grampian Region of Scotland and in Dyfed in Wales, with 12
and 11 positive flocks respectively (see Figure 3.3). However, this was biased by a
particularly high SGHS flock membership rate in both those regions. In Figure 3.4
where seropositive flocks are represented as a proportion of total submissions, both
Grampian and Dyfed are seen to have a flock prevalence at a similar level to most other
regions in Britain. There are however four regions where the proportion of flocks that
were seropositive was greater than 40%. This finding is also slightly misleading, since
in each case the total number of submitting flocks from that county or region was very
small. Samples from only one flock were submitted from both Merseyside and
Nottinghamshire, and on each occasion CLA positive samples were detected. One of the
two flocks submitting from Surrey was found to be seropositive for CLA. Perhaps more
significant is the fact that four out of the seven flocks sampled in Lincolnshire contained
seropositive rams.
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No seropositive flocks were recorded in a number of English and Scottish regions. In
some cases this may be explained simply by an absence ofMV Scheme member flocks
in those areas - for example in Greater London and the Western Isles of Scotland.
However, this cannot be used to explain the apparent lack of infection in regions such as
the Scottish Borders and the Lothians. Membership of the MV Scheme is reasonably
strong in those areas and a significant number of flocks did submit sera during the study
period. The author's personal knowledge of sheep flocks in these areas also indicates
that CLA is indeed present there. The conclusion therefore must be that these findings
do reflect a lower overall disease prevalence there.
The results represented in Figure 3.5 indicate that in total 61% of the seropositive flocks
were composed of sheep from one or more of three particular sheep breeds - Texel,
Charollais and Suffolk. It should also be noted that animals from these breeds were
present in other seropositive flocks where a number of different breeds were run
together. Indeed only 34 of the 134 seropositive flocks contained no animals from these
three breeds. Again the composition of the MV Accreditation Scheme is of relevance in
this regard. As Table 3.2 indicates, the finding is less significant than it might at first
appear, since Suffolk, Texel and Charollais flocks make up approximately 70% of the
scheme members. Thus, it can be appreciated that although the Texel breed made up
34% of seropositive flocks composed of a single breed, it constitutes fully 31% of the
membership of the SGHS. More interesting is the fact that the Charollais breed which
makes up 12% of MV Scheme membership produced 24% of the single breed
seropositive category. Also of note is the Welsh Lleyn breed that comprises only some
4% of the SGHS membership but which produced 10% of the single breed seropositive
total. Of the 34 flocks in which none of the three major breeds (Suffolk, Texel and
Charollais) were represented, nine were composed purely of Lleyn animals and a further
six were composed ofmultiple breeds including Lleyn sheep. Many of the information
forms completed by farmers when submitting blood samples for testing in the MV
Accreditation Scheme give only animal identification numbers and no specific breed
information. In such cases identifying the origins of a particular serum sample from a
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flock containing more than one sheep breed is therefore impossible. Because of this
lack of data, it is not possible to ascribe statistical significance to the breed-related
findings.
One possible complicating factor in this study that should be considered is the effect that
vaccination may have had on the results. Two regulated sources of CLA vaccine were
available during the period of the study. Firstly, a number of shepherds who were aware
ofCLA infection within their flock had sought official approval for the manufacture and
use of an "autogenous" vaccine. To enable such a vaccine to be produced, specific
approval must be given by the Veterinary Medicines Directorate (VMD) within DEFRA.
This is done by way of a Autogenous Vaccine Authorisation (AVA) (VMD 2009a). The
bacteria required for the production of these vaccines are obtained directly from infected
flocks - either through the submission to the manufacturing laboratory of swabs from
CLA lesions or sub-cultures of C. pseudotuberculosis isolates from VI Centres. The
manufacturing laboratory then produces a formalin-inactivated, whole cell vaccine,
which may only be used in the flock of origin. An AVA is valid for one year and must
therefore be renewed annually, on application to the VMD, if the owner wishes to
continue using the vaccine. Consultations with the VMD indicate that an AVA
equivalent (known at the time as a Special Treatment Authorisation) was granted for the
production of autogenous CLA vaccine on 15 occasions during the year 2000-01. No
further information on the location and type of flocks using this vaccine is available.
Since autogenous vaccine production employs a crude bacterin of unwashed cells, it
must be assumed that small traces of PLD exotoxin are present within the prepared
vaccine. As a result, an antibody response to PLD is likely to be elicited in the animals
receiving the autogenous vaccinate. The significance of this in relation to this particular
study is the question of whether prior vaccination of sheep with an autogenous CLA
vaccine may have led to a positive ELISA test. There is no published data on the use of
the Dutch ELISA with sera from sheep that have received autogenous CLA vaccine.
However in one published study from the United States the use of an equivalent bacterin
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to inoculate lambs did not elicit a detectable antibody response (Leamaster and others
1987). A similar finding is described in Chapter 7, when a PLD ELISA assay was used
to test sheep receiving an autogenous CLA vaccine and reactivity was equivalent to that
of non-immunised control animals.
The second type ofCLA vaccine available in the UK is that manufactured commercially
by pharmaceutical companies overseas. No such CLA vaccine product is currently
licensed for use in the United Kingdom. However some three flocks in England were
granted what was then known as an Emergency Product Licence (EPL) by the
Veterinary Medicines Directorate in the late 1990's. These twelve-month licences
allowed for the importation and use of a CLA vaccine Glanvac™ manufactured in
Australia by Commonwealth Serum Laboratories. However the Veterinary Medicines
Directorate ceased issuing Emergency licences for Glanvac™ shortly afterwards, citing
concerns that importation under EPL legislation might discourage an application for full
product licence in the UK. More recent anecdotal evidence suggests that some sheep
farmers are privately importing Glanvac™ into the UK without the required Special
Treatment Certificate (VMD 2009b), although the use of such CLA vaccine obtained
from overseas sources, which do not carry a relevant UK licence remains illegal.
Glanvac™ and similar products are toxoid vaccines which stimulate a highly specific
immune response to the PLD exotoxin produced by the C. pseudotuberculosis organism
(Paton and others 2003). Sera taken from animals that are known to have been
vaccinated with Glanvac™ has not been tested with the ELISA used in this study.
However, since PLD is highly conserved, it is likely that prior use of this proprietary
CLA vaccine would lead to a positive test result in the Dutch ELISA. Again
unpublished data based on the use of a similar ELISA supports this hypothesis (M. C.
Fontaine, personal communication). It is therefore possible that the unregulated use of
imported vaccine may have led to a number of positive results detected within this study.
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It is therefore important to consider the likely effects of vaccine use on the results of this
current study. By definition, an autogenous vaccine is used only in a flock that is
already infected by disease. It is clear that in any event only a small number of flocks in
the UK have used an autogenous vaccine against CLA. Similarly, although the private
importation of CLA vaccine is feasible, it is acknowledged to be an expensive exercise.
It is therefore likely to be undertaken only by farmers who are aware of an existing CLA
problem within their flocks. By its nature the unregulated use of imported commercial
vaccine is impossible to quantify, but it also seems unlikely that many flock-masters
would have gone down that route. In addition, anecdotal reports suggest that the
importation of proprietary CLA vaccines has only recently become widespread, but that
it was at a much lower level in the period 1999-2000.
Thus the use of either autogenous or proprietary vaccines may conceivably have had the
effect of increasing the total number of seropositive rams, but is unlikely to have
increased the number of flocks containing seropositive animals. Therefore, although the
confounding effect of vaccination may have played some part in artificially increasing
the calculated seroprevalence in this study, the overall effect is considered to be
negligible.
When the results of this study are applied to a model of infection in which CLA is
commonly introduced to naive flocks by sub-clinically infected breeding replacements,
the potential for further spread within the UK appears to be considerable. A high
prevalence rate within the terminal sire breeds, coupled with the tendency for rams to be
disproportionately affected by the disease, suggests that the spread of infection will be
accelerated by widespread distribution of these sires through the rest of the sheep
industry. In the UK the majority of rams are bought at a relatively small number of
high profile ram sales. These attract consignors and buyers from outwith the immediate
region, with the result that purchased rams may be transported very large distances.
Analysis of the seropositive flocks in this study indicates that all the dominant terminal
sire breeds are affected by the infection and that disease prevention is unlikely to be
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achieved by purchasers through the selection of one breed over another. The
commercial sector of the industry, which is the recipient of the majority of sale rams,
must therefore be at great risk of buying-in infection in the form of sub-clinically
affected animals.
The results of this study indicate a need to raise awareness of the disease within both the
pedigree and commercial sectors and emphasise the urgent requirement for a reliable
means of controlling the spread of infection. The data, whilst describing the extent of
infection within one important sector of the industry, also provides an encouragement
for a larger scale prevalence study within the wider sheep industry.
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Chapter 4: THE EFFECTS OF COMMERCIAL DAIRY




To test the ability of C. pseudotuberculosis to survive conventional pasteurization
methods, goat's milk that had been inoculated with the bacterium was cultured after
being passed through a pasteurization plant. Batches of ultra heat-treated (UHT) goat's
milk were inoculated with C. pseudotuberculosis to concentrations of approximately
102, 103, 104 and 105 colony forming units (cfu) per millilitre of milk. In order to
simulate natural caseous lymphadenitis infection, a further batch of milk was inoculated
with a solution containing purulent discharge recovered from a caseous lymphadenitis
lesion. Each batch of inoculated milk was passed through a pilot pasteurization plant
used in milk hygiene research and equivalent in characteristics to full-scale commercial
pasteurization equipment.
Conditions used in pasteurization during this experiment were equivalent to the UK
legal minimum, in which the milk was rapidly heated to 72°C and held at that
temperature for 15 seconds, before being cooled. Twenty-four hours after
pasteurization, samples of each batch of milk were inoculated directly onto blood agar
and incubated at 37°C for 48 hours. In a process of enrichment, separate samples of the
pasteurized milk were placed in a brain heart infusion broth and maintained at 37°C for
72 hours, before aliquots were used to inoculate blood agar, which was incubated for a
further 48 hours. Any bacterial colonies noted on the blood agar after incubation were
differentiated using standard microbiological techniques. No growth of C.
pseudotuberculosis was identified on culture of samples from any batch of pasteurized
milk. It is therefore concluded that standard commercial pasteurization techniques are
effective in killing C. pseudotuberculosis in milk.
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Introduction
The visceral form of C. pseudotuberculosis infection in domestic animals can include
the development of lesions within the mammary gland. Although occasionally recorded
in other parts of the world (Adekeye and others 1980; Hommez and others 1999),
mastitis in dairy cows due to C. pseudotuberculosis has been identified as a problem of
particular importance in Israel (Yeruham and others 1997). The condition is prevalent in
many Israeli dairy herds, where outbreaks may appear sporadically or in epidemic form.
(Yeruham and others 2003a). The milk production of affected quarters decreases and
may cease completely, while somatic cell counts increase dramatically. The organism is
readily isolated from the milk ofmammary glands suffering acute, chronic and subacute
forms of the disease. In general the condition in dairy cows responds poorly to
antibiotic treatment (Shpigel and others 1993). Similar mastitis has been induced in
dairy cows by the inoculation of as few as 2,000 colony forming units (cfu) of C.
pseudotuberculosis into the teat canal (Aroch and others 2003).
A primary mastitis of the form recognised in cattle has also been reported in sheep and
goats: however, in those species it is recorded very infrequently (Brown and Olander
1987). A rather more common form of infection in goats and sheep is abscessation of
the mammary gland (Figure 4.1), with abscesses forming following a primary mastitis,
or more often as the result of extension from an adjacent foci of infection (Burrell 1981).
Frequently the site of this initial infection is one or both of the supramammary lymph
nodes. Rather than these lesions progressing to discharge their purulent contents
externally, they can rupture internally, with the release of infected material into the
mammary tissue itself. One or more foci of infection are then established within the
udder itself. In such cases the organism is easily identified in milk withdrawn from the
affected quarter (Schreuder and others 1990).
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Figure 4.1 Mammary gland abscess due to C. pseudotuberculosis infection in an adult
ewe (picture taken by author).
The first published case of human infection by C. pseudotuberculosis was reported in
1966 (Lopez and others 1966). Subsequently, most reported zoonotic infections have
been associated with direct contact with clinically affected animals by farmers, shearers
or abattoir workers (Peel and others 1997). Significantly, however, one recorded case of
human infection has been associated with the consumption of raw goat's milk by a city
resident with no other reported direct or indirect contact with farm animals (Goldberger
and others 1981).
Potential contamination of milk by pus from CLA lesions has been a concern in the
dairy goat industry of the Netherlands, where an eradication and control scheme was
established to reduce the risks (Dercksen and others 1996). As CLA has emerged as a
significant disease within the goat industry of the United Kingdom, producers that are
anxious to ensure the quality of their product have expressed similar concerns. In
particular, assurances have been sought that the process of pasteurization currently
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employed in dairies is sufficient to remove all viable C. pseudotuberculosis organisms
from milk for sale.
Most commercial milk pasteurization in the UK is carried out using the High
Temperature Short Time (HTST) method, where continuously flowing milk is heated to
a temperature of 71.7°C or above. It is held at this temperature for a minimum of 15
seconds and then immediately cooled to a temperature not more than 10°C. This
procedure is designed to ensure the microbiological safety of the milk and to enhance its
effective shelf life.
The routine pasteurization of milk was originally established to remove the risk of
potential zoonotic infection by Mycobacterium bovis, the cause of bovine tuberculosis.
Although the majority of pathogenic and spoilage bacteria are rendered non-viable by
this process, a small number of so-called thermoduric organisms are capable of
surviving conventional pasteurization techniques. The types of bacteria most commonly
recognized as possessing this ability are the spore-forming Bacillus genus and the
coryneform group ofbacterial organisms (Muir 1990).
In recent years, concern has focused on the possibility that Mycobacterium avium ssp.
paratuberculosis (Map), the cause of Johne's disease in cattle and other species, may
survive dairy pasteurization and remain viable in commercial milk supplies (Grant and
others 2005). The factors influencing this resistance to heat treatment are not well
understood, but may include the number ofMap present within the milk, the tendency of
the organism to form large clumps in solution, and the protection from heat afforded by
the thick mycolic acid layer around the cell (Klijn and others 2001; Grant and others
2005). C. pseudotuberculosis is known to possess important characteristics in common
with the mycobacteria. It has been suggested that the similar waxy cell wall mycolic
acid enables the organism to survive for extended periods within the environment (West
and others 2002), a feature common to other members of the actinomycetaceae. The
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tendency of the organism to form clumps in solution is another feature that could
enhance the thermoduric properties of C. pseudotuberculosis.
Objectives ofthis study
Under certain circumstances, viable C. pseudotuberculosis organisms may appear in
milk destined for human consumption and produced by cattle, goats or sheep. On this
basis the author considered it important to establish whether the normal process of
commercial pasteurization would kill C. pseudotuberculosis present in otherwise sterile
milk samples. As part of this objective, any potentially protective effect resulting from
the clumping of C. pseudotuberculosis was assessed by increasing the numbers of
bacteria used to inoculate milk samples in log-fold increments. In addition, any thermo-
protective effect resulting from the encasement of C. pseudotuberculosis within pus was
assessed by inoculating milk directly with the contents of active CLA lesions.
Materials and methods
The following experimental procedure was performed on two different occasions.
C. pseudotuberculosis strain 3/99-5 was passaged three times on blood agar base
(Oxoid, Basingstoke, Hampshire, England) supplemented with 5 % (v/v) of citrated
sheep blood (BA), at 37°C for 48 hours. Anti-microbial sensitivity testing of the isolate
was performed in the established manner by the use of antibiotic infused discs (Mast
Diagnostics, Merseyside, U.K.) establishing a resistance in the isolate to streptomycin
sulphate. A growth of C. pseudotuberculosis strain 3/99-5 was then suspended in
phosphate buffered saline (PBS) and the concentration of organisms determined using an
ATB Densimat densitometer (bioMerieux, Basingstoke, UK) and the McFarland
standard (Quinn and others 1994b). This solution was then used to inoculate 20 litre
batches of commercially purchased ultra heat-treated (UHT) goat's milk, to a
concentration of approximately 102, 103, 104 and 105 cfu/ml ofmilk.
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A fifth batch of UHT goat's milk was inoculated with a solution of PBS containing pus
recovered from a natural CLA infection - this being an ovine parotid gland abscess for
the first experimental run and a caprine udder abscess for the second. This less
quantitative approach of introducing a purulent discharge meant that the final effective
concentration of C. pseudotuberculosis organisms within the milk was significantly
different between the two experimental runs. During the first experiment the addition of
purulent discharge produced a final concentration of organisms within the milk of
approximately 6 x 103 cfu/ml, while on the second occasion a concentration of 8 x 104
cfii /ml was achieved.
Each inoculated batch of UHT milk was passed through a pilot pasteurization plant
(Figure 4.2) comparable in characteristics to full-scale commercial equipment. This
plant was located at the Hannah Dairy Research Institute, Ayr, Scotland where it was
constructed for the purposes of milk hygiene related research and operated in line with
industry standards. The heat exchanger plate pack, holding sections, temperature,
pressure and flow monitoring probes and logging equipment were externally accredited
by Honeywell Control Systems Ltd. (Glasgow, UK) and Pressure Technical Services
Ltd. (Manchester, UK), respectively. For this experiment, the pasteurizing plant was
configured such that homogenization was applied upstream of heat-treatment as in a
conventional industrial plant. The pumping speed, and hence flow rate through the heat
exchanger was controlled such that the milk was held at 72°C for 15 seconds before
being rapidly cooled.
After the pasteurization plant was brought up to the correct temperature and the flow
rate stabilised for the specified conditions, the five batches of inoculated milk were
introduced to the plant in succession. The milk sample containing the lowest number of
organisms (102 cfu/ml) was pasteurized first. Water was then passed through the plant
to provide a visible break before the next batch of milk. Subsequent batches of milk
containing progressively higher concentrations of bacteria were passed though the
machine in the same way, with the milk inoculated with pus in PBS being processed last.
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During the pasteurization of each batch, five separate 500 ml samples of the pasteurized
milk were collected. These samples were immediately cooled on ice and then
refrigerated for 72 hours at 4°C. This period of refrigeration was included to allow for
the recovery of any heat-damaged but viable bacteria, before the commencement of
bacterial culture.
Figure 4.2 Pilot pasteurisation plant used during this experiment
at Hannah Dairy Research Institute, Ayr (picture taken by author).
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Five separate 200 pi aliquots from each of the 500 ml samples of pasteurized milk were
used to inoculate blood agar plates (BA; Oxoid, Basingstoke, Hampshire, England),
which were then incubated for 48 hours at 37°C. To enhance detection of viable
bacteria within pasteurized milk, 100 ml of each 500 ml pasteurized sample was
removed and supplemented with 800 ml of brain heart infusion broth (BHI; Oxoid,
Basingstoke, Hampshire, England). To reduce the potential effects of bacterial
contamination, streptomycin sulphate was included within the broth at a concentration of
5 pg/ml. Incubation at 37°C and shaking was then performed for a period of 72 hours,
after which five 200 pi aliquots of the BHI/milk mixtures were inoculated onto BA
plates and incubated for 48 hours at 37°C. Any bacterial colonies observed on BA
plates after incubation were differentiated using standard microbiological techniques,
including observations of colony morphology, Gram-staining and microscopic analysis.
As a positive control, a 10 ml sample from each 20 litre batch ofmilk was retained after
the milk had been inoculated, but prior to pasteurization. Five 200 pi aliquots of each
retained milk sample were inoculated onto BA plates and incubated as above. Bacterial
colonies observed after incubation were again differentiated using standard
microbiological techniques. In addition, the API Coryne diagnostic test kit (bioMerieux,
Basingstoke, UK) was used, according to the manufacturer's supplied instructions, to
positively identify bacteria presumptively identified as C. pseudotuberculosis.
Results
For each of the milk samples inoculated with 102, 103, 104 or 105 cfu/ml, or pus from a
CLA lesion, no growth of C. pseudotuberculosis was evident following pasteurization,
either on direct culture of the milk samples or on culture of pasteurized samples
supplemented with BHI. In addition, there was no growth of C. pseudotuberculosis
following culture of any sample following enrichment in BHI broth. In contrast, the
culture of samples of the inoculated milk taken prior to pasteurization (positive control
samples) produced a moderate to heavy bacterial growth in all cases. These bacterial
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colonies were subsequently positively identified as C. pseudotuberculosis using API
Coryne test, confirming the viability of the initial inoculum.
Discussion
In the duplicate experiments conducted, there was no evidence that C.
pseudotuberculosis in milk could survive pasteurization using conditions equivalent to
the statutory minimum for milk sold in the UK, i.e. heating to a temperature of 71.7°C
for at least 15 seconds. Not only was this the case for milk inoculated with bacterial
cultures prepared in the laboratory, but also for milk containing the purulent discharge of
CLA lesions. This latter situation was felt to most closely replicate natural infection in
dairy cattle, goats and sheep, where the organism enters the milk secondary to mastitis
or following the extension of infection from an abscessed lymph node.
Where milk samples were inoculated with laboratory cultured organisms suspended in
saline, bacteria were likely to be present as single cells and more frequently in larger cell
clumps. In contrast, where purulent discharge from CLA lesions was used for
inoculating the milk, a proportion of the C. pseudotuberculosis organisms were likely to
have been located intracellularly, within monocytes and macrophages (Pepin and others
1994b). In addition, these would have been surrounded by a matrix of living and dead
leucocytes, cellular debris and serum. While this additional coating might have been
thought to provide the organisms with a further degree of protection during the
pasteurization, the results of this experiment indicate that this was not the case.
These results therefore confirm that the current statutory requirements for pasteurization
in the UK are effective in protecting public health. In reality, since 1998 the majority of
commercial dairies processing goat's milk for the retail trade employ heating at 72°C for
a total of 25 seconds, rather than the legal minimum of 15 seconds. This is largely on
the insistence of major supermarket clients, in response to the perceived risks of Map
survival within pasteurized milk products. Clearly, this extended heating time has the
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effect of reducing still further any possibility that C. pseudotuberculosis organisms
might survive the pasteurization process.
Certain other pasteurization processes are currently employed within the sheep and goat
dairy industry. These include batch pasteurization ofmilk at temperatures of 83°C for
15 minutes, in the production of yoghurts and fromage frais. For the production of ice
cream, a temperature of 65.6°C is maintained for 30 minutes. In each of these cases the
potential for the survival in milk of C. pseudotuberculosis is negligible. However,
cheese manufacturers may use a process of thermising, which reduces the number of
viable bacteria within the milk by heating to 65°C for 15 seconds in a continuous flow
pasteurization plant. Others use raw milk from sheep and goats as the basis for cheese
making. A laboratory study that simulated commercial cheddar cheese-making using
raw bovine milk, established that Map was concentrated 10-fold in the production
process (Donaghy and others 2004). Depending upon the type of cheese being
produced, bacterial survival can vary with moisture content, pH, salt content,
temperature and the antagonistic effects of starter bacteria and other organisms. It is by
no means certain therefore, that any C. pseudotuberculosis that may be present within
raw milk for cheese manufacture, would survive in sufficient numbers in the finished
product to represent a potential risk to human health. However, in the absence of
published findings in this area, it would be sensible for producers of such products to be
aware of the possible risks presented by CLA and to take steps to control the infection in
milking animals.
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Chapter 5: CONTROL OF CASEOUS LYMPHADENITIS IN
SIX LOWLAND SHEEP FLOCKS BASED ON CLINICAL
EXAMINATION AND REGULAR ELISA TESTING.
Summary
In an effort to control the spread of infection within a number of CLA-affected flocks,
sheep on six holdings were serologically tested at regular intervals using an antibody
ELISA with a specificity of 99% +/- 1% and a sensitivity of 79% +/- 5%. Western blot
assays that detected antibodies to the PLD exotoxin of C. pseudotuberculosis were used
as a further test for ELISA inconclusive results. Owners were advised that any sheep
demonstrating clinical signs of CLA or testing positive for PLD by ELISA and/or
Western blot be removed from the flock.
Of the six trial flocks, one was dispersed after only two blood tests and in another the
recommendations for CLA control were not followed and infected animals were retained
within the flock. In the remaining four flocks the application of the testing regime and
other advice enabled the disease to be controlled to such an extent that the appearance of
new clinical cases of CLA was effectively halted, this remaining the case for up to five
years after the end of the trial. In two of these flocks a small number of seropositive
animals were detected at the end of the process. However, on the other two holdings all
sheep were seronegative in the final two flock tests, consistent with the complete
eradication of infection. On this basis it is suggested that a test and cull programme may
be considered a legitimate and effective form of disease control in some flocks affected
by CLA.
Introduction
Due to the high level of sub-clinical CLA infection in sheep, efforts at removing those
individuals showing external signs of disease are ultimately unable to establish control
of the disease. Serological tests based on the detection of antibody to PLD have been
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explored as a means of controlling the disease in sheep and goats through the
identification and removal of infected carrier animals (Sutherland and others 1987;
Menzies and Muckle 1989; Muckle and others 1992; Ter Laak and others 1992). Most
promising in this respect was felt to be the development of enzyme-linked
immunosorbent assay (ELISA) methods (Menzies and others 1994).
Initially the antigens employed in CLA-diagnostic ELISAs were preparations of
C. pseudotuberculosis cell wall or exotoxin derived from culture supernatants (Maki and
others 1985; Sutherland and others 1987; Kuria and Holstad 1989b; Ellis and others
1990; Sting and others 1998). In the majority of these assays, test sensitivity was good
but specificity was relatively poor, reflecting potential cross-reactions with extraneous
protein molecules present within the antigen preparations. The developers of more
recent ELISAs have claimed specificity and sensitivity levels that would be sufficient to
allow their use as diagnostic tools in the field. Improvements have included the use in
ELISAs of purer sources of PLD antigen, such as that derived by recombinant
technology from E. coli containing a plasmid bearing the pld gene (Menzies and others
1994). In that paper the assay had a reported test sensitivity of 86.3% and the specificity
of 82.1%. Another ELISA method was reported to have test specificity of 100%, with
the sensitivity of detection of total antibody being 71% (95% confidence interval 63% -
78%), and the sensitivity of detection of IgG antibody to C. pseudotuberculosis being
83% (95% confidence interval 76% - 89%) (Binns and others 2007). The sensitivity of
the IgG antibody assay was believed to be higher because of the greater affinity of IgG
class antibodies compared with the IgM antibodies also detected by the total antibody
ELISA. However, the ELISA coming closest to the requirements of a diagnostic test
was developed in the Netherlands (Ter Laak and others 1992) and was later refined to
further improve specificity and sensitivity (Dercksen and others 2000). This assay is an
indirect double antibody sandwich ELISA, employing PLD exotoxin purified from the
supernatant of C. pseudotuberculosis cultures, and uses polyclonal rabbit anti-PLD
serum as a capture antibody. The improved method is calculated to have a specificity of
99% +/- 1%, and a sensitivity of 79% +/- 5% in sheep. The very high specificity of this
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ELISA, but the relatively low sensitivity, make the assay suitable for a test and cull
scheme as described in this study.
The ELISA method originally described by Ter Laak and others (1992) and the
improved method described by Dercksen and others (2000) has been used as a tool in an
established disease eradication and control scheme in the Dutch dairy goat industry. In
the latter paper a specificity of 98% +/- 2% and sensitivity of 94% +/- 3% was reported
for the improved ELISA when used in goats. A scheme for the eradication of CLA and
subsequent accreditation of disease freedom has been available to goat producers in
Holland for a number of years (Dercksen and others 1996). In 1996 a total of 46 herds
and 11,000 goats had been accredited and trade in stock was then established between
members. By 2007 the membership of the scheme had risen to 605 herds, representing
approximately 220,000 accredited goats.
A similar health scheme was proposed for the control and eradication of CLA in the
smaller Dutch sheep industry using the earlier version of the ELISA test (Schreuder and
others 1994), although problems of test sensitivity in some flocks led to the closure of
that scheme (Dercksen and others 2000). The test was subsequently modified and the
sensitivity in sheep improved by Dercksen and others (2000). However, no further
attempts have been made to establish a CLA Health Scheme in what is a relatively small
Dutch sheep industry.
Material and methods
(a) Sheep and management
Sheep from six different flocks were clinically examined and blood sampled for testing
using an ELISA for CLA at regular intervals over a period of four years. Three of these
flocks were located in Scotland, one in England and two in Northern Ireland.
Farm A was a mixed enterprise on around 22 hectares, farming a small herd of pedigree
Charolais cattle and a flock of pedigree Suffolk sheep. At the start of the project period
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the trial flock was comprised of approximately 50 breeding ewes and was closed in
terms of management, apart from the periodic purchase or hiring of rams. A laboratory
diagnosis ofCLA was made for the first time in February 1997. The source of the CLA
infection was considered to be a shearling ram, which had been purchased during the
autumn of 1996. After a period in the trial and towards the end of 1999 the flock owner
decided to cease active farming. A dispersal sale of the entire Suffolk sheep flock took
place shortly thereafter.
Farm B consisted of a suckler cattle herd, a commercial sheep flock and a pedigree
Suffolk sheep flock, the latter supplying rams for home use and for sale. A diagnosis of
CLA was made within the Suffolk flock for the first time in March 1997. The source of
the CLA infection was believed to be a shearling ram that had been leased for a period
of six months to flock A. On its return to flock B this sheep and other in-contact rams
developed clinical signs of CLA, which were confirmed by cultures. In 2000 stock
numbers on the farm were reduced and a flock of approximately 60 breeding Suffolk
ewes retained.
Farm C consisted of a pedigree Suffolk flock of approximately 75 breeding ewes and a
small livery stable for horses and ponies on approximately 10 hectares. CLA was
diagnosed for the first time within this flock in 1999. During the process of establishing
the Suffolk flock, breeding sheep had been purchased from a number of sources and it is
believed that the infection gained entry to the farm during this process of expansion.
Following the initial bacteriological diagnosis ofCLA infection, the flock was thereafter
managed under essentially closed conditions.
Farm D had a small pedigree Charollais sheep flock of some 20 breeding ewes, as part
of a much larger farming enterprise. The purpose of this flock was to produce rams for
use in the larger commercial flock, with any additional sheep being sold for breeding.
The first diagnosis of CLA was made in 1997 and the infection was believed to have
entered the flock through purchased breeding stock within the previous few years.
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Farm E consisted of a flock of approximately 60 breeding pedigree Suffolk ewes kept on
a smallholding with no other livestock. The first diagnosis ofCLA was made in January
1999. The affected sheep had been purchased into the flock in November 1998.
Farm F consisted of a Charollais flock of 25 breeding ewes, which although on the same
holding, were managed at separate premises from a commercial flock of some 190
crossbred ewes. The first cases of CLA were diagnosed in July 1999 and involved two
shearling rams, both of which had been born on the farm. A further five cases were
confirmed in rams between August and November 1999. It was considered that CLA
had entered the flock with sheep purchased over the previous two years.
At the commencement of the trial period the respective owners were given specific
advice on management changes likely to reduce the spread of CLA infection within their
flocks. This included the immediate isolation of suspect clinical cases pending
bacteriological confirmation, removing the suspect animals from the rest of the flock and
maintaining them in an area where nose-to-nose contact was not possible. Treatment of
housing and pens that had held known infected sheep, by means of steam cleaning and
application of a disinfectant solution from the Defra approved list at specified
concentrations (Anon 2009a) was also recommended. Guidance was given on the
application of hygienic measures during procedures likely to cause damage to the skin,
such as castration, shearing and tattooing. Finally, any sheep already diagnosed with
CLA were required to be either culled, or managed separately for the duration of the
trial.
(b) Clinical examinations
Each sheep flock was visited at intervals of approximately six months over the trial
period of three to four years. On the holdings that were in the trial during 2001, the
application of regulations related to the foot-and-mouth disease epizootic of that year
meant that no farm visits could take place between February and November.
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All trial sheep were individually identified through the recording of ear marks/tags and
examined for clinical signs of CLA. This examination involved the palpation and visual
inspection of the superficial lymph nodes of the head, neck and body. Any sheep
showing enlarged or abscessed lymph nodes were isolated, and where possible, samples
of purulent discharge were taken for bacterial culture. At each visit every sheep over six
months of age was clinically examined in this way, after which it was blood sampled.
Blood samples were taken from sheep on farm A on two occasions during 1999. The
trial was then discontinued following the sale of the flock. Blood samples were taken
from sheep on farm B on seven occasions between May 1999 and June 2003; on farm C
on eight separate occasions between July 1999 and May 2003; on farm D on five
occasions between July 1999 and August 2003; on farm E on five occasions between
February 2000 and July 2003; and on farm F on five occasions between May 2000 and
August 2003.
(c) Serology
Sera were examined blind at the Dutch Central Veterinary Institute (ID-DLO), Lelystad,
in the Netherlands using the refined ELISA method as described by Dercksen and others
(2000). On the basis of the ELISA results samples were designated as negative,
inconclusive or positive. When sera gave an inconclusive test reaction in the ELISA, a
further Western blot technique was applied (Kamp and others 2001). The Western blot
result was taken as positive when at least two bands were clearly visible on the test
membrane at 31 kDa and 68 kDa. If the Western blot gave a negative result (no bands),
or an unconvincing result (one or two very weak bands) the sample was classified as
inconclusive. All sheep classified as seronegative or inconclusive were retained within
the flock and re-sampled in the normal manner at the next flock test. All sheep that were
considered to be seropositive by ELISA and/or Western blot were recommended to be
immediately culled or removed from the flock and managed separately.
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(d) Pathology
During the course of the trial any sheep identified as CLA-positive on the basis of
clinical examination or serology were either isolated from the rest of the trial flock or
culled. A sample of the sheep that were clinically affected and ELISA-positive were
subjected to postmortem examination. In addition, where flock management allowed, a
number of the ELISA-negative cull sheep were also necropsied. A standard operating
procedure was adopted to ensure consistency. Sheep originating from flocks A, B, C
and D were examined by the author at the Scottish Agricultural College Veterinary
Services, Disease Surveillance Centre, St Boswells. Sheep from flocks E and F were
examined by a veterinary colleague at the Agri-Food and Biosciences Institute,
Veterinary Sciences Division, Omagh. Each sheep was condition scored and a general
external examination of the carcase was undertaken, with particular reference to any
enlarged superficial lymph nodes or purulent sinus discharges. A detailed necropsy
examination was then undertaken, once again with particular reference to carcase lymph
nodes and to the lungs.
Any suspect lesions, and in addition all prescapular, submandibular, parotid,
retropharyngeal and a portion of broncho-mediastinal lymph nodes (LN), were cultured
and examined as described by Cowan and Steel (1993). Tissues not showing gross
lesions of CLA were first dipped in 40% alcohol and flamed to remove any surface
contaminating organisms. They were then macerated in nutrient broth using a
mechanical stomacher (Wolf Laboratories Ltd, York), prior to plating-out onto blood
agar. Plates were then incubated aerobically at 37°C and inspected at 24 and 48 hours.
If C. pseudotuberculosis was present, visible growth tended to be limited at 24 hours,
with colonies reaching a diameter of some 1 to 2 mm at 48 hours. Presumptive
identification of recovered bacteria was made on the basis of colony morphology,
catalase activity and microscopic examination following standard Gram-staining. A
definitive identification of the organism was made using the Analytical Profile Index
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Flock A: Prior to the first round of clinical examinations in this flock, eleven sheep had
clinical signs consistent with CLA and had been removed from the flock (Figure 5.1).
No clinically suspect sheep were detected at the first or second rounds of blood testing
and clinical examination in this trial.
Figure 5.1 An adult Suffolk ewe from flock A showing signs of a CLA lesion
in the region of the parotid lymph node (picture taken by author).
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Flock B: Prior to the first round of clinical examinations in this flock, four sheep had
been confirmed as clinically and bacteriologically positive for CLA. A further three
sheep had clinical signs consistent with CLA at the first round of testing. No further
clinically positive sheep were detected in subsequent rounds of testing.
Flock C: Immediately prior to the first round of clinical examinations in this flock, one
sheep had been confirmed as clinically and bacteriologically positive for CLA. At the
first round of testing a further thirty sheep had clinical signs consistent with CLA. No
further clinically positive sheep were detected in subsequent rounds of testing.
Flock D: Prior to the first round of clinical examinations in this flock, three sheep had
been confirmed as clinically and bacteriologically positive for CLA and a further one
animal had clinical signs consistent with CLA at the first round of testing. The owner of
the flock continued to report visible evidence of disease throughout the trial period.
Flock E: Prior to the first round of clinical examinations in this flock, five sheep had
been confirmed as clinically and bacteriologically positive for CLA. There were no
further clinical cases ofCLA detected throughout the trial period.
Flock F: Prior to the first round of clinical examinations in this flock seven sheep had
been confirmed clinically and bacteriologically positive for CLA. Thereafter there were
no further clinical cases ofCLA detected throughout the trial period.
Contact with the owner of flock B confirmed that the sheep flock remained clear of
clinical evidence ofCLA until it was sold in 2005. Contact with the owners of flocks C,




The results of the serological examinations in the six trial flocks are summarized in
Table 5.1. In all four flocks where testing was completed and management advice on
control of infection was followed the serological incidence of infection declined. In
flocks B and C seroprevalence reduced to such an extent that at the final two flock tests
no seropositive sheep were detected. On the final test, two sheep were seropositive in
both flocks E and F. These four animals were subjected to postmortem examination and
CLA lesions were not found. The decline in seroprevalence apparent in flock C during
the course of the trial is indicated in Figure 5.2. The owners of flock D failed to follow
advice given on the removal of seropositive sheep and as a result both seroprevalence
and incidence of clinical signs increased during the course of the trial. This steadily
rising seroprevalence is indicated in Figure 5.3.
(c) Pathology
A total of 88 postmortem examinations were undertaken on sheep of known serological
status from the six trial flocks. Of these, 28 carcases were found to have gross evidence
of abscessation, subsequently confirmed as CLA by bacteriology. CLA lesions were
most commonly seen in the lungs (n=13), parotid lymph node (n=10), broncho¬
mediastinal lymph node (n=8) and prescapular lymph node (n=3) (Table 5.2). In
summary, of the 13 sheep with lung abscesses, seven also had lesions in at least one
other superficial or visceral lymph node site or within the parenchyma of the liver. Half
of the animals examined showed no macroscopic evidence of disease (Table 5.3).
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Table 5.2 Site of caseous lymphadenitis (CLA) lesions in 28 sheep.
Site of culture +ve CLA lesions Number (%) of sheep with CLA
lesions (N=28)
Lungs 13 (46%)
Parotid lymph node 10(36%)
Broncho-mediastinal lymph node 8 (29%)
Prescapular lymph node 3 (11%)
Submandibular lymph node 2 (7%)
Liver 2 (7%)
Prefemoral lymph node 1 (4%)
Table 5.3 Distribution of caseous lymphadenitis (CLA) lesions in 28 sheep.
Distribution of culture +ve CLA lesions Number of sheep (%)
Internal CLA lesions only (lungs and/or visceral lymph nodes) 14 (50%)
CLA lesions in superficial lymph nodes only 8 (29%)
Both internal and superficial CLA lesions present 6(11%)
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Figure 5.2 Seroprevalence of CLA in flock C during course of the eradication trial.
Blood sampling round




Since the arrival of C. pseudotuberculosis in the UK the prevalence of CLA within the
sheep industry has risen inexorably. The proprietary vaccines used so widely to control
CLA in other parts of the world have not been licensed for use in many European
countries including the UK. Farmers concerned about the spread of infection between
and within flocks have therefore had to rely on clinical examination alone to identify
affected sheep.
Whilst serological testing has been employed as a research tool in a number of other
countries (Chikamatsu and others 1989; Kuria and Holstad 1989a; Ellis and others 1990;
Sutherland and others 1992), the use of blood tests to control and eradicate disease has
not been practised widely. The development of an ELISA method for detecting
antibody to the PLD exotoxin of C. pseudotuberculosis (Ter Laak and others 1992) led
to the establishment of a CLA health scheme within the Dutch dairy goat sector
(Dercksen and others 1996). This scheme established a means whereby the owners of
infected goat herds could eradicate CLA, with the ultimate aim of becoming an
accredited CLA-ffee herd.
In this study it has been established that the regular use of an ELISA to test and remove
positive sheep, in association with clinical inspections and changes in farm management,
can greatly reduce the incidence of CLA in affected UK flocks. Additionally, the
finding that 50% of sheep with gross lesions showed only the internal or visceral form of
CLA, was somewhat higher than in previous reports from the UK, where between a
quarter and a third of sheep were affected in this way (Malone and others 2006; Baird
and Fontaine 2007). Approximately one half of the visceral lesions identified in this
study were located within the lung parenchyma. Sheep affected with such pulmonary
lesions have been identified by several authors as the principal source of infection to
other sheep (Ellis and others 1987; Pepin and others 1994a). The first mathematical
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model of C. pseudotuberculosis infection indicated that while transmission from
superficial lesions may predominate during the early spread of infection within a naive
population, transmission from respiratory abscesses dominates the endemic phase of
disease (O'Reilly and others 2008). This indicates that CLA management based purely
on the removal of visibly affected sheep is unlikely to be successful. The possibility that
serology might be employed to identify such sheep therefore offers the opportunity to
exert enhanced disease control.
The most significant effects of such a strategy were seen in trial flock C, where at the
commencement of the study seroprevalence was greater than 60%, and approximately
40% of all adult sheep showed clinical signs of disease. Although seven rounds of
testing over a period of three years were required to remove all seropositive sheep from
this flock, the two final tests, which took place six months apart, failed to identify any
antibody positive sheep. No further clinical cases of CLA were detected by the owner
during the following five years. Although clinical inspection cannot detect the minority
of animals with the internal form of the disease alone, the absence of external signs of
CLA for this length of time in the view of the author constitutes effective eradication of
disease. In future, postmortem examination of fallen stock or abattoir examination of
cull sheep may be suitable methods of disease monitoring in flocks that have adopted
CLA eradication by regular ELISA testing.
This study indicates that effective control over CLA may be achievable in flocks with
the highest prevalence, through the use of serology allied to management changes.
However, it also makes clear that a reduction in disease prevalence is not possible in
situations where owners are insufficiently motivated to make the required changes in
management, or are unwilling to remove clinically or serologically positive sheep. This
was indicated most clearly in trial flock D, where advice on control of infection and
culling was not followed, and as a consequence both the clinical and serological
incidence ofCLA increased during the course of the study.
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This trial was fully funded, such that flock owners were not required to pay for any
testing or veterinary visits and received payment for those animals that were culled and
subjected to necropsy examination. If such a test and cull programme was to operate
commercially, this would not be the case. As a consequence, it would seem likely that
the owners of CLA-affected flocks of high value and small size would be most likely to
consider such a scheme. For the owners of larger flocks, where the costs of testing,
culling and sourcing replacements would be correspondingly greater, the chances of
such a scheme proving attractive would be much less.
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Chapter 6: CONTROL OF CASEOUS LYMPHADENITIS IN
A LARGE UPLAND SHEEP FLOCK BASED ON
CLINICAL EXAMINATION AND REGULAR ELISA
TESTING.
Summary
The application of a test and cull policy to control CLA in a commercial hill flock in
northeast Scotland is described. A commercially available ELISA test kit (ELITEST
CLA ELISA, Hyphen, France) for the detection of antibody to PLD was employed on
blood samples taken from the main flock at approximately three-monthly intervals
between November 2007 and August 2009. A Western blot assay was used on
occasions when ELISA test results were considered inconclusive. Following each round
of testing all animals identified as seropositive were removed from the flock. Similarly,
any sheep diagnosed as CLA-positive through clinical examination and bacteriology,
were also removed from the flock. In addition, a range of general hygiene and
management measures aimed at reducing the likelihood of disease transmission were
also encouraged on the holding.
Initial testing in November 2007 indicated a seroprevalence of CLA within the flock of
10% (n=1010). By August 2009 the application of the test and cull protocol described,
the flock seroprevalence was reduced to 0.4% (n=538). No cases of CLA have been
identified within the flock on the basis of clinical examination from June 2008 to date
(November 2010); however in May 2009 CLA was confirmed at necropsy examination
in a ewe that had previously tested positive serologically. The potential role of
serological testing as a tool in the eradication of CLA from large flocks under extensive
hill conditions is discussed.
83
Introduction
As described in Chapters 3 and 5, the increase in CLA prevalence recorded in the UK
since the 1990s has occurred principally within the terminal sire breeds, in relatively
intensive lowland farming systems (Baird and others 2004). However by the mid-2000s,
reports began to emerge of CLA being detected in extensively managed hill flocks.
Predominantly this was in the North Country Cheviot and Scottish blackface breeds
(Anon 2004, 2007c), with infection commonly identified for the first time in rams.
Investigation of these outbreaks identified as a common risk factor, the practice of over¬
wintering rams from hill flocks on low ground holdings on the east coast of Scotland.
Here rams from a number of different flocks are managed together in very large groups.
These ram groups are composed of animals of varied breeds and from many different
farms. It seems likely that contact between the rams during the winter months enabled
the transmission ofCLA to rams of the hill breed, which then introduced the infection to
their holding of origin.
This trial was conducted in a Scottish blackface flock in the north of Scotland. Caseous
lymphadenitis was first diagnosed in the flock in August 2003 when C.
pseudotuberculosis was isolated from lesions identified on a Texel and a Charollais ram,
both of which were three-years-old and purchased for breeding purposes in 2002. The
case history indicated that during the previous year, the same Texel ram had suffered an
abscess that had been lanced and flushed, and had appeared to heal. Following the
diagnosis ofCLA in 2003, both affected animals were culled.
Between August 2003 and December 2006, swabs were submitted from superficial
purulent lesions affecting rams on a total of 12 occasions. In three cases CLA infection
was confirmed by bacteriology and the affected animals were culled. This practice
appeared to control the spread of infection, and when the 17 rams within the stud in
August 2006 were tested, no CLA ELISA positive animals were detected. However,
around shearing time in the summer of 2007, a number of ewes and gimmers were
identified with enlarged or abscessed superficial lymph nodes. At the time, the visiting
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local veterinary practitioner estimated a 5% prevalence of such lesions, mostly affecting
the nodes of the head and neck. Samples were taken for bacteriology from 18 animals
and a growth of C. pseudotuberculosis subsequently confirmed in nine cases. These
nine and another 31 animals with enlarged lymph nodes in the head and neck area were
culled at that time.
Chapter 5 describes the use of an antibody ELISA as part of a test and cull programme
in six small CLA-affected lowland sheep flocks. For two of those flocks it was
concluded that complete disease eradication had been achieved, while in another two,
the incidence of clinical CLA was reduced to zero, although a small number of
seropositive animals could still be detected. In this trial similar principles of disease
eradication were applied to a much larger flock in a more extensive hill setting. While
the logistics of such a programme were more demanding, the basic model remained the
same: the testing of the whole flock at regular intervals, allied with increased farmer




The trial flock was located on a holding in Ross-shire, Scotland. No other livestock
were kept on this holding, which covered approximately 500 ha at an elevation of
between 100 to 500 metres, with the majority of grazing on rough hill ground with a
limited amount of improved pasture. In November 2007 the flock consisted of some 670
Scottish blackface ewes, 180 ewe hoggs and 30 mule ewes. The ram stud was composed
of 15 Scottish blackface rams, seven Bluefaced Leicester rams and a single Suffolk ram.
Established practice in the flock was for all Scottish blackface female replacements to be
homebred, while the majority of female mule progeny were sold as breeding animals.
All male blackface and mule lambs were sold at light slaughter weights or as stores. In
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addition, the small group of mule ewes were bred to the Suffolk ram, with all progeny
sold fat. Prior to the commencement of the trial all replacement breeding rams were
sourced locally. No serological screening of these purchased male animals was
performed, nor was any period of quarantine observed prior to their introduction to the
stud.
Female lambs were away-wintered on a lowland farm where there was no contact with
other sheep. The majority of the flock was grazed on hill pastures or on in-bye grassland
throughout the year. Only twin-bearing ewes were housed for a short period around
lambing. Grazing animals were supplemented with hay or silage provided in round
feeders as necessary. Shearing each year was carried out by the farmer with local help.
At the commencement of the trial period the owner of the flock was given specific
advice on management changes designed to reduce the likelihood of CLA transmission.
This included the immediate isolation of suspect clinical cases pending bacteriological
confirmation, removing the suspect animals from the rest of the flock to an area where
nose-to-nose contact was not possible. Treatment of housing and pens that had held
known infected sheep, by means of steam cleaning and application of a disinfectant
solution from the Defra approved list at specified dilutions (Anon 2009a) was also
recommended. During shearing, any animals known to be seropositive or clinically
affected by CLA were sheared last. If any sheep was discovered to have abscesses at
shearing, the blades used were disinfected before being used on the next animal.
Ectoparasite control within the breeding stock was based upon the use of injectable
drugs and pour-on treatments during the first year of the trial. Thereafter dipping of ewe
lambs for ectoparasite control was allowed, provided that sheep from seronegative
groups were treated prior to sheep from the seropositive groups. Ectoparasite control
remained by pour-on treatment and injectable drugs in the adult breeding flock.
Similarly whenever the flock was handled for worming, shearing, scanning or any other
procedure, the seronegative group was handled before any retained seropositive animals.
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Following such handling the holding areas and the race were to be thoroughly cleaned
and disinfected before the next use.
Guidance was given on the application of hygienic measures during procedures likely to
cause damage to the skin, such as castration, shearing and tattooing. No hypodermic
needles used in vaccination or parasite treatments were shared between seropositive and
seronegative groups of animals. Finally, any sheep already diagnosed with CLA was
either culled, or managed separately for the duration of the trial.
All breeding rams introduced into the flock during the trial period were either certified
under the CLA Monitoring Scheme, or appropriately quarantined for at least two
months, with clinical examination and ELISA testing at the beginning and end of the
quarantine period. The advice to the owner was that female breeding replacements
should only be retained from those dams with no evidence of visible lesions or
serological history of CLA infection. However, in the first year of the trial when
insufficient ewe lambs were available from seronegative dams, 30 female progeny born
to ewes in the seropositive group were retained. As a precaution, these 30 ewe lambs
were run as a separate group until they had passed three consecutive blood tests, at
which time they were then added to the main breeding flock.
(b) Clinical examinations
The trial flock was visited on eight occasions at intervals between November 2007 and
August 2009. On each occasion every sheep over six months of age was individually
identified through the recording of ear tags, subjected to a brief clinical examination and
blood sampled. The physical examination involved the palpation and visual inspection
of the superficial lymph nodes; to include the regions of the parotid, submandibular,
retropharyngeal, prescapular and prefemoral nodes. The identity of any sheep showing
enlarged or abscessed lymph nodes was noted. Where a sample of discharge could be
collected the animal in question was separated from the flock pending the results of
bacteriology. In these cases bacterial cultures were performed under standard aerobic,
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anaerobic and 10% CO2 conditions at SAC Veterinary Services Centres in Inverness or
Perth. If C. pseudotuberculosis was confirmed on culture the affected animal was
immediately culled or removed from the main flock and managed separately.
In addition to the visits by a veterinary surgeon, the owner of the flock was also asked to
examine sheep for clinical signs of CLA at every handling, and especially at shearing.
Any discharging skin lesions identified at these times were to be sampled and the swabs
sent for bacteriological examination.
(c) Serology
Blood samples were taken from animals in the main flock on eight occasions between
November 2007 and August 2009. These samples were submitted to SAC Veterinary
Services Inverness, where they were assayed for the presence of anti-PLD IgG by
ELISA using the ELITEST CLA (HYPHEN BioMed, France).
The ELISA test was performed according to the manufacturer's instructions, as follows:
microplate strips supplied in the kit were coated with highly purified recombinant PLD
(rPLD) constituting the solid phase antigen. The test sample was incubated in the well
and specific antibodies to rPLD, if present in the sample, bound to the solid phase
immobilized antigen. A mouse monoclonal anti-goat/sheep IgG labelled with
horseradish peroxidase (HRP) was then added. When IgG antibodies were present,
these reacted with the coated antigen and were revealed by the HRP-labelled second
antibody. Subsequent incubation with tetramethylbenzidine peroxidase (TMB/H2O2)
substrate produced a blue colour in the test well, which turned to yellow when the
reaction was stopped by the addition of 100 pi of 2 M sulphuric acid. If the sample
contained no antibodies, the HRP-labelled second antibody did not bind and no colour
developed. The absorbance of each sample at light wavelength 450 nm was then
determined using an ELISA plate reader.
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On the basis of the ELISA results, serum samples were designated as negative or
positive. When sera gave a low positive test reaction in the ELISA, a further Western
blot technique (Burnette 1981) employing recombinant PLD antigen supplied by the
ELISA kit manufacturers was carried out on the sample at SAC VS Inverness. The
Western blot result was taken as positive when at least two bands were clearly visible on
the test membrane at 31 kDa and 68 kDa. If the Western blot gave a negative result (no
bands), or an unconvincing result (one or two very weak bands) the sample was
classified as inconclusive.
All sheep classified as seronegative were retained within the flock and re-sampled in the
normal manner at the next flock test. All sheep that were considered to be seropositive
by ELISA and/or Western blot were immediately culled or removed from the flock and
managed separately. Sheep that had shown an inconclusive result were isolated for four
weeks before being blood sampled and re-tested in the ELISA.
At the first farm visit in November 2007 all breeding sheep present on the farm were
blood sampled and tested by CLA ELISA. This included a group of older ewes that had
already been selected for culling on the basis of age, body condition or history of
abscesses. This group was included in the flock test in order to achieve a more complete
record ofCLA seroprevalence at the commencement of the trial. All ewe lambs born in
spring 2007 were also blood sampled at this first visit in order to assess the extent of the
spread of infection into the lamb group.
(d) Pathology
After the initial flock visit in November 2007, and after all subsequent tests, any sheep
confirmed as CLA positive by bacteriology or deemed positive in the ELISA and/or
Western blot assays was removed from the main flock. On most occasions those
animals with superficial CLA lesions were immediately culled; whilst those sheep that
were simply seropositive but with no visible abscesses, were kept separate until removal.
At intervals during the trial a proportion of the animals from this latter category were
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subjected to full necropsy examination, both to monitor test specificity and to assess the
extent of internal CLA lesions. A standard operating procedure was adopted in all
postmortem examinations to ensure consistency (see Chapter 5). These examinations
were carried out at SAC VS Inverness by the author.
Results
(a) Clinical examinations
In the period between the commencement of the trial in November 2007 to the end of
May 2010, swab samples taken from superficial abscesses were submitted on 22
occasions, with a total of 27 sheep sampled for culture. On no occasion was C.
pseudotuberculosis identified on subsequent bacterial culture. In more than 50% of
cases growths of either Arcanobacterium pyogenes or Actinobacillus lignieresii were
identified, or cultures proved sterile after 48 hours incubation. Other organisms isolated
on culture from individual animals were identified as Actinomyces hyovaginalis,
Staphylococcus epidermidis, Bibersteinia trehalosi, Staphylococcus aureus and Bacillus
licheniformis.
(b) Serology
Western blot analysis was carried out on all ELISA positive sera after the first round of
testing. As the trial progressed and seroprevalence by ELISA test declined, all positive
samples were again tested by Western blot. These results are shown in Table 6.1.
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Nov 2007 1,010 101 10.0 94/101
Feb 2008 781 16 2.0 N/A
May 2008 711 6 0.8 N/A
Aug 2008 515 2 0.4 N/A
Nov 2008 707 12 1.7 10/12
Feb 2009 693 4 0.6 4/4
May 2009 664 8 1.2 4/8
Aug 2009 538 2 0.4 2/2
(N/A - not applica ?le, no Western blots per brmed on those occasions)
In November 2007 the overall seroprevalence in the flock was 10%. None of the rams
within the flock were seropositive at the time of testing (n=23), whilst seroprevalence
was greatest in the group of cull ewes at 27.3% (n=205). This group contained a large
proportion of animals with a clinical history of suspicious superficial lesions. In the
group of ewe lambs 1.8% of animals were seropositive (n=228), while 7.4% of the
remaining ewes and gimmers (n=554) tested positive for PLD antibody. Following the
flock blood test carried out in August 2009 two animals were found to be positive for
antibody by ELISA and Western blot, indicating a flock seroprevalence of 0.4%
(n=538).
(c) Pathology
A total of eleven necropsy examinations were undertaken on trial sheep. In November
2007, five animals that had previously tested positive by ELISA were examined. In four
cases purulent lesions were noted in the superficial or thoracic lymph nodes or the lungs,
from which C. pseudotuberculosis was subsequently isolated. In one case no purulent
lesions were detected and routine cultures from sampled lymph nodes were negative.
In August 2009, five of the eight animals that had tested ELISA positive in May 2009
were subjected to a necropsy examination, the other three animals having been sold for
slaughter shortly after the test. On this occasion the delay of three months between
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blood testing and necropsy examination was to allow these ewes to rear their lambs.
Following euthanasia, gross inspection of one carcase identified slight enlargement of
the right prefemoral lymph node and when incised the node was found to contain a small
quantity of purulent material. On subsequent culture of the contents of this lesion a
growth of C. pseudotuberculosis was identified. No lesions were recorded on necropsy
examination of the remaining four carcases and routine lymph node cultures produced
no significant findings.
In September 2009 one of the two ELISA positive/Western blot positive animals tested
in August 2009 was examined at necropsy examination, the other having been sold for
slaughter by the owner. No lesions were recorded on examination of this animal and
routine lymph node cultures produced no significant findings.
Discussion
This study confirms that the programme ofCLA control, described for lowland pedigree
sheep flocks in Chapter 5 - namely a test and cull policy employing a PLD antibody
ELISA assay, allied to an increased farmer vigilance and certain management changes -
may be successfully applied to reduce the prevalence of the disease in a large
commercial hill flock. In this case, C. pseudotuberculosis infection was well established
within the flock before the commencement of the trial. In the four years following the
first confirmed diagnosis of CLA within the ram stud, the infection appeared to have
been controlled in that group through the immediate culling of affected animals.
However, the discovery of clinical signs of CLA in an estimated 5% of ewes between
June and July 2007, and thereafter the detection of 10% seroprevalence in November
2007, confirmed active infection with the lambing flock. Through application of the
test and cull programme this seroprevalence was reduced to a very low level and
evidence of clinical disease eliminated for a period of 31 months (at time of writing in
July 2010). At the end of this trial the author would have welcomed an opportunity for
one further round of testing, in the hope of establishing an entirely seronegative status
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within the flock. Unfortunately the limitations of funding meant that this was not
possible.
Although there was no history of carcase rejections, weight loss or other systemic effects
of CLA, the sudden rise in disease incidence recorded within the female stock during
2007 led to great concern on the part of the owner. For an enterprise based on the sale
of quality female breeding replacements, it was felt that the reputation of the business
would be put at risk were CLA-affected stock to be marketed. The flock owner was
therefore enthusiastic and highly motivated throughout the trial. As a consequence, he
was willing to accept the additional efforts required in gathering the flock for testing and
in applying the management measures aimed at reducing disease transmission. In
addition, because the flock was undergoing a period of managed reduction, the owner
could accept the premature loss of the 151 animals that were to test seropositive during
the course of the trial, and the further 43 animals that were either diagnosed with CLA
by bacteriology before the trial commenced or were removed on the basis of suspicious
lesions.
Although the owner saw CLA control in this flock as being an economic imperative,
without financial support of the veterinary visits for blood-sampling and all serological
testing, an eradication programme of this type would not have been possible. During the
trial period, the equivalent commercial cost of the CLA EL1SA test was between £4.00
and £4.50 per sample. Given that the trial involved eight separate veterinary visits for
blood-sampling, and that a total of 5,619 samples were tested, the likely costs for this
part of the trial would have been in the region of £30,000, had it been under commercial
conditions.
As discussed in Chapter 5, the definition of complete disease eradication is important in
assessing this trial. The absence of any confirmed cases of superficial CLA for a period
of 31 months is consistent with effective eradication of this form of the disease.
However, the trial also confirms how difficult it is to achieve complete eradication of C.
93
pseudotuberculosis infection in a large flock under extensive conditions. The detection
of two seropositive animals after eight rounds of testing, and the discovery of one animal
with the visceral form of infection during a necropsy examination in August 2009,
confirms this problem.
In the accreditation schemes for maedi-visna and Chlamydophila abortus (enzootic
abortion of ewes, EAE) currently operated in the UK, an absence of any serological
evidence of infection is a requirement of full membership (PSGHS 2008, 2009). The
nature of caseous lymphadenitis infections in sheep and the relatively modest sensitivity
of the ELISA test would make this a difficult objective to achieve in any large flock
suffering a significant level of infection.
In conclusion, it would seem likely that the owners ofCLA-affected flocks of high value
and small size would be most likely to consider such a test and cull programme. For the
owners of larger flocks, the costs of testing, culling and sourcing replacements are
correspondingly greater. Although this trial has shown that effective control can be
applied in such situations, on the basis of a cost-benefit analysis, such as programme is
unlikely to prove attractive for the majority of larger producers.
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Chapter 7: VACCINATION TO PROTECT SHEEP
AGAINST A VIRULENT UNITED KINGDOM STRAIN OF
CORYNEBACTERIUMPSEUDOTUBERCULOSIS.
Summary
Using a virulent United Kingdom C. pseudotuberculosis isolate, an ovine experimental
model of caseous lymphadenitis was developed, in which the manifestation of disease
was equivalent to the naturally-observed infection in this country. The ability of several
experimental vaccines to protect against bacterial challenge was then determined. Sheep
were immunized with a recombinant PLD derived from the virulent UK isolate, a
formalin-killed bacterin of the same strain, or a bacterin supplemented with the
recombinant PLD. Following experimental homologous challenge, the PLD and
bacterin vaccines were observed to confer statistically significant protection against
infection, and restricted dissemination of challenge bacteria beyond the inoculation site
in the majority of animals. More importantly, the combined vaccine succeeded in
providing absolute protection against infection, whereby challenge bacteria were
eradicated from all vaccinates. In addition to the experimental vaccines, a commercially
available CLA vaccine, currently unlicensed for use in the European Union, was
assessed for its capacity to protect against heterologous challenge. The proprietary
vaccine conferred significant protection, although the dissemination of infection beyond
the inoculation site was not restricted as it had been with the other vaccines. However,
no animals vaccinated with this proprietary product manifested infection within the
lungs; thus eliminating a potentially important route of disease transmission. The results
of this study provide information pertinent to the development of an effective caseous
lymphadenitis vaccination strategy in the UK.
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Introduction
The potential to vaccinate sheep against infection with C. pseudotuberculosis has been
the focus of research attention for many years. A prepared vaccine against CLA was
said to be used to protect flocks in France as early as the 1920s (Howarth and Young
1926). Bacterin vaccines, or those comprising cellular components, have been shown to
offer a degree of protection against experimental infection (Cameron and others 1972;
Brogden and others 1984a, 1985; Brogden and others 1990). In addition, they have also
shown some success when used to vaccinate against naturally acquired infection in
sheep and goats (Menzies and others 1991; Brogden and others 1996).
Some of the earliest investigations into vaccination against C. pseudotuberculosis
infection reported the capacity of the potent C. pseudotuberculosis exotoxin to induce
protective immunity in guinea pigs (Petrie and McClean 1934). Despite these
encouraging results, the consensus view at the time was that the chronic nature of C.
pseudotuberculosis infections in sheep, compared to the relatively acute manifestation in
guinea pigs, meant that exotoxin vaccines were unsuitable for use against ovine CLA
(Carne and others 1956; Cameron and Smit 1970). Later work revealed that the C.
pseudotuberculosis exotoxin, now characterised as PLD (Cameron and Smit 1970), did
in fact offer protection against infection in sheep (Jolly 1965). Subsequent studies
employed formalin-inactivated toxoid vaccines derived from PLD-rich C.
pseudotuberculosis culture supernatants, and established that this conferred varying
levels of protective immunity in both sheep and goats (Jolly 1965; Nairn and others
1977; Burrell 1978b; Eggleton and others 1991a).
Currently there is no commercially available CLA vaccine licensed for use in the UK.
Permission may be sought by veterinary practitioners from the UK Veterinary Medicines
Directorate (VMD) for the importation of proprietary vaccines under a Special
Treatment Certificate or for the production of autogenous vaccine under the Autogenous
Vaccine Authorisation arrangements. The latter are adjuvanted bacterins derived from
C. pseudotuberculosis isolates from flock outbreaks and are intended only for the
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immunisation of animals on the holding where the outbreak occurred. However, the
protective capacity of this type of relatively crude preparation has been purely anecdotal.
Similarly no assessment of the proprietary vaccines available in other countries has yet
taken place in the UK.
In this study the capacity of a C. pseudotuberculosis bacterin to protect sheep against
homologous challenge with a virulent UK isolate of C. pseudotuberculosis was assessed.
In addition, the capacity of a recombinant derivative of PLD and of a recombinant PLD-
supplemented C. pseudotuberculosis bacterin to protect against equivalent challenge was
evaluated. Finally, the capacity of an Australian commercial vaccine preparation to
protect against heterologous challenge with a UK C. pseudotuberculosis strain was also
assessed.
Materials and methods
(a) Media and culture conditions
C. pseudotuberculosis was propagated on blood agar (BA) plates derived from Blood
Agar Base (Oxoid) and 5% (v/v) sheep blood, or in Brain Heart Infusion broth (BHI;
Oxoid, Basingstoke, Hampshire, UK), at 37°C (mixed at 200 rpm for liquid cultures) for
up to 48 hours. Unless otherwise specified, Escherichia coli strains were routinely
cultured at 37°C (mixed at 200 rpm for liquid cultures) in Luria Bertani medium (LB;
Oxoid) containing ampicillin (100 pg/ml), or carbenicillin (50 pg/ml) and 10 mM
glucose as required. This widely used rich medium broth is popular with bacteriologists
because it permits fast growth and good growth yields for many bacterial species
(Sezonov and others 2007).
(b) Molecular biological techniques
Unless otherwise specified, all DNA manipulations were performed according to
standard techniques (Sambrook and Russell 2001). Restriction endonucleases and other
modifying enzymes were purchased from Promega (Southampton, UK) or Roche (East
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Sussex, UK) and used according to the manufacturers' supplied instructions. Small-
scale extraction and purification of plasmid DNA from E. coli was performed using the
QIAquick Spin Miniprep Kit (QIAGEN, Crawley, West Sussex, UK), and genomic
DNA was extracted from C. pseudotuberculosis using the NucleoSpin Tissue Kit (BD
Biosciences (Clontech), Erembodegen, Belgium). PCR-amplified DNA fragments were
purified using the Strataprep PCR Purification Kit (Stratagene, La Jolla, CA, USA), and
cloned into pPCR-SCRIPT using the PCR-SCRIPT Cloning Kit (Stratagene). For
cloning, restriction endonuclease-digested DNA fragments were electrophoresed
through 1.0% (w/v) agarose gels and fragments of the desired size were purified using
the QIAquick Gel Extraction Kit (QIAGEN). Custom PCR and sequencing primers
were synthesised to order by Sigma-Genosys (Sigma-Genosys Ltd., Haverhill, Suffolk,
UK), and are presented in Table 7.1. Automated DNA sequencing was performed using
a MegaBACE sequencing apparatus (Amersham Biosciences UK Ltd.,
Buckinghamshire, UK) by the Functional Genomics Unit of the Moredun Research
Institute, Pentlands Science Park, Penicuik, Scotland.
(c) Cloning ofthe C. pseudotuberculosis pld gene
The gene encoding for the PLD exotoxin (designated pld) of the virulent UK
C. pseudotuberculosis isolate, 3/99-5 (Connor and others 2000) was amplified by PCR.
The published pld sequence (GenBank accession #L16586) was used to design the
primers pld#01b and pld#02, and to facilitate cloning, primers were designed to contain
restriction endonuclease cleavage sites. The amplified fragment, corresponding to the
truncated pld gene lacking the first 72 base pairs (encoding the 24 amino acid (aa)
secretion signal sequence), was cloned into pPCR-SCRIPT and the resulting construct
was designated pMMF003. To allow expression of the truncated 3/99-5 pld gene,
pMMF003 was digested using the restriction enzymes NdeI and BamRl, and the 859
base pair fragment was ligated into pET-15b. Following transformation of E. coli
XLIO-Gold Kan (Stratagene), the desired construct was identified and designated
pMMF004. DNA sequencing of both leading and complementary strands was
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performed using the primers pET(fwd) and pET(rev), to confirm the identity of the
cloned fragment.
(d) Expression andpurification of recombinant PLD (rPLD)
To allow expression of the cloned pld gene, pMMF004 was used to transform E. coli
BL21(DE3). Bacterial cultures were propagated in LB containing carbenicillin and
glucose and protein expression was induced in the exponential growth phase (ODaoonm of
«0.6) by the addition of IPTG to 1 mM final concentration. Induced cultures were
incubated for one hour prior to the addition of rifampicin to 150 pg/ml final
concentration. Incubation was continued for a further three hours, and then cells were
harvested by centrifugation at 6,000 x g for 15 minutes at 4°C. Culture supernatants
were discarded and cells were resuspended in BugBuster Protein Extraction Reagent
(Merck Biosciences (Novagen), Nottingham, UK) to approximately 5 ml per gram of
wet cell pellet. Complete Protease Inhibitor Cocktail (Roche) was added (lx final
concentration) to inhibit proteolytic degradation, then Benzonase enzyme (Novagen)
was added to 1 pg/ml final concentration, and incubation was performed with gentle
rotation on a shaking platform for 40 minutes at room temperature. During this
incubation, cells were lysed and viscosity due to nucleic acids was reduced.
Subsequently, centrifugation was performed at 16,000 x g for 30 minutes at 4°C to pellet
cell debris, and then cleared supernatants were supplemented with imidazole to a final
concentration of 10 mM.
rPLD was purified by immobilised metal-ion affinity chromatography. Twelve ml
EconoPak columns (Bio-Rad, Hemel Hempstead, Hertfordshire, UK) were loaded with
2 ml (bed volume) of Ni-CAM HC resin (Sigma-Aldrich Company Ltd., Irvine, UK),
pre-equilibrated with lysis buffer (Column Buffer (CB) [50 mM Tris-HCl, pH 8.0 and
300 mM NaCl] supplemented with 10 mM imidazole). To each column was added 5 ml
of cell lysate (originating from approximately 500 ml of culture), and the volume was
supplemented with a further 5 ml of lysis buffer. Columns were sealed and incubated
for 16 hours at 4°C on a tube rotator. Subsequently, columns were drained by gravity
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flow and washed with 25 x 2 ml of wash buffer (CB supplemented with 20 mM
imidazole). Finally, column-bound protein was eluted in 5 x 2 ml of elution buffer (CB
supplemented with 250 mM imidazole). Eluted proteins were concentrated and buffer
exchanged in 10 mM PBS (pH 7.2), supplemented with 0.1% SDS and lx Complete
protease inhibitors, through 10 K Mr Amicon Ultra centrifugal filters (Millipore,
Watford, UK) at 3,080 x g and 4°C. The final concentration of purified rPLD was
determined using the DC Protein Assay (Bio-Rad).
(e) Preparation ofchallenge inoculum
C. pseudotuberculosis 3/99-5 (a bacterium originally isolated from a CLA affected
sheep in a Scottish Borders flock) was passaged three times on BA plates, and then
bacterial growth was collected using sterile, cotton-tipped swabs. Bacteria were
resuspended in PBS, in polystyrene Universal tubes, by gently rolling swab tips against
the tube sides. Dilutions of the primary suspension were prepared to give the required
concentration (cells/ml) for subsequent challenge. This was estimated by use of a
Densimat (bioMerieux, Basingstoke, UK), and then quantified accurately using a Thoma
counting chamber.
(f) Preparation offormalin-killed C. pseudotuberculosis
For vaccination, C. pseudotuberculosis was cultured on BA plates, as for Section 2.5.
Approximately 1011 cfu were suspended in 20 ml of PBS in a Universal tube and
supplemented with 40% formalin to a final concentration of 0.2% (v/v). Cells were
incubated overnight at 4°C, and then quantified using a Thoma counting chamber.
Subsequently, cells were pelleted by centrifugation at 3,080 x g for 15 minutes at 4°C,
and resuspended in distilled water to a final concentration of 1.25><1010 cells/ml. To
confirm complete killing, 100 pi aliquots of the bacterial suspension were plated onto
blood agar plates, then incubated at 37°C and monitored daily for five days.
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(g) Experimental challenge and vaccination
For all challenge/vaccination experiments, one-year-old male Suffolk-cross sheep were
used. These animals were sourced from the Institute's own closed sheep flock, which
was known to be CLA-ffee and each was tested by CLA ELISA to establish a
seronegative status prior to the start of the trial.
Prior to undertaking the vaccination study, a dose titration experiment was performed to
determine the minimum cells/ml required to induce experimental infection manifesting
clinical signs and pathology similar to naturally observed CLA. Groups of two animals
were inoculated with 102, 103, 104 or 108 bacteria, and an unchallenged control group
was also included, administered sterile saline. The identification of the animals in each
challenge group was 1578N + 1638N, 1630N + 1570N, 1549N + 153IN, 1689N +
1728N, and 1640N + 1603N, respectively. For challenge, a 1 ml bacterial inoculum was
administered subcutaneously, 2 cm caudal to the base of the left ear of each animal, on a
line passing through the ear to the left eye. Subsequently, animals were housed in their
respective groups for nine weeks, during which time blood was collected at regular
intervals for serology. Animals were then sacrificed, a full necropsy examination was
performed, and samples corresponding to inoculation site abscesses, lung, liver, spleen
and brain tissues, as well as left- and right-hand-side (LHS and RHS) parotid,
prescapular, sub-mandibular, retropharyngeal, mediastinal, prefemoral, inguinal and
popliteal lymph nodes were collected for determination of the presence of bacteria.
For immunisations, vaccine antigens were formulated in physiological saline to final
volumes of 1 ml, containing 50% (v/v) of a 13 mg/ml colloidal suspension of aluminium
hydroxide (Alhydrogel; Sigma). Groups of six animals were immunised with either
saline (group 1; control), 50% Alhydrogel (group 2; control), 50 pg of rPLD (group 3),
5><109 formalin-killed C. pseudotuberculosis whole-cells (group 4), or a combination of
50 pg of rPLD and 5x109 killed whole-cells (group 5). Group 2 was included to ensure
that there was no effect of the adjuvant on the host resistance to infection. In addition,
animals were immunised with the commercial inactivated-PLD vaccine, Glanvac-3™
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(Commonwealth Serum Laboratories (CSL) Ltd., Victoria, Australia), currently
unlicensed in the UK (Group 6). Vaccines were administered sub-cutaneously to the
RHS lateral neck. A four week interval was allowed between the first and second
immunisations. Subsequently, vaccinated animals were challenged with the determined
optimal bacterial dose as described earlier in this section, following which they were
housed in their respective groups for three months until postmortem examination.
(h) Post mortem bacteriological analyses
To determine infection with C. pseudotuberculosis, the post mortem tissue samples
listed in section (g) were macerated in PBS using a stomacher (Wolf Laboratories Ltd,
York), and aliquots were then plated onto BA plates, and incubated to allow colony
development. Presumptive identification of recovered bacteria as C. pseudotuberculosis
was made on the basis of colony morphology, catalase activity, Gram-stain and
appearance by microscopical analysis. A random selection of samples was also analysed
using the API Coryne test (bioMerieux).
(i) Serology
Animals' immunological responses to vaccination and/or infection were determined by
measurement of serum anti-C. pseudotuberculosis and anti-PLD IgG by ELISA.
Ninety-six well microtitre plates were coated with either rPLD (rPLD-ELISA) or whole
C. pseudotuberculosis cells (WC-ELISA) and blocked with lx TBS buffer containing
0.05% (v/v) Tween 20 (TBST) and 3% (w/v) Top-Block (Sigma). Subsequently, plates
were incubated in the presence of experimental serum samples, diluted (1/200) in TBST
containing 1% Top-Block. Plates were washed with TBST, and bound anti-C.
pseudotuberculosis and anti-rPLD IgG was detected by use of a horseradish peroxidase-
conjugated mouse anti sheep/goat IgG monoclonal antibody (Clone GT-34; Sigma) and
3,3',5,5'-tetramethylbenzidine substrate (Sigma). Colorimetric reactions were stopped
and intensified with 2 M H2SO4, and the absorbance of each sample at 450nm was
subsequently determined.
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(j) Computational and statistical analyses
Analysis ofDNA sequences and design of oligonucleotide primers was performed using
the Clone Manager Professional Suite (Scientific and Educational Software Ltd.,
Durham, NC, USA). Statistical analyses were performed using Genstat (8th edition;
VSN International Ltd., Hemel Hempstead, Hertfordshire, UK). Because of the lack of
independence between measurements made on the same animal, a repeated measures
model was fitted to the rPLD IgG ELISA data. The correlation structure was modelled
using a power model and the parameters of the statistical model were estimated using
the restricted maximum likelihood directive in Genstat. Several analyses were carried
out on the necropsy examination data to determine differences in the extent and pattern
of infection in the various tissues. A one-way analysis of variance (ANOVA) was used
to investigate the mean percentage of tissues infected with C. pseudotuberculosis in the
different groups. An angular transformation of the percentages was used to stabilise the
variances within the groups and mean differences between groups were assessed using a
least significant difference (LSD) approach. Three different patterns of infection were
defined: no tissues infected; infection at the inoculation site only; and infection at the
inoculation site and at least one other tissue.
. Animals were classified as having one of
these three pattern types and a Fisher exact test was performed to determine whether
there was an association between groups and pattern types. The nature of the association
was illustrated using the statistical methodology correspondence analysis.
Results
(a) Optimisation ofinfection model
In order to determine the optimal dose of C. pseudotuberculosis required to induce a
similar disease manifestation in experimentally-infected animals to that observed in
natural cases of CLA, a dose titration experiment was performed. Prior to infection, the
absence of clinical symptoms and of circulating anti-C. pseudotuberculosis whole-cell or
anti-PLD IgG was confirmed by clinical examination and ELISA analysis of blood
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samples taken from experimental candidates using the rPLD- and WC-ELISAs (Figure
7.1). Thus, the absence of natural infection within the flock was established.
Bacteriological analysis of tissue samples taken post mortem was performed, and the
sites from which C. pseudotuberculosis was recovered from each animal are presented in
Table 7.2. In light of the observation that no bacteria were recovered from either brain,
spleen or liver tissue samples or inguinal, popliteal and prefemoral lymph nodes from
any of the experimental animals in the current study or in infection experiments
conducted previously (unpublished data), subsequent experiments were refined by
eliminating the sampling of these sites. From the bacteriological data, it was apparent
that as few as 102 cells were capable of causing infection. A challenge dose of 104 cells
was chosen for subsequent experiments, due to the observation that, with this dose,
infection occurred in multiple lymph nodes and the lungs {i.e. was not restricted to one
specific site).
Serological analysis of the blood samples taken from the experimental animals during
the course of infection was performed. The levels of anti-C. pseudotuberculosis whole-
cell and anti-PLD IgG of each animal were determined, and are presented in Figure 7.1
as the absorbance values at 450nm (OD45onm), obtained using either ELISA. As
expected, all infected animals were observed to have mounted an immunological
response to the challenge bacterium, as determined using the WC-ELISA; however there
was no evidence that the magnitude of the response was directly associated with the
number of challenge bacteria administered. Results were similar for anti-PLD IgG
determination using the rPLD-ELISA. However, it is interesting to note that, despite
mounting an immune response against C. pseudotuberculosis whole cells, one animal
(153 IN) failed to mount any observable response to PLD during the time-course of the
experiment (see Figure 7.1).
(b) Vaccination and challenge ofexperimental animals
Prior to vaccination, experimental candidates were screened by clinical examination and
by both ELlSAs; all animals were free from observable signs of infection and lacked
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circulating anti-C. pseudotuberculosis whole-cell and anti-PLD IgG. Unfortunately, one
animal in group 3 died unexpectedly in the period between the first and second
immunisations. No inoculation site reaction was observed, and it was determined that
cause of death was not associated with any effects of vaccination.
Prior to experimental challenge, serology was performed to monitor the response to
vaccination in each animal, using the rPLD-ELISA and WC-ELISA (Figure 7.2, top and
bottom panels, respectively). To compare immune responses between treatment groups,
data are presented as average OD450nm values (as determined by either ELISA) per
group, and standard errors at each time point are included. As expected, using the
rPLD-ELISA, the highest levels of anti-PLD IgG were observed for the animals
immunised with rPLD (groups 3 and 5) and Glanvac™ (group 6). For groups 3 and 5,
anti-PLD IgG levels reached a maximum at the point of the booster vaccination.
Furthermore, given the similar responses in animals in these groups, the whole-cell
portion of the vaccine administered to group 5 was not considered to contribute to the
immune response measured using the rPLD-ELISA. Levels of anti-PLD IgG in
Glanvac™ vaccinates were consistently less than those observed for groups 3 and 5,
and, rather than peaking, continued to rise following the secondary vaccination.
A repeated measures model was fitted to the rPLD IgG ELISA data. There was strong
evidence (P<0.001) of a different pattern in the responses over time, particularly where
the levels of anti-PLD IgG in groups 3 and 5 were significantly higher than those of
group 6 in the weeks immediately post-immunisation and pre-challenge (see Figure 7.2).
Levels of anti-PLD IgG in animals immunised with formalin-killed whole-cells (group
4) were similar to those of non-immunised animals (groups 1 and 2), confirming the
observation that the immune response measured in group 5 animals was likely to be as a
result of the rPLD portion of the vaccine.
In contrast to results using the rPLD-ELISA, the WC-ELISA was able to determine the
presence of high levels of anti-C. pseudotuberculosis IgG in killed whole-cell-
105
vaccinated animals (groups 4 and 5), while not detecting an immune response in those
animals vaccinated with rPLD or Glanvac™ (groups 3 and 6). This was probably due to
the fact that PLD is a secretory antigen, which would have been sparingly present in the
killed whole-cell vaccine, and also in the cell preparations used in the WC-ELISA.
Therefore, given the similarities in IgG levels between groups 4 and 5, the response in
group 5 can only have been against the whole-cell portion of the vaccine. As with
groups 3 and 5 (using the rPLD-ELISA), antibody levels in groups 4 and 5 reached their
maximum level prior to administering the secondary vaccination. Overall, using the
combined results of the two ELISAs, it was possible to determine that all animals,
except for those of the control groups, had mounted observable immunological
responses to vaccination.
The levels of serum anti-PLD and anti-C. pseudotuberculosis IgG were determined, as
for the pre-challenge serum samples, following bacterial challenge at week six (Figure
7.2). After challenge, average anti-PLD IgG levels in the control groups (1 and 2)
increased to their maximum level by week ten (four weeks post-challenge). Anti-PLD
IgG levels in killed whole-cell vaccinates (group 4) remained similar to those of the
control groups, rising steadily to a maximum level by week 10. Anti-PLD IgG levels in
groups 3 and 5 remained essentially constant until week 10, by which point anti-PLD
IgG in group 6 animals had reached an equivalent level. From that point on, anti-PLD
levels in groups 3, 5 and 6 declined gradually to coincide with the anti-PLD levels
observed in animals of groups 1, 2 and 4. Levels of anti-C. pseudotuberculosis IgG in
groups 4 and 5 remained essentially constant from the point of challenge. Anti-C.
pseudotuberculosis IgG levels in groups 1, 2, 3 and 6 were similar to each-other, rising
slightly after challenge, but never reaching an equivalent level to that observed for killed
whole-cell vaccinates.
(c) Postmortem examination
Postmortem examination and bacteriological sampling of tissues from vaccinated
experimental animals yielded significant findings. The numbers of infected sites varied
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between groups, and to a lesser extent between individual animals. However,
C. pseudotuberculosis was not recovered from the RHS parotid or the LHS and RHS
submandibular lymph nodes of any animal in the study. Data pertaining to the loci
within animals of each treatment group from which bacteria were isolated is presented in
Table 7.3. Significantly, no evidence of infection was found within any of the animals
in group 5, including the apparent resolution of inoculation site abscesses. The observed
number of lung lesions varied to a large extent, both between groups and individual
animals. Therefore, rather than directly comparing the actual numbers of lung lesions as
a means of determining disease severity, a more definitive method of comparing the
presence or absence of lesions was used to determine differences, as follows below.
An ANOVA was performed to determine whether the mean percentage of tissues
infected with C. pseudotuberculosis varied significantly between the different treatment
groups. Only the eight tissues observed to show infection in any of the animals were
used in the analysis (RHS parotid excluded). There was strong evidence (P<0.001) that
the mean percentage of tissues infected was different between the different treatment
groups. The mean percentages and standard errors on the original scale are shown in
Table 7.4. Groups 1 and 2 had similar means, and there was no evidence of an affect of
Alhydrogel on the outcome of infection. Furthermore, groups 1 and 2 were both
significantly different from groups 3, 4, 5 and 6 (using an LSD at the 5% level),
confirming that all of the vaccine antigens assessed in the study offered a significant
level of protection against infection.
In the experimental subjects, the most commonly encountered site of infection was the
LHS prescapular and retropharyngeal lymph nodes, which is consistent with the
drainage of challenge bacteria from the site of administration to a local draining lymph
node. To determine whether spread of C. pseudotuberculosis from the inoculation site
to other internal sites was more or less likely within the different treatment groups, each
animal was assigned to one of three different pattern groups, which were determined on
the basis of there being no tissues infected (P1), infection in the inoculation site but no
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other tissues (P2), infection in the inoculation site and at least one other tissue (P3). A
Fisher exact test indicated that there was very strong evidence (P<0.001) that some
treatment groups displayed different patterns of infection to other groups.
The association between treatment group and lesion pattern type was investigated further
using correspondence analysis (see Figure 7.3). The scores of the first and second
components were plotted against each other for treatment groups and lesion pattern
types separately. It was expected that if a pattern type (PI, P2 or P3) was associated
with a particular treatment group (G1 -6) then the pattern and treatment groups would be
located close to each other on the correspondence plot. It was observed that PI and G5
were clearly associated with each other and separated from the other groups on the first
component. Furthermore, on the second component, P2 and P3 were distinct, with G3
and G4 associated with P2 and G1 and G2 associated with P3. Interestingly, G6 did not
cluster well with any pattern group, but was most closely associated with P3.
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Figure 7.1 Measurement of humoral immune response in sheep challenged with C. pseudotuberculosis.
Levels of IgG (presented as OD450nm values) against C. pseudotuberculosis whole-cells (top) and rPLD
(bottom) were determined. Challenge was performed at week 0, and groups correspond to: Control,
1640N ( 1 ) and 1603N(—X—); 102, 1638N (---a---) and 1579N (---A--- ); 103, 1570N
























Figure 7.2 Measurement of anti-PLD and anti-C. pseudotuberculosis IgG.
Serum anti-PLD (top) and anti-C. pseudotuberculosis whole cell (bottom) IgG levels were calculated for
each treatment group, expressed as the mean and standard error of OD45o„m per group. Samples were
obtained following primary and secondary vaccinations (weeks 0 and 4 respectively) and for 3 months
following bacterial challenge (at week 6). Treatment groups are 1. (—♦—) saline control, 2. (- - m - -)
Alhydrogel control, 3. (- - - a- - -) rPLD, 4. ( _ _) killed-whole cells, 5. ( —*— ) rPLD + killed-




Figure 7.3 Correspondence analysis of treatment groups and pattern of infection. Treatment
groups were saline (Gl), Alhydrogel (G2), rPLD (G3), killed whole-cells (G4), rPLD + killed whole-
cells (G5) and Glanvac-3 (G6). Patterns of infection were defined as no tissues infected (PI),
infection in the inoculation site but no other tissues (P2) and infection in the inoculation site and at














This is the first UK study to consider the vaccination of sheep against CLA and
confirms statistically significant levels of protection against challenge with a UK-
derived C. pseudotuberculosis strain. In the homologous challenge model,
vaccination with either the highly-purified rPLD antigen, or formalin-killed C.
pseudotuberculosis cells, prevented spread of bacteria beyond the site of inoculation
in the majority of immunised animals. More importantly, vaccination with a
combination of rPLD and killed whole-cells resulted in complete protection against
challenge, inasmuch as no evidence of infection was identified in any of the tissue
samples from challenged animals. Vaccination with the commercial vaccine,
Glanvac™, also offered significant protection against heterologous challenge,
although it was less effective in preventing the dissemination of infection beyond the
site of inoculation.
The experimental infection model that was used produced a pattern of lesions in
sheep that was consistent with clinical CLA as recognised in the UK (Rizvi and
others 1997; Malone and others 2002). The initial dose of bacteria used was chosen
to be high enough to ensure that infection was consistently achieved, but low enough
to avoid any possibility that the host immune response might be overwhelmed,
thereby masking any protective effects of vaccination. This is important since
theories ofCLA pathogenesis suggest that natural infection may be initiated by small
numbers of aerosol-borne bacteria (Pepin and others 1994a).
Earlier studies have considered different forms of PLD-based vaccine capable of
inducing protective immunity by stimulating production of anti-PLD antibodies
(Batey 1986c; Brown and others 1986; Eggleton and others 1991a; Eggleton and
others 1991b; Sutherland and others 1992; Hodgson and others 1999), with no
apparent effect on cell-mediated immunity (Hodgson and others 1999). In this trial a
highly-purified recombinant derivative of PLD was used. Of the five rPLD
immunised sheep (group 3), dissemination of the challenge bacteria beyond the site
of inoculation was prevented in all but one individual that manifested evidence of
lung infection.
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In this study the animals vaccinated with rPLD mounted a rapid antibody response,
which peaked around the time of the second immunisation (Figure 7.2). In contrast,
antibody response to the PLD contained within Glanvac™ corresponds to earlier
observations (Hodgson and others 1994; Chaplin and others 1999) where anti-PLD
IgG rose relatively modestly with successive vaccinations, but increased further
following challenge. The reason for this statistically significant difference between
vaccines may relate to the relative amounts of rPLD and wild-type PLD in the
experimental and Glanvac™ vaccines, respectively.
To date, evidence for the protective effects of autogenous CLA vaccination in the
UK has been purely anecdotal. However, the study demonstrated significant
protection against homologous challenge using a C. pseudotuberculosis bacterin
vaccine. Vaccination with killed whole-cells was sufficient to prevent the spread of
C. pseudotuberculosis beyond the site of inoculation, and in one animal even the
inoculation locus was found to be sterile.
The genome of C. pseudotuberculosis of sheep and goat origin from the UK and
other countries would appear to be extremely stable (Connor and others 2000;
Connor and others 2007). However, PFGE analysis of multiple C.
pseudotuberculosis isolates from a CLA-affected flock has revealed the presence of
different, albeit related, clones in different animals (M. C. Fontaine, personal
communication). This has important implications for the success of autogenous
vaccination strategies, should they be found not to confer protection against
heterologous C. pseudotuberculosis strains.
These results support previous findings that neither rPLD nor whole cell vaccine was
sufficient on its own to resist artificial infection (Cameron and others 1972; Cameron
and Fuls 1973). In contrast, immunisation of sheep with a combination of rPLD and
formalin-killed whole-cells produced an apparently complete protection against
experimental challenge. Even the infected sites of inoculation, which frequently
contained live C. pseudotuberculosis cells in other experimental groups, completely
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resolved and were found to be sterile on culture. These observations are consistent
with those of a previous study (Burrell 1983).
C. pseudotuberculosis has been shown to survive killing by non-activated
macrophages of several species (Hard 1972; Tachedjian and others 1995) and the
importance of activated macrophages in the suppression of C. pseudotuberculosis
growth and lesion development has been shown in a murine model (Hard 1970;
Simmons and others 1997). In addition, murine macrophage killing of C.
pseudotuberculosis following opsonisation with hyperimmune ovine serum has been
demonstrated (Hard 1972). Taken together, these observations may help to explain
the effectiveness of the combined rPLD/whole cell vaccination. Neutralisation of
PLD (and other C. pseudotuberculosis proteins) by serum antibodies and
opsonisation of bacteria for killing by non-activated macrophages, would be
combined with priming of the cell-mediated immune response, thus allowing
activated macrophages to more effectively kill introduced bacteria. It should be
noted however that no attempt was made to measure a possible cell-mediated
immune response during any stage of the experiment.
While the protection offered by Glanvac™ was lower than with the other
experimental vaccines tested, it is of relevance that this was the only vaccine tested
for its capacity to protect against heterologous challenge. For this reason, direct
comparison between the protective capacity of Glanvac™ and the rPLD vaccine is
not possible. It is noteworthy that although the number of infected loci was reduced
in Glanvac™ immunised animals, there was only one animal which appeared
completely free from infection. In contrast to observations of the rPLD and killed
whole-cell vaccines, immunisation with Glanvac™ was not effective in preventing
the dissemination of C. pseudotuberculosis beyond the primary site of infection.
Interestingly, no lung lesions were identified in Glanvac™-vaccinated animals. An
aerosol route of C. pseudotuberculosis transmission has previously been postulated
(Stoops and others 1984), and it is therefore possible that, despite not completely
preventing infection, the removal of a potential route of disease transmission could
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have a significant impact on the spread of infection to other animals. This hypothesis
is consistent with the findings of an Australian study, in which Glanvac™ vaccinated
sheep with CLA were observed to have 96% fewer lung abscesses compared with
unvaccinated infected sheep (Paton and others 1995). In that study, 77% of disease
transmission was found to occur around the fourth or fifth shearing, and in the
absence of obvious superficial discharging abscesses, implying spread from
discharging lung abscesses.
One question that remains unanswered is whether the difference in protection
between Glanvac™ and the experimental vaccines was simply due to issues with the
heterologous versus homologous challenge models, or due to the fact that Glanvac™
was simply outperformed by the experimental vaccines. This is relevant, since a
single vaccine, if chosen wisely, might have the capacity to protect against infection
by a variety of different isolates, irrespective of their geographical origin. Clearly,
protection against heterologous challenge by the experimental vaccines needs to be
determined, and future experiments would be required to address this.
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Chapter 8: CASEOUS LYMPHADENITIS IN THE UK-
JUSTIFICATION FOR AND MEANS OF CONTROL
While the commonly accepted view is that C. pseudotuberculosis infection arrived in
Britain with a single consignment of goats in September 1987 (Meldrum 1990), it is
impossible to substantiate this suggestion. Indeed, tracings carried out after the first
isolation of the organism from a homebred sheep, failed to indicate any obvious links
with recently imported animals (Robins 1991), suggesting that the infection may
have been present in the UK rather longer than appreciated. What does appear
indisputable, is that C. pseudotuberculosis was absent from the UK until the late
1980's. Consequently, the emergence of CLA within the domestic sheep industry
over the last 20 years represents a national epidemic, albeit one occurring at a
relatively slow pace.
The initial spread of CLA was undoubtedly assisted by a lack of awareness of this
novel condition by famers and veterinary surgeons, combined with the sub-clinical
nature ofmany CLA cases. This was exacerbated by established practices of animal
trade and movement within the industry, which enabled infection to spread widely
around the country.
As discussed in Chapter 3, this epidemic was at first restricted to the terminal sire
sector of the industry. That study showed clearly how far infection had extended in
the ten years after the first diagnosed case ofCLA in a UK sheep, with some 18% of
sampled flocks showing serological evidence of infection. Given the stratified nature
of the British sheep industry, the presence of any disease in flocks at the top of the
breeding pyramid is cause for concern, and recent events have tended to confirm
fears that infection would spread from these elite flocks to the wider commercial
sector.
CLA has now been identified as a problem in some hill and upland breeds, with
several outbreaks being reported in North Country Cheviot flocks in the north of
Scotland (Anon 2004). As indicated in Chapter 6, CLA is a disease quite capable of
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spreading effectively within flocks managed in much more extensive systems. This
is consistent with findings from Australia where CLA is highly prevalent in
extensively managed flocks that are maintained at stocking densities broadly
equivalent to that ofmany flocks in this country (Paton 1997).
Based on experience gained in this country over the last 20 years, and on the
epidemiology of the infection in other parts of the world, the assumption for the UK
must be that if left unchecked, CLA will become a highly prevalent disease within
the sheep industry as a whole. Given that CLA is already effectively enzootic within
Britain, the question becomes one of whether disease control is worthwhile, and if
so, how this might best be achieved.
Why is control necessary?
It has been argued that whilst CLA is contagious and aesthetically unpleasant, its
relatively mild systemic effects do not justify significant expenditure of time and
resources in its control. It has also been suggested that since C. pseudotuberculosis
is prevalent world-wide, the presence of infection within the UK national flock will
have little impact on this country's ability to trade, or place this country at an
economic disadvantage when compared to competitor nations. This was the
principal justification used by MAFF when it deregulated the emerging disease of
CLA in the early 1990's (Robins 1991). Another argument used at the time, was that
while C. pseudotuberculosis does possess a potential for zoonotic infection, this
occurs infrequently, and does not justify significant expenditure to mitigate the risks.
Indeed, in other countries the condition in man is seen mostly as an occupational
hazard, and as such is best avoided by way of workplace health and safety measures
on farms or in abattoirs (Peel and others 1997).
However, reference to the sheep industries in other parts of the world would tend to
counter an argument to do nothing. In the majority of countries CLA is regarded as a
problem worthy of control, usually by means of routine vaccination and the
application of certain management practices. In Australia particularly, it has been
recognised that although a minor condition for the majority of animals, the
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cumulative financial effects of CLA on the national sheep flock, through decreased
wool production and carcase condemnation, was significant (Paton 1997); and that
this justified a disease control programme on economic grounds. Similar
observations have been made in North America (Williamson 2001) and South Africa
(Paton and others 2005).
Whilst CLA has been recorded in many different breeds and in all regions of the UK,
it remains an uncommon diagnosis. Because of this, the disease carries a stigma
amongst producers of pedigree breeding animals. Many such producers feel that the
disease would place their enterprise at a competitive disadvantage, and are therefore
anxious to avoid buying the problem into their flocks (Davies and Baird 2007).
Recent concerns have also been voiced in the Netherlands following the importation
of several consignments ofUK Suffolk rams that were subsequently diagnosed with
the condition (D. P. Dercksen, personal communication). The owners of UK flocks
where CLA has already been diagnosed are similarly anxious that their sale animals
are not sub-clinically infected. It was these considerations that motivated the owners
of the flocks in Chapters 5 and 6 to regard CLA control as a priority.
Another driver for CLA control to emerge recently is the clinical similarity of the
condition to tuberculosis (TB) due to Mycobacterium bovis in small ruminants.
Outbreaks of TB have been diagnosed in goats (Crawshaw and others 2008; Daniel
and others 2009) and sheep (Houlihan and others 2008) in recent years, and have
caused some alarm within the farming community. During the investigation of these
outbreaks CLA was considered to be a differential diagnosis, based on the clinical
signs of lymphadenopathy and ill thrift (Van Der Burgt 2010). In one case a
concurrent TB and CLA infection was diagnosed in a herd of goats (Sharpe and
others 2010). This led the authors of that report to warn practitioners to be aware of
these similarities, and to urge them to suspect TB where serological or
bacteriological evidence ofCLA was lacking in a particular case.
The past two decades have shown us that where efforts at controlling CLA are
absent, or at best limited to the culling of clinically affected animals, the spread of
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infection is relentless. If control of CLA is accepted as being desirable, the optimal
means by which this can be achieved then becomes important. The preceding
chapters have described ways in which this objective might be reached through the
use of serology and vaccination.
Serological testing
Test and cullprogrammes
Chapters 5 and 6 of this thesis describe the potential benefits of an ELISA-based test
and cull programme for the control of CLA. Complete disease eradication is likely
to be an achievable objective, albeit one that is immensely challenging, requiring
significant organisational effort and the likelihood of substantial financial cost.
In recent years, work in the UK carried out by the author and colleagues has led to
the development of a commercially available CLA ELISA kit (and a related Western
blot assay based on the test recombinant PLD antigen) for use in sheep and other
species (Anon 2007a). This assay was used in the trial reported in Chapter 6 and has
similar levels of sensitivity and specificity to the ELISA used in the trial reported in
Chapter 5. More than 10,000 ELISA tests were run for the purpose of CLA control
and potential eradication in flocks within the UK during 2009. As anticipated, the
expense associated with testing a large number of animals, means that the majority of
this work is currently done within small flocks ofhigh value pedigree sheep.
Pre-sale screening ofbreeding animals
A second way in which the CLA ELISA has been used in recent years is as a tool in
the pre-sale screening of breeding animals. The CLA Monitoring Scheme was
established by the author under the auspices of the Premium Sheep and Goat Health
Schemes (Anon 2005). The basis of this scheme is the certification of animals that
have undergone specified serological and clinical examinations during a three month
quarantine period. Since the establishment of the programme in 2005, approximately
5,200 sheep have been tested within the CLA Monitoring Scheme. This represents
around 300 groups, of mostly breeding rams, which were marketed as CLA-
monitored at ram sales in Kelso (Roxburghshire), Builth Wells (Powys), Lairg
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(Sutherland) and elsewhere. While the intention of this scheme was to introduce a
level of quality assurance for buyers, with a potential for added value for sellers, it
has not been widely supported by the terminal sire breed societies.
A local initiative that has gained considerably more support has been the screening
for serological evidence ofCLA of all sheep entering the Shetland Islands, which has
been in operation since 2008. This scheme was established after two major flock
outbreaks on the Islands (Anon 2007b, 2008) led to local concern on the part of local
farmers, who import up to 500 rams each year. These animals are from the terminal
sire breeds (mainly Suffolk) and are used for crossing with the indigenous Shetland
sheep breed. The Shetland CLA scheme is enhanced by general acceptance from
farmers, the single point of entry via the port of Lerwick and substantial financial
backing from the local Council.
Vaccination
Chapter 7 describes how the use of vaccination can substantially prevent the
development of clinical CLA in animals infected with UK isolates of
C. pseudotuberculosis. Vaccination is the primary means of disease control in most
major sheep producing countries, where immunisation reduces the spread of
infection, and leads to a gradual decline in disease prevalence. However, no
proprietary CLA vaccine currently available offers complete protection against
infection by C. pseudotuberculosis', hence, animals will continue to develop clinical
disease, albeit in reduced numbers. This is evidenced by a report from Australia
which indicated that, despite the widespread use of a commercial CLA vaccine in
that country since 1983, disease prevalence remained at approximately 20% in 2002
(Paton and others 2003). One explanation for this is provided by evidence that as
few as 9% of producers may be employing CLA vaccination effectively (Paton
2010), a trend that might very well be repeated in the UK.
A hurdle that may now stand in the way of CLA eradication by means of ELISA
testing is that of vaccination. Although as stated, no fully licensed vaccine is
available in the UK, the use of vaccination against CLA is possible with the
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authorisation of the VMD. With the agreement of VMD an autogenous C.
pseudotuberculosis vaccine may be prepared in this country. Alternatively, on
receipt of a Special Treatment Certificate from the VMD, a veterinary practitioner
may on behalf of a client, import a proprietary CLA vaccine into the UK. However,
anecdotal evidence suggests that unauthorised importation and use of proprietary
vaccines may also be occurring. This is significant, since as described in Chapter 7,
CLA vaccines containing PLD antigen have been shown to produce seroconversion
detectable as positive titres in the ELISA test. For this reason the use of current
vaccines is incompatible with a test and cull programme as described here.
Modelling disease control
Mathematical modelling techniques have now been applied to CLA epidemiology
and control in the UK. In the first such model, data from four infected flocks was
used to describe epidemic CLA and to estimate transmission coefficients for different
routes of disease transmission (O'Reilly and others 2008). This model was then used
to evaluate strategies for control of the disease and the potential for complete
elimination of C. pseudotuberculosis from affected sheep flocks; the latter being
defined as a 99% confidence that no sheep remained infected (O'Reilly and others
2010). The overarching conclusion of this work was that CLA control programmes
should begin as soon as C. pseudotuberculosis infection is first confirmed. The
model predicts that elimination of the infection is most likely using a serological test
with sensitivity and specificity of at least 90%. This was deemed to be achievable
after five tests, although with a significant impact on flock productivity likely due to
the removal of seropositive animals. The model also predicted that a combination of
vaccination and clinical examination would also reduce infection rapidly, but with
less likelihood of total elimination of the pathogen.
Scientific contributions made by this work
It is the author's hope and belief that the work described in this thesis has advanced
the understanding of CLA in the UK and provided guidance on how effective control
may be established. In the authors view the most salient contributions have been:
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1. The identification ofhigh CLA prevalence within the terminal sire sector, at a
time when the industry awareness of this disease was relatively low.
2. Confirmation that conventional dairy pasteurization protects consumers from
potential C. pseudotuberculosis contamination in milk
3. The demonstration that a CLA control programme incorporating ELISA
testing can, under certain circumstances, facilitate disease eradication.
4. The eventual commercialisation of a CLA ELISA assay and its use today in
disease eradication and sheep health schemes.
5. A demonstration that vaccination can protect sheep in a UK infection model
and that a combined recombinant PLD and bacterin vaccine is potentially the
most effective product.
Remaining gaps in our knowledge
Work conducted by the research team of which the author was a member, indicated
that the genome of C. pseudotuberculosis strains responsible for CLA in this country
is largely identical to that of isolates from other parts of the world (Connor and
others 2007). Consequently, an explanation other than bacterial strain differences
must exist to account for the contrasting clinical presentation of CLA in the UK
compared to other countries (as described in Chapter 2). Although the principles of
CLA disease pathogenesis are now well established in the literature, there are as yet
no satisfactory explanations of why lesion distribution varies in different parts of the
world. Although certain theories have been suggested, questions over mode of
transmission and common routes of infection in the UK remain to be answered
before guidance on disease prevention can confidently be given.
As indicated by recent modelling work, complete eradication of CLA becomes more
feasible as the specificity and sensitivity of the serological tests improve. Whilst
currently available ELISA tests offer specificity in sheep that is significantly greater
than the 90% specified by modelling, sensitivity falls below this level - a feature
which it shares with most other recent tests. Further development in the area of
serology - perhaps in uncovering other conserved antigens associated with C.
pseudotuberculosis - is required if test sensitivity is to be improved.
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Debate continues over the best methods of controlling CLA in the UK. Vaccination
is the main strategy in most of the countries where CLA is endemic and many in the
UK farming community advocate the licensing of a proprietary vaccine. However, at
present there seems little likelihood that the relevant pharmaceutical companies will
complete the work required to obtain a full licence in the UK. In any case, as
discussed in Chapter 7, simply licensing the existing proprietary vaccines for use in
this country may not provide the solution that many in the farming community might
hope for. This leaves the use of those proprietary vaccines under emergency licence
from the VMD and the use of autogenous vaccines as the only legal options currently
available to UK producers.
Development of a novel CLA vaccine is proceeding in the UK and this provides
some encouragement that vaccination could become a more serious option for CLA
control in the future. Reports indicate that a novel product based upon a Scottish
C. pseudotuberculosis isolate is to be manufactured as a marker vaccine (Anon
2009b). This would in theory enable farmers to differentiate between serological
responses produced in natural CLA infections and those resulting from vaccination.
If successful that would enable a combined serological and vaccination approach to
disease control, which would be expected to offer greater flexibility and significant
benefits over either approach on its own. Further work and the agreement of the
regulatory authorities would be required to enable these developments to become
useful in the field.
Outlookfor the UK
It is the author's opinion, based on the work described in this thesis, that accurate
serodiagnosis together with segregation or culling of infected animals, currently
offers a method for the complete eradication of CLA. The demonstration that
vaccination can protect sheep from the UK form of disease offers further hope that
the condition may be preventable in the wider sheep industry. Any future
improvements in serodiagnosis and vaccination will require continued effort to
understand the mechanisms by which C. pseudotuberculosis interacts with its host,
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causes disease, and often persists throughout life. The story ofCLA over the last 20
years has provided the UK with an object lesson on how an animal infection can
progress from being a minor epizootic to a nationally enzootic disease. Whether the
future is one of continuing disease spread or of eradication and control, will depend
largely on whether the lessons learnt in the laboratory can be effectively
communicated to and applied by, the farming industry.
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Summary
Caseous lymphadenitis (CLA) of sheep, caused by Corynebacterium pseudotuberculosis, has been a significant disease
in the majority ofsheep-rearing regions for over a century. Because of the chronic and often sub-clinical nature of
the infection, it has proved difficult to control and prevalence is high in many parts of the world, which in turn
leads to significant economic losses for farmers. This review describes the important characteristics of C. pseudotu¬
berculosis and examines the pathogenesis and epidemiology of the infection in sheep. The review also discusses the
immune response to infection and describes the methods that have been developed to control CLA, with particu¬
lar emphasis on the use of vaccination and serological testing.
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Introduction
The perceived importance of caseous lymphadenitis
(CLA) as a disease of sheep varies greatly around the
world. Thus, in the UK, where this disease appeared
for the first time in the early 1990s, the steady and ap¬
parently relentless spread of infection in sheep and
goats has prompted great concern amongst both farm¬
ers and veterinary surgeons. However, in the sheep in¬
dustries of Australia and New Zealand infection is
regarded as relatively minor, albeit widespread. The
roots of these contrasting attitudes lie in differences in
disease prevalence, available means of control, and
meat inspection practices.
To the veterinary pathologist, the causative organ¬
ism of CLA, Corynebacterium pseudotuberculosis, has a va¬
lid claim to being the "perfect parasite". Once
successfully established within the host, this pathogen
will evade the immune system with apparent ease. As
a result, chronic infections may last for most or all of
an animal's life, although they are rarely fatal. If left
unchecked, the disease may infect the majority ofsheep
in a flock. Even away from its mammalian host, the or¬
ganism is well equipped for long-term survival in the
environment. As a result of these formidable character¬
istics, flock infections by C. pseudotuberculosis are gener¬
ally "managed", rather than eradicated.
History
In 1888, the French bacteriologist Edward Nocard iso¬
lated an unusual organism from a case of lymphangitis
in a cow (Nocard, 1896). Some 3 years later, the Bulgar¬
ian bacteriologist Hugo von Prelsz identified a similar
bacterium in cultures from a renal abscess in a ewe
(Preisz and Guinard, 1891). As a consequence of these
related discoveries, the organism in question became
known as the "Prei'sz-Nocard" bacillus, a vernacular
name with which it was linked for decades thereafter.
Towards the end of the 19th century the bacterium
was described by the German bacteriologists Lehmann
and Neumann in the first edition of their bacteriologi¬
cal atlas (Lehmann and Neumann, 1896). In that pub¬
lication, the Prei'sz-Nocard bacillus was renamed
Bacillus pseudotuberculosis—a derivation of the Greek
pseudes tuberculosis or "false tuberculosis" and a reference
to the supposed clinical similarity of the lesions to case¬
ous nodules ofmycobacterial tuberculosis. In the First
Edition of Bergey's Manual ofDeterminative Bacteriology,
published in 1923, the organism was placed in the Cory-
nebacteriumgenus, which had originally been created as a
category for the human pathogen Corynebacterium
diphtheriae. This edition of the Manual referred to work
showing that B. pseudotuberculosis resembled C. diphther¬
iae in morphology and cell wall composition, leading
to a further change ofname to Corynebacterium ovis. Sub¬
sequently, however, the organism was isolated from
purulent infections and ulcerative lymphangitis in
other mammalian species, including goats, horses and
human beings. In recognition of this, by the time the
Sixth Edition of Bergey's Manual was published in
1948, the species name had been changed back from
ovis to the earlier designation ofpseudotuberculosis. Since
that point, the officially recognized designation of Cor¬
ynebacterium pseudotuberculosis has remained consistent
(Euzeby, 2005), notwithstanding the fact that several
authors continued to refer to the organism as C. ovis un¬
til the 1980s.
Geographical Distribution
The global range of C. pseudotuberculosis reflects that of
farmed small ruminants, the bacterium having been
identified in Europe, Australasia, North and South
America, Africa and the Middle East (Robins, 1991;
Paton et al., 2005). In many of these countries CLA has
been an established and economically important infec¬
tion of livestock, particularly sheep, for decades. As
early as the 1930s it was acknowledged that the disease
"very extensively affected" the flocks of most mutton-
exporting countries (Cesari, 1930). It is surprising
therefore, that the first diagnosed case in an animal ori¬
ginating from the UK was not confirmed until as re¬
cently as 1989 (Lloyd et al., 1990; Meldrum, 1990).
Some suggestions have been made that the origins of
the infection may lie in Europe, and that spread of C.
pseudotuberculosis around the world followed the expor¬
tation of sheep by the 18th-century colonial powers.
The Merino breed, which originated in Spain, was
widely valued as a dual meat and wool animal and
was exported extensively, first to South Africa and sub¬
sequently to Australia and the Americas. It has been
suggested that this early exportation may, at the very
least, have assisted in the spread of C. pseudotuberculosis
(Paton, 2000). Such a theory is difficult to prove, but
supporting evidence might be provided by demonstra¬
tion of a close genotypic relationship between isolates
from different parts of the world. Certainly, it is inter¬
esting to speculate that the absence of the Merino as a
commercial breed in the British Isles may have gone
some way to protecting this country from the infection.
CLA first became a significant political issue in the
1920s when mutton carcases, imported into Great Brit¬
ain from a number of countries, were frequently found
to be affected by the disease. It was noted at the time
that evidence of infection would often remain unob¬
served at import meat inspection "only to be revealed
when the roast leg ofmutton appears on the table and
is cut through" (Rolleston andWooldridge, 1926). Mut¬
ton from Argentina was particularly badly affected,
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forcing the British Government of the time to take ac¬
tion in relation to consignments of carcases from that
country (Anon, 1929). The extent of the problem was
demonstrated by a report that in a single season 9770
mutton carcases (representing 27% of the total
throughput) were rejected at one Patagonian meat
plant because of CLA (Mills, 1928). Other mutton-ex-
porting countries took heed of the concerns in Britain
and it was soon acknowledged that "Argentina, Uru¬
guay, Chili (sic), Australia and New Zealand are ac¬
tively occupied...in a struggle against this tenacious
chronic disease which, completely neglected up to
now, is very extensively affecting the flocks of those
countries" (Gesari, 1930). These concerns also stimu¬
lated veterinary research, principally in Australia,
leading to important early discoveries on pathogenesis,
bacterial survival and risk factors (Seddon et al., 1929;
Bull and Dickinson, 1935).
Research interest in CLA was renewed in the 1970s,
when the authorities in the USA, Canada and Japan
applied strict regulations relating to the presence of le¬
sions in imported sheep carcases. A further series of
studies into disease pathogenesis and epidemiology
was then initiated in Australia, which, as a major ex¬
porter of sheep and a high CLA prevalence within its
national flock, had much to lose from the stricter regu¬
latory regime. This in turn led to the formulation of
control strategies aimed at reducing disease prevalence
and provided a catalyst for developments in the field of
vaccination.
Global Prevalence of CLA
C. pseudotuberculosis is recognized as having a worldwide
distribution and it is accepted that CLA is present in
the majority of the sheep-rearing areas. However,
farm- and abattoir-based research aimed at establish¬
ing disease prevalence rates has been limited to rela¬
tively few countries. The average prevalence of CLA
amongst adult sheep inWestern Australia was recorded
as 58% in 1973, and as 53% in 1984 (Batey, 1986a). In an
Australian abattoir survey, 54% of adult ewes and
3.4% of lambs showed evidence of infection at meat in¬
spection (Batey, 1986b). In another abattoir survey, in¬
dividual flocks in Tasmania and Western Australia
demonstrated prevalence levels within the adult popu¬
lation as high as 61% (Middleton et al., 1991). Subse¬
quent surveys tended to identify steadily decreasing
prevalence rates, this generally being attributed to the
introduction of a CLA vaccine in 1983 and its increas¬
ing acceptance within the farming community. A field
study of412 sheep flocks, once again inWestern Austra¬
lia, recorded an average prevalence of 45% (Pepin
et al., 1994a). A combined abattoir and postal survey of
farmers, conducted in 2002, suggested that the average
prevalence had fallen to 20% in Western Australia,
23% in Victoria and 29% in New SouthWales (Paton
et al., 2003).
A survey conducted in 1986/1987 by meat inspectors
in New Zealand identified lesions ofCLA in 7.1 % ofthe
adult sheep slaughtered and 0.64% of lambs (Nuttall,
1988). CLA was also identified as the leading cause of
sheep carcase condemnation in South African abat¬
toirs (Collett et al., 1994) where losses of between
0.24% and 0.3% of all sheep carcases were attributed
to CLA and substantial additional losses were incurred
due to carcase trimming (Paton et al., 2005). In the wes¬
tern USA, average disease prevalence amongst adult
ewes was estimated to be as great as 42.5% (Stoops
et al., 1984). Similar studies have been conducted in the
Canadian province ofQuebec, where the prevalence of
clinical CLA was found to range from 21% to 36%
amongst culled adult sheep (Arsenault et al., 2003).
Abattoir statistics from Alberta indicated that up to
5% of mutton carcases and 0.03% of lamb carcases
were condemned due to CLA, and that a further 8%
of all carcases were trimmed to remove CLA lesions
(Stanford et al., 1998). Unfortunately, similar published
statistics do not exist in respect of Europe. In the UK,
where small abattoir surveys of CLA prevalence have
been carried out, the results have been of limited scope
and significance (Mechie, 1998).
Bacterial Characteristics
Classification
The Corynebacteriaceae are now considered to belong
to the Actinomycetaceae, a family that also contains
the Mycobacterium, Rhodococcus and Nocardia genera
(Clarridge and Spiegel, 1995). C. pseudotuberculosis pos¬
sessesmany of the classical features of its genus (Collins
and Cummins, 1986). It consists of non-motile pleo¬
morphic rods (0.5-0.6 pm by 1.0-3.0 pm) that are
Gram-positive, although such staining may sometimes
be irregular. Groups of the bacteria tend to show a
characteristic palisade or "Chinese letter"arrangement
in smears.
At a temperature of 37 °C, C. pseudotuberculosis will
grow under aerobic or anaerobic conditions. On solid
media, the bacterial colonies are pale in colour, dry
and friable in consistency, and may be moved freely
over the surface of the agar with the point of a probe
(Quinn etal., 1994). After incubation for 24 h, small yel¬
lowish colonies will appear, increasing to a diameter of
1-2 mm after 48 h (Coyle et al., 1985). Bacterial growth
benefits from the addition of serum or whole blood to
nutrient media. When whole blood is used, a narrow
band of /f-haemolysis is seen around each colony,
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although it may appear only after incubation for
48-72 h.
When grown in liquid media or when in aqueous
suspension, C. pseudotuberculosis has a tendency to form
clumps. This has been related to the presence of long-
chain 2-branched 3-hydroxy fatty acids (so-called "my-
colic acids"), on the outside of the cell wall (Carne etal.,
1956). Mycolic acids were first identified in 1939, in the
tubercle bacillus (Asselineau and Laneelle, 1998) and
were subsequently found to be a feature common to
the actinomycete family as a whole. Mycolic acids may
be solvent-extracted from C. pseudotuberculosis without
impairing the viability of the organism (Carne et al.,
1956).
The so-called "chemotaxonomic" approach to the
classification of bacteria, based on analysis of the che¬
mical composition of the cell wall, was at one time used
relatively commonly. Analysis ofcell wall mycolic acids
greatly aided clarification of the taxonomy of actino-
mycetes, especially those of the genera Corynebacterium,
Mycobacterium, Rhodococcus and Nocardia (Minnikin
et al., 1975; Goodfellow et al., 1976; Keddie and Cure,
1977; Minnikin and Goodfellow, 1980; Collins et al.,
1982). In these studies, thin-layer (pyrolysis) chromato¬
graphic analysis ofmycolic acid revealed that fatty acid
chain length varied according to the genus and to a les¬
ser extent the species. It was shown that mycobacterial
mycolic acids normally consist of chain lengths of be¬
tween 60 and 90 C14 atoms, and may possess a number
of distinct functional groups (Minnikin et al., 1978). In
contrast, nocardiae and rhodococci were shown to pos¬
sess shortermycolic acids, consisting ofbetween 36 and
66 C14 atoms, and with fewer functional groups (Min¬
nikin and Goodfellow, 1976). The mycolic acids ofcory-
nebacteria were found to be even smaller, being
between 20 and 36 C14 atoms in length, and usually sa¬
turated or containing a single double bond (Minnikin
etal., 1978). Collins et al. (1982) reported that, consistent
with the mycolic acid classification of corynebacteria,
strains of C. pseudotuberculosis possessed mycolic acids
with carbon chain lengths of between C26 and C36,
which contained predominantly saturated C14 side-
chains (Collins et al., 1982).
There are few published data on the resistance of C.
pseudotuberculosis to chemical disinfectants. However,
most common disinfectants, including calcium hypo¬
chlorite, formalin and cresol solution, appear to be ef¬
fective in killing the organism, but the presence of
organic material necessitates increased exposure time
(Ismail and Hamid, 1972). This protective effect is
clearly significant for a pathogen commonly found
within a thick matrix ofpurulent debris. The organism
is capable of surviving in commercial sheep dip solu¬
tions for 24 h or more, a point of relevance to disease
control (Nairn and Robertson, 1974).
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Early reports showed that C. pseudotuberculosis isolates
from different mammalian species shared identical
biochemical characteristics, with the exception of ni¬
trate reduction. Thus, the majority of isolates from
horses and cattle reduced nitrate to nitrite, while those
from sheep and goats did not (Knight, 1969; Sutherland
et al., 1996). This led to the proposal of two distinct bio-
types or subspecies (Biberstein et al., 1971). Based on
this property of nitrate reduction, Songer et al. (1988)
proposed the designations C. pseudotuberculosis biovar
ovis (biotype 1) and C. pseudotuberculosis biovar equi (bio-
type 2). However, the isolation in recent years of
nitrate-negative strains of C. pseudotuberculosis from
cattle (Yeruham et al., 1997) and from horses (Connor
et al., 2000) suggests that such categorization may be
unsatisfactory.
A further minor difference between certain isolates
lies in the area ofantibiotic sensitivity. In a comparison
ofsusceptibility to 17 different antimicrobial agents, the
minimum inhibitory concentration of amikacin was
higher for nitrate-negative sheep and goat isolates than
for nitrate-positive equine and bovine isolates (Costa
et al., 1998); however, the significance of this finding is
not clear.
Virulence Factors
No avirulent strain of C. pseudotuberculosis has yet been
described; however, the organisms virulence mechan¬
isms remain poorly understood. Since no plasmids have
been identified in isolates of C. pseudotuberculosis, the ab¬
sence ofplasmid-encoded virulence determinants must
be assumed. To date, research has focussed mainly on
two known virulence factors identified as phospholi-
pase D and mycolic acids. The genome of C. pseudotuber¬
culosis, unlike that of a number of other bacterial
pathogens, has yet to be fully sequenced; as a result,
there is at present no opportunity to identify novel gene
sequences that may encode other virulence factors.
Phospholipase D. The designation "phospholipase" is
used to describe a varied group of enzymes able to hy-
drolyse one or more ester linkages in glycerophospholi-
pids; the letters A-D are used to distinguish between
phospholipases and to denote the specific phospholipid
ester bond that is cleaved (Ansell and Hawthorne,
1964). In eukaryotic cells, phospholipase enzymes play
a role in signal transduction and normal membrane
maintenance. Some mammalian cells also produce
phospholipases as part of the cellular inflammatory re¬
sponse (Schmiel and Miller, 1999). Eukaryotic cell
membranes are composed ofproteins and lipids, which
constitute a significant target of attack during micro¬
bial invasion ofhost tissues. As part of their invasive ar¬
senal, many microbes have developed their own
phospholipase enzymes, which may be used to hydro-
Ovine Caseous Lymphadenitis 183
lyse phosphate bonds within membrane phospholipids
(Ghannoum, 2000). The result of this is the damage or
destruction of host cell membranes, which in turn may
lead to their dysfunction or disruption, or both (Salyers
andWitt, 1994). Various bacterial genera are known to
secrete phospholipase enzymes, and in some cases these
have been shown to play a role in virulence (Schmiel
and Miller, 1999). Phospholipase D (PLD) has been
identified as a potent exotoxin in C. pseudotuberculosis,
and a key virulence factor in the development of
CLA.
PLD in this organism was first characterized by
Carne (1940) and has since been detected in every iso¬
late of C. pseudotuberculosis that has been studied, includ¬
ing isolates of both of the suggested biotypes, and all
known strains of the organism recovered from infected
mammalian species (Songer et al., 1988). The conten¬
tion that PLD represents a significant virulence factor
is supported by much experimental evidence. Isolates
of C. pseudotuberculosis in which the pld gene, encoding
PLD, has been deleted from the chromosome or ren¬
dered inactive by mutation are incapable of causing
the classic lymph node abscesses of CLA in sheep
(Hodgson al., 1992; McNamara etal., 1994). Similarly,
the presence of specific antibody to PLD greatly limits
the progress of the clinical disease.
PLD is defined as a sphingomyelin-specific phospho¬
lipase that catalyses the dissociation of sphingomyelin
into ceramide phosphate and choline (Bernheimer
et al., 1980; Pepin et al., 1994a). The C. pseudotuberculosis
pld gene has been cloned and sequenced. Analysis
reveals that it encodes a protein of some 31.4 kDa, pre¬
ceded by a probable secretory signal sequence of
2.7 kDa (Hodgson et al., 1990). The relatively large size
of the protein molecule assists in its purification in the
laboratory and enables large quantities to be collected
(Egen et al., 1989). Several biological activities have
been reported for PLD, including dermonecrosis (Carne,
1940; Muckle and Gyles, 1986), lethality (Brogden and
Engen, 1990), synergistic lysis oferythrocytes in the pre¬
sence ofan extracellular Rhodococcus equi factor (Fraser,
1961), and inhibition ofstaphylococcal lysin-induced ly¬
sis of erythrocytes (Zaki, 1976); the two latter activities
are employed as laboratory tests for the identification of
C. pseudotuberculosis. PLD also interferes with ovine neu¬
trophil chemotaxis and is lethal to the cells themselves
(Yozwiak and Songer, 1993). In terms of the significance
of PLD as a virulence factor, the activity that has been
the focus ofmost interest is the increase in vascular en¬
dothelial membrane permeability engendered by the
hydrolysis ofsphingomyelin. This increased permeabil¬
ity leads to the leakage of plasma from blood vessels
and into the surrounding tissues, and from there into
the lymphatic drainage (Jolly, 1965; Carne and Onon,
1978). This effect may assist pathogenesis by favouring
the lymphatic drainage of C. pseudotuberculosis in tissue
fluid (Batey, 1986c).
PLD may assist the organism at the site of initial in¬
fection in other ways. It is known to activate the com¬
plementary pathway of the innate immune system,
thereby depleting complement in the region surround¬
ing the invading bacteria and protecting them from op¬
sonization (Yozwiak and Songer, 1993). It may also
impair the chemotaxis of neutrophils and, as a conse¬
quence, decrease the likelihood of phagocytosis early
in infection (\ozwiak and Songer, 1993). In some re¬
spects this suggestion is at odds with other theories of
pathogenesis, which propose that in the early stages of
disease the organism parasitizes phagocytic cells and
multiplies within them. Indeed, other authors have in¬
dicated that PLD may play a role in the escape of the
bacterium from within macrophages. It is possible that
this role is related to the action of PLD on the inner
phospholipid layers of the macrophage cell membrane,
as indicated by comparable observations on other bac¬
terial infections (Titball, 1993).
Exotoxins with similarities to the PLD of C. pseudotu¬
berculosis are known to be important virulence factors
for other bacterial pathogens. For example, there is
97% homology between C. pseudotuberculosis PLD and
the active exotoxin of C. ulcerans, a rare cause of hu¬
man diphtheria (McNamara et al., 1995). A PLD-like
exotoxin is also considered to be an important viru¬
lence factor in Pseudomonas aeruginosa (Wilderman
et al., 2001). Likewise, pld shows homology to theymt
gene from the plague-causing organism Yersinia pestis
(Hinnebusch etal., 2000). PLD also demonstrates an in¬
triguing similarity in structure and biological activity
to an enzyme toxin produced by the venomous North
American brown recluse spider, Loxosceles reclusa (Bern¬
heimer et al., 1985). This toxin induces dermonecrosis,
haemolysis, platelet-aggregation and, on rare occa¬
sions, fatal renal failure (Lee and Lynch, 2005). Simi¬
larly, Hsu et al. (1985) showed that severe haemolytic
crises resulted from the injection of C. pseudotuberculosis
culture supernates or crudely purified exotoxin pre¬
parations into small ruminants
Mycolic acid. C. pseudotuberculosis does not produce a pro¬
tective capsule but has instead a waxy mycolic acid coat
on the cell wall surface (described above). This coat has
well-established cytotoxic properties, which play a ma¬
jor role in pathogenicity (Hard, 1972; Muckle and
Giles, 1983; Tashjian and Campbell, 1983). The subcuta¬
neous injection into mice of mycolic acid extracted
from C. pseudotuberculosis results in the production of a
localized swelling, with congestion and a central area
of haemorrhagic necrosis. In addition, mycolic acid in¬
duces degenerative changes and death in phagocytiz-
ing leucocytes (Carne etal., 1956). However, unlike the
lethal effect of injection of similar molecules extracted
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from mycobacteria, the cytotoxic effect ofC.pseudotuber¬
culosis mycolic acid is confined to the site of injection
(Hard, 1975).
Some authors have suggested that the mycolic acid
coat enables C. pseudotuberculosis to survive for extended
periods within the environment, a feature common to
other members of the actinomycete family. C. pseudotuber¬
culosis is indeed relatively resistant to environmental con¬
ditions (West etal., 2002). Low ambient temperatures and
mixing with particulate fomites enhance survival of the
organism in discharged pus, viable bacteria being reco¬
verable from inanimate surfaces for up to 55 days after
contamination (Augustine and Renshaw, 1986). Batey
(1986c) reported that under cold and damp conditions,
the organism may remain viable in a farm environment
for 6 months or more. Soil experimentally contaminated
with pus still contained viable bacteria 8 months later
(Brown and Olander, 1987). Thus, the environment may
remain infectious for a significant period after contami¬
nation by an affected sheep.
In natural infections, the waxy mycolic acid coat of
C. pseudotuberculosis provides the organism with mechan¬
ical, and possibly biochemical, protection from the hy-
drolytic enzymes present within lysosomes.This in turn
enables the bacterium to survive phagocytosis and to
exist within the host as a facultative intracellular para¬
site (Williamson, 2001). This capacity is likely to be es¬
sential for the migration of the organism from the point
of initial entry to the eventual site of lesion develop¬
ment. In addition, the toxic nature of mycolic acid
seems to contribute to abscess formation. In artificial
infections of mice, a direct relationship was demon¬
strated between the quantity ofcell wall lipid produced
by different isolates ofC.pseudotuberculosis and their abil¬
ity to produce chronic abscessation (Muckle and Gyles,
1983).
Other virulencefactors. A previously unreported 40 kDa
protein antigen of C. pseudotuberculosis, suggested by
Walker et al. (1994) to be a virulence factor, has yet to
receive detailed study.
Othersecondaryfactors. Undetermined differences in viru¬
lence factors have been suggested to account for the
specific "ovine/caprine" and "equine/bovine" strains of
C.pseudotuberculosis, which are in other respects (cultural,
antigenic and toxigenic) equivalent (Valli and Parry,
1993). The fact that the equine disease syndromes asso¬
ciated with the organism appear to be absent from large
parts of the world in which the ovine infection is ende¬
mic, supports the existence of such differences. As dis¬
cussed later, the probable importance of secondary
factors, such as insect vectors, in C. pseudotuberculosis in¬
fections of horses may go some way to explaining this.
However, in order to clarify the matter experimental in¬
fections with ovine and equine strains in parallel would
be required.
Clinical and Pathological Features of Caseous
Lymphadenitis in Sheep
C. pseudotuberculosis infections in sheep are classically as¬
sociated with the formation of pyogranulomas (Valli
and Parry, 1993), and this accounts for the name "case¬
ous lymphadenitis". The lesions occur in two main
forms, namely external (also known as superficial or
cutaneous) and visceral, which may co-exist within
the same animal. The external form is characterized
by abscessation of those lymph nodes that may be pal¬
pated externally (Fig. 1). Any of the superficial lymph
nodes of the body may be affected, dependent upon
the original point of entry of the organism. Less com¬
monly, localized purulent lesions not directly asso¬
ciated with the superficial lymph nodes may occur
within the subcutaneous tissues. Such lesions may ap¬
pear as organized abscesses, with swelling, fibrous en¬
capsulation, loss of overlying hair and eventual
Fig. 1. A caseous lymphadenitis (CLA) abscess in the parotid lymph
node ofan adult ewe.
Fig. 2. CLA abscesses in the lung parenchyma. Note the close proxi¬
mity of the lesion to the airways.
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rupture, resulting in the discharge of pus (Radostits
etal., 2000).
The visceral form is associated with abscesses in
the internal lymph nodes and other organs. In sheep,
the principal location of these internal CLA lesions is
the lung parenchyma and mediastinal lymph nodes
(Fig. 2). Lesions may also be found in the liver, kidneys
or udder, and more rarely the heart, testis, scrotum,
uterus, joints, brain or spinal cord (Valli and Parry,
1993).
Pathogenesis in Sheep
There is a general consensus among recent reviewers
regarding the stages through which C. pseudotuberculosis
infection progresses. After initial entry, the organism
spreads rapidly to the local drainage lymph node.
Here, multiple microscopic pyogranulomas develop,
growing in size and coalescing to form larger abscesses.
This is sometimes followed by a further extension of in¬
fection via the blood or the lymphatic system, leading
to similar lesions in other organs. The nature of these
slowly developing CLA lesions means that chronic,
and frequently lifelong, disease is the rule rather than
the exception. Viable bacteria may be recovered from
abscesses several years after initial infection. Reactiva¬
tion ofdisease may also occur, with the development of
lesions at new sites after a considerable period ofappar¬
ent quiescence.
Numerous routes of inoculation have been used to in¬
duce experimental CLA in sheep; intradermal, subcu¬
taneous, intravenous, intratracheal, intravaginal, and
intralymphatic inoculation have all proved successful
in establishing disease (Nagy, 1976; Burrell, 1978a;
Pepin et al., 1994b; Fontaine et al., 2006). In natural in¬
fections, however, the principal route of entry is be¬
lieved to be through the skin (Batey, 1986c; Brown and
Olander, 1987; Davis, 1990; Collett etal., 1994). This in¬
itial infection is facilitated by minor cutaneous wounds
and abrasions, especially those caused by shearing
(Paton et al., 1988a). Wounds caused during castration
or docking have also been suggested as an occasional
route ofentry, as has the umbilicus in neonatal animals
(Valli and Parry, 1993). Entry via the oral cavity has
been postulated to account for the small number of
head and neck lesions seen in sheep from the Antipodes
and North America, and themany more such lesions in
goats (Ashfaq and Campbell, 1979). In contrast, the
more distal parts of the intestinal tract are not believed
to provide a portal of entry for the organism, even in
the presence of parasitic damage (Valli and Parry,
1993).
A respiratory route ofinfection, postulated by Stoops
et al. (1984), has been widely quoted in subsequent re¬
views. This theory was based on the observations that
some naturally infected sheep show only pulmonary le¬
sions, and that a small number of these lesions are lo¬
cated within the walls of airways (Fig. 2). Moreover,
Brown and Olander (1987) reported the production of
disseminated pulmonary abscesses by injecting intra-
tracheally a broth culture of C. pseudotuberculosis. How¬
ever, other studies have indicated that such pulmonary
lesions may develop as part of a systemic infection in¬
itiated elsewhere in the body. Thus, after the intrave¬
nous inoculation of lambs with C. pseudotuberculosis, the
majority of internal lesions appeared in the lungs and
associated thoracic lymph nodes (Brogden et al., 1984).
It has also been noted that in natural ovine CLA infec¬
tions, the patterns ofdistribution of pulmonary lesions
are consistent with haematogenous or lymphogenous
spread rather than with aerogenous spread (Nairn
and Robertson, 1974). It would therefore appear that
entry of infection via the respiratory tract, although a
theoretical risk, is ofminor importance.
As already described, purulent cutaneous or subcu¬
taneous lesions from which C. pseudotuberculosis may be
isolated occur infrequently in sheep, even in flocks in
which the incidence of classic lymph node lesions is
high. It therefore follows that, on infecting the host via
the skin, the organism is poorly suited to establishing
persistent infections at the site ofentry, and on most oc¬
casions must progress to the local drainage lymph node
and beyond if infection is to be sustained (Valli and
Parry, 1993). The means by which the organism spreads
from the initial point of entry, eventually to form the
classic lesion of CLA, has received close examination.
Of crucial importance is the survival and replication
ofC.pseudotuberculosis in macrophages, which then carry
the organism to the site of the eventual CLA lesion.
The use of radioisotopically labelled inflammatory
cells and scintigraphic imagery demonstrated that,
within a few hours of subcutaneous inoculation with
bacteria, huge numbers of neutrophils were recruited
to the injection site, and by 24 h post-inoculation, these
neutrophils began to appear in the local drainage
lymph node (Pepin etal., 1992); the relative importance
of neutrophils decreased from day 3, while the relative
numbers ofmacrophages at the site of inoculation rose
dramatically. As suggested above, the ability of C. pseu¬
dotuberculosis to survive phagocytosis by such cells and to
exist as a facultatively intracellular parasite enables the
organism to be carried within these cells via the lym¬
phatic drainage to the local lymph node (Pepin etal.,
1994a). Thus, phagocytic cells recruited to the area in
response to infection become the means by which
further colonization of the body is brought about.
Once a lymph node has been colonized by C. pseudo¬
tuberculosis it undergoes a short period ofgeneralized in¬
flammation. PLD, the soluble exotoxin produced by
C. pseudotuberculosis, is the probable initiator of this
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lymphadenitis. Pepin et al. (1991) reported that within
24 h of the subcutaneous inoculation oflambs a number
ofmicro-abscesses occurred within the cortical region
of the lymph node draining the site of inoculation.
By day six post-inoculation, these micro-abscesses had
become more numerous and began to expand and coa¬
lesce to form larger purulent foci. The early pyogranu-
lomas contained clumps ofbacteria and cellular debris,
with a relatively high proportion ofeosinophils, giving
the purulent core a slightly green hue. At the same
time, and in parallel with the cellular events at the
point of entry, the infiltration of neutrophils dimin¬
ished and monocytes/macrophages became the predo¬
minant cell type within the lesion (Pepin etal., 1994b).
A process during which the lesion is encapsulated fol¬
lowed shortly thereafter, leading to a diminution of
the inflammatory reaction in the parenchyma of the
node. Continued slow expansion of the lesion some¬
times then occurred, depending on the location of the
node and whether or not it ruptured to discharge its
contents. Such enlargement progressed through a re¬
peated cycle of necrosis and reformation of the outer
capsule. In the early stages, the purulent contents of
the abscess were soft and semi-fluid; however, as time
progressed, the pus within the lesion took on a more
plastic or solid form, in which scattered clumps of bac¬
teria were sometimes noted. Small nodules ofminerali¬
zation formed within the purulent material, causing it
to become progressively paler in colour. These calcified
foci tended to be laid down in concentric layers reminis¬
cent of the cross-sectional view of an onion (Figs 3—5).
This classic "onion ring" presentation is regarded as vir¬
tually pathognomonic for CLA in countries such as
Australia and New Zealand, but is rarely reported in
the UK. This probably reflects the relatively small
number ofchronic infections amongst sheep in Britain,
where C. pseudotuberculosis is a relatively recent arrival
and infected animals are still likely to be culled after
diagnosis (Baird, 2003). Superficial lymph node ab¬
scesses may expand to reach a diameter of as much as
15 cm, but 3-5 cm is a more common size (Valli and
Parry, 1993).
The majority of reviews of ovine CLA have been
written from a North American orAustralian perspec¬
tive. These reviews describe the external form of CLA
as most commonly affecting the superficial lymph
nodes of the torso (Nagy, 1971; Stoops etal., 1984; Brown
and Olander, 1987; Williamson, 2001). Ayers (1977), in a
review of the disease in US sheep, reported that the pre-
crural node was most commonly affected, followed by
the prescapular and then by other superficial lymph
nodes with equal frequency. The author regarded the
occurrence of lesions in the head and neck as relatively
rare in sheep, but more common in goats. A similar
statement is made by an Australian author describing
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Fig. 3. Transverse histological section of a prescapular lymph node
from a case ofovine caseous lymphadenitis. Several distinct
concentric layers are discernible within the lesion. Centrally
there is liquefactive necrosis (liquid pus; A) which is sur¬
rounded by coagulativc necrosis (caseous pus; B), both con¬
taining multiple foci of mineralization (F), apparently in
loosely arranged concentric layers. A thin layer of polymor¬
phonuclear neutrophils surrounds the periphery of the coa-
gulative necrosis; there is a further outer layer ofcoagulative
necrosis containing polymorphonuclear neutrophils migrat¬
ing through it at different densities, forming an apparent
bi-layer (E). This is tightly bordered by a layer of immature
fibrosis (C) containing mononuclear inflammatory cells. A
thick layer ofmature fibrosis (D) delineates the extent of the
lesion. Hacmatoxylin and cosin (HE).
Fig. 4. Higher magnification of Fig. 3, showing the border between
the layers ofcaseous necrosis (A) and active immature fibro¬
sis containing mononuclear inflammatory cells (B). Note the
presence of polymorphonuclear neutrophils migrating
across the border into the caseous necrosis (C) and deeper.
HE.
the usual presentation of the disease in that country
(Batey, 1986b). Authors from New Zealand (Nuttall,
1988), South Africa (Collett et al., 1994) and Canada
(Muckle and Menzies, 1993) all describe a similar
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Fig 5. Transverse histological section of the interface between the
outer edge of the mature fibrous capsule (A) and the sur¬
rounding tissue. Note the presence of many multinucleate
giant cells (arrows). HE.
tendency for superficial lesions to develop particularly
in the lymph nodes of the torso. This implies that, in the
countries mentioned above, the skin of the torso is a fre¬
quent site ofentry for the pathogen.
It is likely that the infected superficial lymph node
acts as staging post for the further colonization of inter¬
nal lymph nodes and viscera; however, at which stage
in the course of the infection such colonization occurs
is the subject of some speculation. It seems probable
that purulent emboli detach from pyogranulomas
within the affected nodes, pass into the efferent lym¬
phatic flow and are then delivered into the bloodstream
(Radostits etal., 2000). However, once encapsulation of
a lymph node abscess has taken place, the escape of
such infectious emboli seems likely to occur infre¬
quently, ifat all. Consequently, it has been argued that
in most cases any colonization oforgans beyond the lo¬
cal drainage lymph node must occur relatively quickly
after initial infection, and that phagocytic cells may
once again be the vehicles (Pepin eta!., 1994a).
Other than the lymph nodes, the lung is the most fre¬
quent site ofCLA lesions. As already noted, the gener¬
ally random distribution of lesions within the
parenchyma is consistent with haematogenous or lym¬
phogenous spread, with seeded lesions developing from
within the alveolar vasculature (Batey, 1986c). These
pulmonary lesions most commonly take the form of en¬
capsulated abscesses similar to those seen in the lymph
nodes, but occasionally a more extensive bronchopneu¬
monia is also recorded (Valli and Parry, 1993). The lat¬
ter may lead to areas of pleuritis, resulting in the
development of fibrinous or fibrous adhesions to the
chest wall, pericardium or diaphragm (Renshaw et al.,
1979; Stoops et al., 1984). In animals with pulmonary
abscesses, CLA lesions are occasionally encountered
in the associated mediastinal and bronchial lymph
nodes, implying an additional step in the transit of the
organism from the lung parenchyma. Abscesses within
the mediastinal lymph nodes may become so large as to
put pressure on the adjacent oesophagus, interfering
with normal swallowing and rumination, and leading
to chronic ill-thrift (Paton et al., 2005).
Mastitis due to C. pseudotuberculosis is encountered oc¬
casionally in sheep and is most likely to represent an
extension of infection from the adjacent supra-mam¬
mary lymph node. It may take the form ofan acute sup¬
purative mastitis, or appear as chronic encapsulated
abscesses within the mammary gland. Lesions in other
organs such as the liver, kidneys and scrotum also tend
to be encapsulated abscesses containing a thick caseous
material, which may again take on a lamellated form in
chronic cases (Valli and Parry, 1993). On rare occa¬
sions, the organism has also been isolated from the sto¬
mach contents and tissues of ovine fetuses, consistent
with a role in abortion (Dennis and Bamford, 1966).
Economic Significance of Disease in Sheep
CLA is recognized as a significant cause of financial
loss to the sheep industry in a number of countries
where the disease is endemic. The major cause of these
economic losses lies in the condemnation and down¬
grading of affected carcases at slaughter and meat-in¬
spection. In Australia, where CLA-related losses have
been extensively studied, it is estimated that the disease
costs the meat industry SA12-$A15 million per annum
(Paton etal., 2003).This is due both to carcase losses and
to the requirement for additional meat inspection and
carcase trimming.
Systemic infection by C. pseudotuberculosis is acknowl¬
edged to be detrimental to the productivity of the in¬
fected animal, but to what extent is unclear. Studies of
Merino sheep in Australia failed to show a relationship
between carcase conformation and weight, and the oc¬
currence or extent ofCLA lesions (Batey, 1986b). How¬
ever, workers in that country established that CLA
infection had a detrimental effect on wool production.
In a comparison between CLA-affected and unaffected
Merino sheep in three Australian flocks, the loss of total
clean wool production in the infected animals was as¬
sessed as 4.1-6.6% during the year of initial infection.
Based on disease surveillance and wool production
data from 1992, it was estimated that CLA infection
cost the Australian sheep industry approximately SA17
million per annum in lost wool production (Paton etal.,
1994). However, the same field workers were unable to
confirm that CLA infection had any detrimental ef¬
fects on the live weight gain of young sheep (Paton
et al., 1988b).
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In contrast to much of the Southern Hemisphere,
where the systemic effects of CLA on the individual
sheep are regarded as marginal, in North America the
disease is considered to be much more significant
clinically. There, the visceral form of infection with
C. pseudotuberculosis has been associated with so-called
"thin-ewe syndrome", a chronic emaciation of ewes,
occurring despite good appetite and in the absence of
significant parasitic infestation or specific clinical
signs. Two studies conducted in the US concluded that
CLA infection had an economically significant effect
on culling rates and reproductive efficiency in ewes
(Gates et al., 1977; Renshaw et al., 1979), but Arsenault
etal. (2003) considered that these studies lacked experi¬
mental controls. Certainly, the diagnostic criteria
of "thin-ewe syndrome" are vague, and although
C. pseudotuberculosis is the principal bacterial causative
agent, other organisms such as species of Moraxella,
Arcanobacterium and Staphylococcus may be present in
mixed culture (Renshaw et al., 1979). On occasion,
Moraxella species may also be isolated in the absence of
C.pseudotuberculosis. More significantly, there would appear
to be some evidence of a synergistic relationship between
CLA and maedi visna-induced pneumonia in sheep.
In the Middle East, considerable economic losses
arise through the condemnation of lamb carcases with
CLA lesions, most commonly in the submandibular
lymph nodes. Prevalence rates of 20-40% have been
reported amongst lambs from intensively reared flocks
ofNajdi sheep (Pepin et al., 1994a). CLA lesions in lambs
destined for slaughter as part of religious festivals may
render the carcases virtually worthless—equivalent to a
loss of$200 per head.
Epidemiology of Infection in Sheep
Transmission of Infection
Much CLA research has focussed on how C.pseudotuber¬
culosis cells, commonly contained within thick-walled
abscesses, are transferred from one animal to another.
Several possible routes have been suggested. The num¬
bers of viable bacteria in purulent discharge from a
CLA lesion have been estimated as between 10(> and
5 x 107/g (Brown and Olander, 1987). The rupture of
superficial abscesses therefore releases huge numbers
of viable bacteria on to the adjacent skin and fleece,
and may readily contaminate the immediate environ¬
ment. Other animals may then be exposed, either by
direct physical contact with the affected animal, or in¬
directly via contaminated fomites. In addition, the
ability of C. pseudotuberculosis to survive in the environ¬
ment for a number of weeks or months extends the po¬
tential period of infection well beyond the point of
initial rupture and discharge.
The recovery oforganisms from the faeces of infected
animals was recorded from the earliest days ofCLA re¬
search (Seddon et al., 1929) and its potential signifi¬
cance for disease transmission has been noted in
subsequent reviews. However, in the absence of CLA
lesions in the intestinal tract, the organisms probably
originate from the respiratory tract, or represent bac¬
teria that have traversed the gut, having been ingested.
The fact that bacteria have also been isolated from the
faeces of uninfected sheep would tend to support the
latter hypothesis (Benham et al., 1962). Despite the abil¬
ity of C. pseudotuberculosis to survive in the environment
for protracted periods of time, attempts to isolate the
organism from the soil in areas of endemic infection
have been unsuccessful (Knight, 1969). Therefore, the
presence of C. pseudotuberculosis organisms in faeces and
the consequent risk to other animals are likely to be of
minor importance.
In CLA-infected sheep flocks, animals with lung le¬
sions are thought to represent the principal source of
infection for other animals (Pepin etal., 1994a;William¬
son, 2001). This conclusion is based principally on epi¬
demiological observations recorded in Australia, in
which the seroprevalence ofCLA increased rapidly in
groups of sheep, despite the absence ofsuperficial CLA
lesions (Ellis etal., 1987; Paton etal., 1988a). In addition,
C. pseudotuberculosis has been isolated from the tracheae
of sheep with pulmonary abscesses, confirming that
discharge from lung lesions into the airways does in¬
deed occur (Stoops et al., 1984; Pepin et al., 1994a). The
assumption is made that even a relatively small number
of animals with lung abscesses can create an aerosol of
infectious organisms. Under conditions ofclose contact
and reduced airflow, as in a covered shed, such an aero¬
sol might be capable of infecting a large number ofani¬
mals in a short period of time (Paton et al., 1996).
The usual means of entry of a new infection into a
naive flock is via the introduction of a clinically or sub-
clinically infected carrier animal (Ayers, 1977). A role
for transmission of infection by farm workers and their
equipment between animals within the same flock has
been established. It has also been suggested that human
activity may, on rare occasions, be responsible for in¬
troducing infection to previously disease-free flocks. In
flocks with a high prevalence of CLA, shearers and
their equipment are inevitably exposed to the purulent
discharges ofsuperficial CLA lesions. Ifsubsequent de¬
contamination measures are inadequate, it is possible
that shearing gear, clothing and mobile handling
equipment may act as a mechanical vector of infection
to other flocks. A circumstantial link between new dis¬
ease outbreaks in previously unaffected closed sheep
flocks, and visits by contract shearers has been sug¬
gested inWestern Australia, Canada and England; such
reports, however, remain anecdotal.
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Other mechanical vectors of infection have been sug¬
gested. The investigation of an outbreak of CLA in a
closed and accredited disease-free goat herd in the
Netherlands identified the most likely source of infec¬
tion as bales ofhay purchased from another farm. This
second farm was known to have a herd ofgoats inwhich
CLAwas highly prevalent, and infected goats had been
housed in the hay shed (Dercksen etal., 1996).
Risk factors suggested for the spread of C. pseudotuber¬
culosis infection amongst sheep include the breed
(Bruere and West, 1990), increasing age of animals
(Pepin et al., 1994a; Paton et al., 1995) and a dusty farm
environment (Bruere and West, 1990). However, the
principal risk factor identified in Australia and other
parts of the world is minor skin damage due to shearing
of the fleece (Nagy, 1976; Paton et al., 1988a, 1996; Seri-
kawa et al., 1993; Al Rawashdeh and Al Qudah, 2000).
In Australia, sheep are frequently housed or yarded to¬
gether for a period immediately after shearing, before
being returned to their grazings. This spell ofclose con¬
finement is regarded as the period ofgreatest risk, dur¬
ing which the organism may pass via an infectious
aerosol from one animal to another (Paton et al., 1996).
The risks inherent in shearing may be increased if a
plunge or shower dipping is applied within a few days
ofshearing (Nairn and Robertson, 1974; Augustine and
Renshaw, 1986; Ayers, 1986; Paton et al., 1996), the sug¬
gestion being that organisms from affected animals
persist in the dip solution for a period.
Comparison with Goat Infection
Natural CLA infections in goats demonstrate a number
of similarities with the disease in sheep, not least that
the same biotype of C. pseudotuberculosis is responsible.
However, consideration of the differences in clinical
presentation between sheep and goats may be instruc¬
tive in respect of pathogenesis and specific risk factors.
This is ofparticular interest in the UK, where the clin¬
ical presentation ofovine CLA is closely similar to that
of the caprine infection in other parts of the world
(Baird, 2003).
In both sheep and goats, the major sites of infection
are the superficial lymph nodes, visceral lesions being
encountered in only a minority of animals. In sheep,
however, visceral lesions, and especially lung lesions,
occur more frequently and in greater numbers than in
goats (Renshaw et al., 1979; Hein and Cargill, 1981;
Ayers, 1986; Muckle and Menzies, 1993). In caprine
CLA, the principal sites of superficial lesions are the
nodes of the head and neck (Ayers, 1977; Burrell, 1981;
Batey, 1986c; Brown and Olander, 1987; Williamson,
2001). As already noted, most reports of ovine CLA in¬
dicate that head and neck lesions are uncommon, the
more frequent site of abscessation being the superficial
lymph nodes of the torso. These observations are con¬
sistent with the notion that the main routes of infection
in goats are via the oral cavity or via skin of the face and
head. If bacteria are present on the skin or in the im¬
mediate environment, certain behavioural traits shown
by goats, such as mutual grooming, head butting, and
an inquisitive attitude (including browsing and mouth¬
ing behaviour), would increase the risk of exposure to
infection. In contrast, such behavioural traits are less
frequently observed in sheep. Most goats are neither
shorn nor subjected to plunge or shower dipping.
Corynebacteriumpseudotuberculosis
Infections in Other Animal Species
C. pseudotuberculosis is pathogenic for a variety ofmam¬
malian species. Although a wide range of warm¬
blooded creatures are susceptible to the infection,
specific disease syndromes are recognized in a smaller
subset. In addition to the globally important diseases of
sheep and goats, significant syndromes are recognized
in horses and dairy cattle.
In horses, C. pseudotuberculosis is the cause of three re¬
cognized disease syndromes: ulcerative lymphangitis,
contagious folliculitis and furunculosis, and deep-
seated subcutaneous abscessation (Miers and Ley,
1980). In the US, C. pseudotuberculosis has also been
recorded as a rare cause of abortion (Poonacha and
Donahue, 1995) and mastitis in mares (Addo et al.,
1974), and with generalized visceral abscessation
(Paton et al., 2005). The three main equine syndromes
tend to have a distinct geographical distribution, sug¬
gesting the importance ofsecondary disease factors. In¬
deed, the western areas of Canada and the US
represent the only region in which all three syndromes
have been recorded (Aleman et al., 1996). In a study by
Spier et al. (2004) a real-time polymerase chain reac¬
tion-based analysis of flies collected from the vicinity
of horses with C. pseudotuberculosis infections detected
the PLD-encoding gene in a significant proportion
of test subjects; this was considered to indicate active
carriage of C. pseudotuberculosis. In total, three fly
species were identified as potential vectors for transmis¬
sion of disease; significantly, C. pseudotuberculosis
was identified in up to 20% of the houseflies (Musca do-
mestica) examined.
In ulcerative lymphangitis, infection appears to en¬
ter via wounds, generally those of the lower limbs. This
is followed by extension to the afferent lymphatic ves¬
sels and the formation of abscesses along their course.
These abscesses appear as subcutaneous nodular le¬
sions, which rupture to discharge pus and form necrotic
ulcers (Radostits etal., 2000). Such infections may per¬
sist for many months, as successive crops of ulcers de¬
velop and then resolve. Transmission commonly
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occurs by direct contact between horses; an arthropod
vector, however, has also been suggested to be of impor¬
tance in Africa (Addo, 1983).
Equine folliculitis and furunculosis (also referred to
as equine contagious acne, Canadian horsepox and
equine contagious pustular dermatitis) is a much less
clinically important form of disease, which probably
represents a secondary infection by C. pseudotuberculosis
of a pre-existing seborrhoea or dermatitis. The lesions
tend to develop at points ofcontact with harnesses and
other tack, and spread may occur through the use of
contaminated grooming equipment. Again, the char¬
acteristic lesion is a small nodule that develops into a
pustule before rupturing to discharge purulent materi¬
al. These lesions usually resolve spontaneously but may
occasionally result in an ulcer at the site of infection.
Deep-seated C. pseudotuberculosis abscessation (pigeon
fever, Wyoming strangles, false strangles) is the most
serious manifestation of the infection in horses. It is
usually seen as abscesses in the musculature of the chest
and shoulder, and is of economic significance in much
of the western US (Hughes and Biberstein, 1959; Rum-
baugh etal., 1978; Miers and Ley, 1980), where its inci¬
dence is highest in the months of September to
November (Aleman etal., 1996; Doherrrfa/., 1998).This
probably reflects the seasonal incidence of various spe¬
cies ofbiting arthropod that act as mechanical vectors
(Doherr etal., 1999).
The recognized equine syndromes have not been de¬
scribed in the UK in recent years, despite the isolation
ofC. pseudotuberculosis from horses on a number of occa¬
sions (Connor etal., 2000).The apparent significance of
seasonality, environmental conditions and arthropod
vectors in C. pseudotuberculosis infections of horses has
been emphasized by a number of authors. It would
therefore appear that, although equine pathogenic
strains exist in the UK, essential contributory risk fac¬
tors do not. It is noteworthy that ulcerative lymphangi¬
tis was not uncommon in the UK duringWorld War I,
but this probably resulted from the introduction of in¬
fected horses from Russia and the Balkans where the
condition was present (Petrie and McClean, 1934; Ben-
ham etal., 1962).
In recent years infections of dairy cattle have been
recorded in Israel, commonly in the form of deep sub¬
cutaneous abscesses that develop into granulating and
discharging ulcers, which respond poorly to systemic
antibiotic treatment. The disease is sporadic but may
sometimes occur in an epidemic form (\hruham et al.,
2003b). Morbidity rates of up to 35% have been re¬
corded in some Israeli dairy herds (Yeruham et al.,
1997). A less common mastitic form ofdisease is also re¬
cognized. This may be mild, the only sign being the ap¬
pearance of clots in the milk, or severe, with a greatly
enlarged and tender mammary gland and complete
cessation ofmilk production. The severe form often ne¬
cessitates premature culling, as the response to antibio¬
tic therapy is poor (Shpigel et al., 1993). In a rare
visceral form of disease, widespread abscessation oc¬
curs in lymph nodes associated with the upper and low¬
er respiratory tract. In severe cases this may lead to
swelling and obstruction of airways (Shpigel et al.,
1993). Finally, the organism has also been associated
with a necrotic and ulcerative dermatitis of the heel in
heifers, a morbidity rate of 91 % having been reported
in one outbreak (Yeruham etal., 2003a). C.pseudotubercu¬
losis has been recorded as a cause of an ulcerative lym¬
phangitis and mastitis ofcattle in countries other than
Israel, albeit rarely (Purchase, 1944; Adekeye et al.,
1980; Kariuki and Poulton, 1982; Anderson et al., 1990;
Shpigel etal., 1993).
C. pseudotuberculosis was isolated from houseflies col¬
lected over a C. pseudotuberculosis lesion in a cow (\hru-
ham et al., 1996). Braverman et al. (1999) examined
houseflies that had fed on a superficial C. pseudotubercu¬
losis lesion in a cow, or on contaminated milk from ani¬
mals with C. pseudotuberculosis mastitis. The study
revealed that a significant proportion of flies har¬
boured the organism either on their body surfaces or
in their intestines, the bacterium being present in the
faeces. It was concluded that this species of fly had a
predilection for feeding on milk residues of cow teats,
and therefore played an important role in harbouring
and disseminating C. pseudotuberculosis infections in
dairy herds in Israel.
C. pseudotuberculosis is commonly identified as the
cause of a purulent lymphadenopathy affecting large
numbers of farmed llamas and alpacas in Chile and
other South American countries (Braga etal., 2006). It
is also encountered sporadically as the cause of ab¬
scesses in companion camelids in North America (An¬
derson et al., 2004). In parts of the Middle East C.
pseudotuberculosis has been isolated from lymph node ab¬
scesses of buffaloes (Ali and Zaitoun, 1999) and from
similar lesions in camels (Esterabadi et al., 1975; Nashed
and Mahmoud, 1987; Abubakr et al., 1999). Sporadic
natural infections have been recorded in deer (Ham-
mersland andjoneschild, 1937; Eghetti and McKenney,
1941), pigs (Zhao et al., 1993), coypus, primates and
ducks (Benham etal., 1962) and a hedgehog (McAllis¬
ter and Keahey, 1971). Experimental infections are
readily induced in laboratory species such as mice, rab¬
bits and guinea-pigs (Carne, 1940; Jolly, 1965).
Zoonotic Infections
Reports ofhuman infection with C.pseudotuberculosis are
relatively few, the first published case appearing some
40 years ago (Lopez et al., 1966). Most human cases
were classified as occupational infections, affecting
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workers who had regular contact with sheep, such as
shepherds, shearers, abattoir workers and butchers
(House et al., 1986; Peel et al., 1997). Human infections
tend to be chronic, presenting as a localized suppura¬
tive granulomatous lymphadenitis and affecting the
axillary, inguinal or cervical lymph nodes (Mills etal.,
1997). The lymphadenitis may follow a period of influ¬
enza-like symptoms and increasing lethargy. Treatment
with systemic antibiotics is generally unrewarding, the
majority of cases requiring surgical excision of the af¬
fected lymph node. Even then, the healing of surgical
wounds and infected sinuses may be protracted, and re¬
currence of lesions in other sites is not uncommon
(Henderson, 1979). Because affected human lymph
nodes are not always cultured after excision and be¬
cause unspecified axillary lymphadenitis is not uncom¬
mon in shearers, it has been speculated that human C.
pseudotuberculosis infections are under-reported in coun¬
tries such as Australia, where ovine CLA is especially
prevalent (Hamilton et al., 1968). More serious human
infections, extending beyond localised lymphadenopa-
thy, have been recorded. On one occasion an eosino¬
philic pneumonia due to C. pseudotuberculosis was
diagnosed in a veterinary surgeon from the US (Keslin
et al., 1979), but there are no published records of fatal
human infections. A noteworthy case was recorded in
a city-dweller, who had no apparent connection with a
farming environment or livestock. In this instance, the
only potential cause identified was the regular con¬
sumption by the patient of unpasteurized goats' milk
(Goldberger et al., 1981). No case of human infection
with C. pseudotuberculosis has yet been reported in the
UK; there is, however, a reference to an isolate of C.
pseudotuberculosis from a human lymph gland submitted
to the UK National Collection ofType Cultures (Hill et
al., 1978), but the origin of the sample was not men¬
tioned.
A recent report described a case o{C. pseudotuberculo¬
sis necrotizing lymphadenitis in a 12-year-old girl in
France (Join-Lambert et al., 2006), thought to be the
first reported childhood case. The girl contracted the
infection after having had contact with sheep while on
vacation in a rural part of France. The nitrate-negative
organism was susceptible in vitro to a range ofcommon
antibiotics, but treatment with amoxicillin and clavu-
lanic acid failed to clear the infection. A second course
ofamoxicillin/clavulanate was then administered with¬
out success. After the infection had increased in sever¬
ity and spread beyond the affected inguinal lymph
node, intravenous antimicrobial therapy with imipe-
nem/cilastatin, rifampicin and ofloxacin was adminis¬
tered, followed by surgical resection of affected tissue
other than lymphatic tissue (to avoid post-lymphade-
nectomy oedema). Intravenous antibiotic administra¬
tion was continued for a further 4 months, followed by
oral rifampicin and ofloxacin treatment for a further 6
months. Two years after the cessation of treatment, no
relapse had occurred.
Control and Eradication of Disease in Sheep
Diagnosis
For the successful control ofCLA, it is first necessary to
identify infected animals, so that they can be prevented
from coming into contact with uninfected animals. The
diagnostic criterion for CLA is the culture and identifi¬
cation ofC. pseudotuberculosis. It is usually possible to iso¬
late the organism from lesions ofall ages, although the
number of viable bacteria present in chronic abscesses
may be low and apparently sterile lesions are occasion¬
ally encountered. In sheep, the presence of abscesses in
external lymph nodes is highly suggestive of the dis¬
ease, particularly ifseveral animals in a group are simi¬
larly affected. Other bacterial pathogens, such as
Actinobacillus licheniformis, Arcanobacterium pyogenes, and
in some countries Staphylococcus aureus subsp. anaerobius,
are all capable of producing suppurative lymphadeno-
pathy (Bek-Pederson, 1997; Pekelder, 2000); however,
these other infections tend to be sporadic in nature
and are rarely seen as a flock problem.
In the past, identification of Corynebacterium spp. has
proved difficult for several reasons. These reasons in¬
clude (1) insufficient numbers of reference strains with
which to compare isolates, (2) inadequacies in the refer¬
ence data obtained from characterized strains, (3) the
relative lack of appropriate criteria, and (4) the inap¬
propriate use of test criteria, since coryneform bacteria
frequently give rise to negative results with orthodox
tests (Hill et al., 1978). It has long been considered that
C. diphtheriae, C. pseudotuberculosis and C. ulcerans are re¬
lated, as they share a similar morphology and cell wall
composition, and all produce a characteristic halo on
Tinsdale medium, indicating the production of a cysti-
nase enzyme (Barksdale, 1970). However, on the basis of
DNA homology, there would seem to be less similarity
between the three species than was at one time thought
(Groman et al., 1984). Nonetheless, C. pseudotuberculosis
and C. ulcerans can be made to produce diphtheria toxin
by infecting them with toxin-associated phages from C.
diphtheriae (Petrie and McLean, 1934; Saxholm, 1951;
Henriksen and Grelland, 1952; Maximescu, 1968; Max-
imescu et al., 1974a,b).
In the laboratory, C. pseudotuberculosis cultured from
clinical samples may be identified from its enzymatic
profile and its ability to utilize various carbohy¬
drate sources. The task of biochemical profiling has
been greatly simplified by the introduction of standar¬
dized and miniaturized proprietary test kits, an exam¬
ple of which is the Analytical Profile Index (API)
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identification system (bioMerieux [UK], Basingstoke,
Hampshire, UK). The "API Coryne" kit (used for the
identification of coryneform bacteria) comprises 21 in¬
dividual test substrates for the determination of enzy¬
matic activity or carbohydrate fermentation. After
inoculation with the test organism and incubation for
a defined period, the metabolic end-products of the en¬
zymatic tests result in the development of specific col¬
our changes, either spontaneously or following the
addition of reagents. For substrate fermentation tests,
pH change is also detected colorimetrically. Subse¬
quently, a particular combination ofpositive and nega¬
tive test results is used to compile a numerical profile
(an Analytical Profile Index; API), which is then used
to "interrogate" a proprietary software database.
For the API tests, computer software is used to calcu¬
late the percentage fit of the test isolate results to a con¬
sensus profile for the identified species. The database
takes into account natural intra-species variation in
certain biochemical attributes. The use of computers
to aid in bacterial identification (so-called "probabilis¬
tic" identification) was reported as far back as 1973
(Bascomb et al., 1973; Lapage et al., 1973; Willcox et al.,
1973). Briefly, the methodological process described at
the time was to record the results of different taxo-
nomic (e.g., biochemical) tests as the probability of a
positive result (ranging from 0.99 to 0.01). The results
obtained for the test isolate were then recorded as
either " + "or and a computer programme was used
to compare these test results with the probabilities asso¬
ciated with the corresponding tests for each bacterial
taxon in the database. Subsequently, the probabilities
were used to calculate an 'identification score' for the
test isolate, which was then compared with the identifi¬
cation scores for those taxa in the database. The final
outcome was the identification of the test isolate, com¬
plete with the probability of a correct identification.
Subsequently, an identical technique was applied to
the identification ofcoryneform bacteria, and impress¬
ive results were obtained, including the successful use of
the database to identify field isolates of C. pseudotubercu¬
losis (Hill et al., 1978).
In addition to substrate utilization, further labora¬
tory-based tests are available to identify C. pseudotubercu¬
losis. Some years ago, it was noted that when /?-lysin-
producing staphylococci were cultured on blood-con¬
taining solid media in the presence of strains oiStrepto¬
coccus agalactiae that produce a secreted 'factor',
enhanced zones of haemolysis were observed. This led
to the discovery of an S. agalactiae protein, designated
CAMP-factor (after the initials of its discoverers,
Christie, Atkins and Munch-Petersen), which on its
own was unable to cause erythrocyte lysis. The syner¬
gistic lysis phenomenon was designated the CAMP-re-
action (Christie et al., 1944). Similarly, when C.
pseudotuberculosis and Rhodococcus equi are cultured to¬
gether on solid blood-containing media, colonies of
both species in close proximity to each other cause sig¬
nificant zones oferythrocyte lysis (Fraser, 1961). A simi¬
lar phenomenon was noted when C. pseudotuberculosis
was cultured in the presence of (5-lysin-producing sta¬
phylococci (Lovell and Zaki, 1966). The R. equi protein
(so-called equi factor) involved in synergistic lysis was
found to be a phospholipase C enzyme (Bernheimer
et al., 1980). Currently this assay, which may also be per¬
formed by supplementing blood-containing solid med¬
ia with R. equi culture supernate (containing equi
factor), is used in diagnostic laboratories for the identi¬
fication of C. pseudotuberculosis (Fig. 6). However, it
should be noted that C. ulcerans also produces PLD,
although significantly it is the only other corynebacter-
ial species found to do so (Barksdale et al., 1981). Hence,
PLD activity is a distinctive marker within the genus
Corynebacterium.
In contrast to the synergistic lysis described above, it
was reported (Soucek etal., 1962) that C. pseudotuberculo¬
sis exerted an inhibitory effect on the haemolysis pro¬
duced by staphylococcal /Llysin, and the inhibitory
agent was thought to be associated with PLD. A com¬
parable inhibition of haemolytic activity was also ex¬
erted upon the a-toxin of Clostridium perfringens
(Soucek et al., 1967). As with the synergistic lysis test,
the so-called reverse-CAMP, or CAMP-inhibition test
(Fig. 7) is still exploited to this day in diagnostic labora¬
tories, although the same issue of the production of
PLD by C. ulcerans must again be taken into account.
Fig. 6. Synergistic lysis between Rhodococcus equi (1.) and Corynebacler-
ium pseudotuberculosis (2.). The zone of enhanced lysis (arrows)
is apparent where the soluble factors from each organism
come into contact with each other.






Fig. 7. The CAMP-inhibition test. Erythrocyte lysis resulting from
diffusion of Staphylococcus aureus (1.) haemolysin is apparent
(A), as also is enhanced lysis resulting from the synergistic
effects ofStreptococcus agalacliae (2.) CAMP factor and S. aureus
haemolysin (CAMP reaction; B). The PLD-deficicnt control
strain, Corynebacteriumjeikeium (3.), has no effect on the extent
of the CAMP reaction, while diffusion ofPI.D by C. pseudotu¬
berculosis (4.) is inhibitory (C).
Treatment
In vitro, C. pseudotuberculosis is sensitive to a range of anti¬
biotic chemicals. In standard laboratory-based tests,
most commonly used antibiotic classes have been
shown to prevent bacterial growth and multiplication
(Muckle and Gyles, 1982; Judson and Songer, 1991).
However, in vivo, clinical CLA is generally refractory
to antibiotic therapy, probably because of the thick en¬
capsulation around the typical lesions, and the thick
and caseous nature of the pus contained within (Wil¬
liamson, 2001). The intracellular nature of the organism
during parts of the disease cycle is also believed to con¬
fer some protection from certain commonly employed
antibiotics. Surgical treatment of external lesions has
been suggested as an alternative to culling in the case
ofparticularly valuable animals (Davis, 1990).Whether
the lesion is surgically removed, or simply lanced and
flushed-out daily until healed, parenteral antibiotic
treatment for 4-6 weeks has been recommended to re¬
duce the likelihood of recurrence. This course ofaction
is still seen as unreliable at best, since it relies upon the
antibiotic to remove all infecting organisms from the
treated lesions, and assumes that no internal lesions
are present. As a result, reports on the use of such tech¬
niques are not encouraging (Gezon et al., 1991; Rizvi
etal., 1997).
Significantly, in a recent report claims were made of
successful treatment of C. pseudotuberculosis-intected
sheep with a combination of the antibiotics rifamycin
and oxytetracycline (Senturk andTemizel, 2006). Rifa¬
mycin is primarily used against Mycobacterium tuberculo¬
sis and Mycobacterium leprae infections, and has an
established ability to kill susceptible intracellular bac¬
teria. In this small trial, 10 CLA-affected animals re¬
ceived twice-daily treatment with rifamycin for a
period of 10 days, in association with injections of a de¬
pot formulation of oxytetracycline at intervals of 3
days. This led to a decrease in the size of CLA lesions
in the external lymph nodes of affected sheep, produ¬
cing what was described as a clinical resolution of the
lesions. However, no necropsies followed the intensive
treatment regime and the report did not indicate for
how long the sheep remained disease-free. Further stu¬
dies are required before treatment of CLA cases be¬
comes a viable alternative to culling (Baird, 2006).
Serology
Whilst isolation and identification of C. pseudotuberculo¬
sis remains the gold standard in diagnosis ofCLA, this
may not always be advantageous or possible. The punc¬
ture of CLA abscesses generally releases pus on to the
animal's skin or into the environment, presenting a risk
of transmission of infection to other animals. Further¬
more, chronic external lesions that have ruptured fre¬
quently become fibrosed and may contain little pus
and few viable organisms. Finally, animals suffering
from the visceral form ofdisease may show no external
lesions that can be sampled, but remain a potential
source of infection to others. Much research interest
has therefore focussed on serological tests that might
identify CLAwithout recourse to bacteriology.
Most serological diagnostic tests for CLA are based
on the detection of a humoral response to PLD exotox¬
in. Such tests have been explored as a method for con¬
trolling the disease in sheep by identifying and
removing infected carrier animals. The use of serologi¬
cal tests for the laboratory diagnosis of C. pseudotubercu¬
losis infection dates from the early years of the 20th
century. Originally, determination of infection status
relied upon the in-vivo demonstration of antitoxins
(Forgeot and Cesari, 1912; Nicolle et al., 1912; Watson,
1920; Mitchell andWalker, 1944; Doty etal., 1964; Zaki,
1976). Experimental subjects (mice, rabbits or guinea-
pigs) were given injections of serum from animals sus¬
pected of being infected with C. pseudotuberculosis', they
were then given lethal doses of PLD toxin, prepared
from C. pseudotuberculosis culture supernates. A reduc¬
tion in the rate ofmortality of serum-treated animals,
as compared with that ofcontrols, was considered to in¬
dicate passive protection by serum antitoxin, and to be
highly suggestive of C. pseudotuberculosis infection.
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In a development that was to facilitate in-vitro sero¬
logical screening, it was found that inclusion of antitox¬
in-containing sera in the CAMP-inhibition test
resulted in neutralization of the inhibitory effect that
C. pseudotuberculosis exerted on staphylococcal /5-lysin;
this led to a new method designated the anti-haemoly-
sin-inhibition (AHI) test for testing sera from animals
suspected of having CLA. This test has been used for
disease diagnosis in sheep, goats and horses, avoiding
the use of experimental animals (Zaki, 1968; Knight,
1978; Burrell, 1980a; Brown etal., 1986).
Other tests used in the study ofCLA include tube ag¬
glutination assays (Cameron et al., 1972; Husband and
Watson, 1977), an indirect haemagglutination test (Shi-
gidi, 1978) and a double immunodiffusion test (Burrell,
1980b). However, the enzyme-linked immunosorbent
assay (ELISA) for use in diagnosis has shown particu¬
lar promise. Initially CLA-diagnostic ELISAs em¬
ployed crude C. pseudotuberculosis cell wall preparations
or supernate-derived exotoxin as antigen (Maki et al.,
1985; Sutherland et al., 1987; Kuria and Holstad, 1989;
Ellis et al., 1990; Sting et al., 1998). Test sensitivity was
usually regarded as good, but specificity was relatively
poor—possibly due to cross-reactions with other pro¬
teins present in the antigen preparations. However,
some ELISAs have been claimed to be sufficiently spe¬
cific and sensitive for field diagnosis. One such ELISA
was based on a PLD antigen derived by recombinant
technology from E. coli containing a plasmid bearing
the pld gene (Menzies et al., 1994), a test sensitivity of
86.3% and specificity of 82.1% being reported. The as¬
say coming closest to the requirements of a diagnostic
test was reported by workers in the Netherlands (Ter
Laak et al., 1992) and was later refined to improve spe¬
cificity and sensitivity (Dercksen etal., 2000). This is an
indirect double antibody sandwich ELISA, based on
PLD exotoxin purified from the supernate of C. pseudo¬
tuberculosis culture, polyclonal rabbit anti-PLD serum
being used as a capture antibody. The improved meth¬
od is reported to have a specificity in sheep of99+ 1 %,
and a sensitivity of 79 + 5%.
Other potential tests include a polymerase chain re¬
action (PGR) method (Cetinkaya etal., 2002) and a bo¬
vine interferon (IFN)-y whole blood ELISA (Menzies
et al., 2004). The latter was the first test in which assay of
cellular immunity to C. pseudotuberculosis was used as a
diagnostic tool. Over the course of 1 year, the IFN-y
test accurately detected goats experimentally infected
with C. pseudotuberculosis with a reliability of 89.2%,
and non-infected goats with a reliability of 97.1 % Over
the same period, a recombinant PLD ELISA detected
the experimentally infected goats with a reliability of
81.0% and non-infected goats with a reliability of
97.0%. The PLD ELISAwas, however, more predictive
than the IFN-y ELISA of the lesions subsequently
observed at necropsy. A later study of INF-";1 production
in cultures ofwhole blood compared infected goats fol¬
lowing stimulation with either secreted bacterial anti¬
gen or somatic antigen; IFN-y production by blood
cells was found to be significantly higher in response
to the secreted antigen (Meyer et al., 2005).
The use of serology as a tool in disease eradication
and control has been pioneered in the Netherlands,
principally in relation to dairy goats. Indeed, a CLA
Health Scheme for goats exists in that country, based
upon the use of a PLD antibody ELISA and Western
blot analysis (Dercksen et al., 1996). A similar scheme
was proposed for the control and eradication of CLA
in Dutch sheep (Schreuder et al., 1994), but the plans
foundered due to poor test sensitivity in certain flocks
(Dercksen et al., 2000). Plans for serological control of
the disease in sheep have recently been revived in the
UK, with the launch in 2005 of a pre-sale testing re¬
gime incorporating the use of a serodiagnostic ELISA
andWestern blot analysis based on a recombinant PLD
antigen (Anon, 2005).
Vaccination
Historical perspective. Despite the relative lack of knowl¬
edge pertaining to C.pseudotuberculosis virulence factors,
there exists a significant body ofwork exploring the po¬
tential for immunization to prevent disease caused by
this organism. Due to the relatively recent introduction
ofCLA into the UK, there has been little research ori¬
ginating from this country; however, the same is not
true ofelsewhere in the world. In particular, significant
work has been conducted in both South Africa and
Australia over the last 75 years. Many of the earliest re¬
ports were somewhat confusing, partly because lack of
knowledge at the time prevented isolation of the organ¬
ism in a pure form and characterization of the cellular
antigens. As stated by Batey (1986c),"it is likely that in¬
fection by C. pseudotuberculosis involves a unique mode of
pathogenesis"; these words continue to bear weight as
progress towards an understanding of this organism is
advanced through a combination of molecular dissec¬
tion and an accurate analysis of the interaction of
pathogen with host.
One of the earliest reports, cited by Petrie and
McClean (1934), of protection against the deleterious
effects of C. pseudotuberculosis products appeared in 1907,
when a degree of resistance against the lethal effect of
the exotoxin (PLD) was apparently produced in gui¬
nea-pigs by administration of a high dose of horse-de-
rived antiserum against the toxin of C. diphtherial
(Petrie and McClean, 1934). This work was performed
at a time when it was thought that there was a relation¬
ship between the exotoxins of C. pseudotuberculosis and
C. diphtheriae. It was subsequently shown that the two
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toxins were distinct, and that the protective effect ob¬
served at the time was probably due to the prior occur¬
rence ofanti-C. pseudotuberculosis antibodies in the horse
from which the antitoxin was derived (Petrie and
McClean, 1934). Later work revealed that immuniza¬
tion with toxoided C. pseudotuberculosis exotoxin gave
some protection to guinea-pigs against the lethal effects
of the active exotoxin (Petrie and McClean, 1934).
Despite this observation, the general consensus of opi¬
nion held that the exotoxin was unsuitable for use as a
protective antigen against CLA in sheep (Carne et al.,
1956; Cameron and Smit, 1970) due to the chronic
nature of the natural disease, in contrast to the acute
nature of C. pseudotuberculosis infection in mice and
guinea-pigs.
In the early 1960s it was suggested that the immuniz¬
ing property of C. pseudotuberculosis was associated with
the toxicity of cell endoplasm preparations and with
the ability of formalin-killed cells to produce sterile ab¬
scesses when injected into guinea-pigs (Cameron, 1964).
However, it was subsequently shown that these 'toxic
factors' and those responsible for conferring immunity
to infection were in fact distinct (Cameron and Buchan,
1966). Later studies showed that mice could be signifi¬
cantly protected against challenge with C. pseudotubercu¬
losis by immunization with formalin-killed, washed,
whole C. pseudotuberculosis cells, combined with one of a
variety of adjuvants (Cameron and Minnaar, 1969).
The cellular component believed to confer the most
immunity was the cell wall. Through a process ofelim¬
ination it was discovered that the antigen responsible
was an "integral part of the cell wall", but was not the
cell wall lipid, which did not appear to induce protec¬
tive immunity (Cameron et al., 1969). The ability ofcell
wall components to induce immunity was reduced by
prior treatment with formalin; the reason for this was
thought to be the denaturation of cell wall-associated
protein or proteins, resulting in a loss of biological ac¬
tivity, which was believed to be required for immuno-
genicity (Cameron etai, 1969).
In continuing previous work, Cameron and Smit
(1970) investigated toxic components in C. pseudotubercu¬
losis protoplasmic preparations, with a view to under¬
standing the cause of the sterile abscesses formed on
inoculation of animals with killed C. pseudotuberculosis
cells. It became apparent that a toxic cytoplasmic com¬
ponent was identical with the exotoxin found in culture
supernates. However, consistent with an earlier report
(Petrie and McClean, 1934), Cameron and Smit hy¬
pothesized that this extracellular exotoxin must have
arisen through lysis of bacterial cells, since the concept
of protein secretion was still not understood. Nonethe¬
less, their work clarified to some extent the confusion
surrounding the various toxic fractions studied in pre¬
vious years.
In the following section the different approaches to
vaccine development will be discussed. However, it is
not within the scope of this review to discuss the merits
ofany given approach or the acceptability of the resulting
vaccines from a commercial or regulatory standpoint.
Bacterin vaccines. The earliest reported vaccination trials
in sheep were conducted in the Patagonia region ofAr¬
gentina, where a formalin-killed C. pseudotuberculosis
vaccine reduced infection by up to 60% (Quevedo
et al., 1957). Cameron et al. (1972) made one of the first
attempts to demonstrate by experimental challenge
the ovine immune response to vaccination, the vaccine
consisting of formalin-killed, whole cells of C. pseudotu¬
berculosis. The intravenous challenge doses investigated
varied from 2 x 107 to 2 x 1010 colony-forming units.
However, it was difficult to obtain satisfactory results,
the higher doses producing acute death due to pulmon¬
ary oedema and the lower doses failing to cause lesions.
Furthermore, vaccination produced increased titres of
serum antibody that persisted for only 3-4 months.
Nonetheless, it was concluded that vaccination could
protect sheep against the lethal effects of sub-acute in¬
fection but not against formation of the lesions asso¬
ciated with chronic infection. It was considered that
effective immunity might not depend solely on circulat¬
ing antibody, but that cellular immune responses might
play a role. It was also suggested that, if used, a whole
cell vaccine should be administered shortly before
shearing.
More recently, in a study of several vaccines, immu¬
nization of sheep with a formalin-killed, virulent, UK-
derived C. pseudotuberculosis isolate and aluminium hy¬
droxide adjuvant resulted in statistically significant
protection against homologous challenge; the vaccine
had prevented the spread of infection beyond the site
of inoculation (Fontaine etal., 2006).
There have been few investigations of the protective
effect of C. pseudotuberculosis bacterins against disease in
the field. Menziesefa/. (1991) conducted a field trial ofa
killed whole-cell vaccine in a flock of sheep and herd of
goats, both populations having shown a prevalence of
CLA in adult animals ranging from 15% to 30% in
the pre-trial period. During the trial, lambs and kids
were vaccinated at 2.5~3.5 months of age, with two
further doses administered at 1 month and 11 months
after the initial vaccination. The animals were regu¬
larly monitored for 36 months after the initial dose of
vaccine. Serum antibody concentrations were signifi¬
cantly increased in vaccinated sheep and goats for the
full term of the experiment. Furthermore, vaccination
significantly decreased the incidence of CLA in the
sheep, and there was a suggestion of a similar effect in
the goats.
In a later study, juvenile sheep and goats were vacci¬
nated with a C. pseudotuberculosis bacterin formulated
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in light mineral oil containing muramyl dipeptide
(Brogden et al., 1995); the results, however, were
inconclusive.
Toxoid vaccines. As noted above, Petrie and McClean
(1934) found that vaccination of guinea-pigs with a
formalin-inactivated exotoxin (PLD) of C. pseudotuber¬
culosis induced a degree of protection against homolo¬
gous challenge. Despite this, it was generally
considered that the chronic nature of C. pseudotuberculo¬
sis infection in sheep rendered toxoid ineffective as a
protective antigen. Most subsequent studies on CLA
vaccination focussed on the use of bacterins, or on vac¬
cines made from components ofwhole cells. However, a
report byjolly (1965) showed that the administration of
toxoid, followed by toxin, reduced the extent of experi¬
mental CLA in sheep. This followed the observation by
Cameron (1964) that an undefined "protoplasmic tox¬
in" of C. pseudotuberculosis played a role in the induction
of protective immunity. It was later demonstrated that
C. pseudotuberculosis exotoxin was in reality identical
with this protoplasmic toxin (Cameron and Smit,
1970), adding weight to the hypothesis that PLD could
be used as a protective antigen.
Purely managemental strategies having failed to pre¬
vent the spread of the disease, studies were conducted
in Australia during the 1970s to develop a CLA vaccine,
work that would eventually lead to the first commercial
CLA vaccine (Eggleton et al., 1991a,c). The ability of
PLD to protect against CLA was reported by both
Nairn etal. (1977) and Burrell (1978b). Work at the Divi¬
sion ofAnimal Health, Commonwealth Scientific and
Industrial Research Organisation (CSIRO), led to the
optimization of procedures for the culture ot C. pseudo¬
tuberculosis. It also resulted in improvements in the
yields and quantification methods of PLD, matters of
importance in view of its immunogenic properties
(Burrell, 1983).
Between 1977 and 1978, the technology required for
production of an effective toxoid vaccine was made
available to the Commonwealth Serum Laboratories
(CSL; Parkville, Victoria, Australia), and details, in¬
cluding optimal antigen dose and combination with
other (clostridial) components, were later published
(Eggleton et al., 1991c). For vaccine production, PLD
was obtained from filtered and concentrated C. pseudo¬
tuberculosis culture supernates, which were subsequently
toxoided with formalin (Burrell, 1983; Hodgson et al.,
1999). A combined clostridial and corynebacterial vac¬
cine, known as GlanvacIM, was released in 1983
(Eggleton et al., 1991a); it subsequently became avail¬
able in Australia and several other countries but is not
licensed for use in the European Union. In one report,
I'M
vaccination ofgoats with Glanvac resulted in statis¬
tically significant protection against subsequent experi¬
mental infection with C. pseudotuberculosis, as measured
by a reduction in the number of lesions (Brown et al.,
1986). In addition, the results of trials performed in the
process of the commercial development ofGlanvac1 M
indicated significant protection of sheep against CLA
(Burrell, 1983; Eggleton et al., 1991a-c). Anderson and
Nairn (1984), however, found that PLD toxoid gave
greater protection when not combined with clostridial
components.
The mechanism by which Glanvac1 M confers immu¬
nity has been the topic of some debate. It has been sug¬
gested that protection against CLA is both humoral and
cell-mediated, but that PLD is neutralized by circula¬
ting antibody (Burrell, 1978b; Batey, 1986c; Eggleton
et al., 1991a; Sutherland et al., 1992). Incontrast, Hodgson
et al. (1999) discussed the possibility that the small
amount (ca 1%) of PLD activity that remained after
formalin treatment (Eggleton et al., 1991b) might be re¬
sponsible for the protection conferred by Glanvac™.
However, Eggleton et al. (1991b) had previously re¬
ported that a four-fold variation in the level of active
toxin remaining in a toxoid vaccine "neither enhanced
nor reduced the protective potency of the vaccines".
Others have reported that anti-exotoxin antibodies are
not on their own sufficient to prevent infection in the ab¬
sence of other (probably cell-mediated) immune de¬
fences (Irwin and Knight, 1975; Cameron and Bester,
1984; Ellis et al., 1990). Significantly, Cameron and Smit
(1970) stated that "...it could be expected that crude
exotoxin preparations could also contain other anti¬
gens. Therefore, unless an absolutely pure preparation
of exotoxin can be produced, its immunizing activity
can never be accurately assessed". This statement was
later reiterated by Burrell (1983), who confirmed that
the culture supernates used to prepare Glanvac1 M con¬
tained other C. pseudotuberculosis somatic antigens, which
varied in amount from batch to batch. Moreover, Walk¬
er et al. (1994) intermittently identified antibodies
against a novel C. pseudotuberculosis antigen in sera from
sheep vaccinated with Glanvac1 M. It would therefore
seem that the presence of other C. pseudotuberculosis pro¬
teins in toxoid vaccines prepared from culture super¬
nates may well contribute to the protective capacity of
the vaccine.
Fontaine etal. (2006) assessed the capacity ofa highly
purified recombinant derivative of PLD to protect
sheep against homologous challenge with a UK-
derived C. pseudotuberculosis isolate. Protection was simi¬
lar to that produced by a bacterin vaccine. After experi¬
mental challenges, infection appeared to be localized to
the inoculation site in all but one experimental animal,
in which evidence of pulmonary infection was also
found. Given that PLD does not stimulate cell-media-
ted immunity (Hodgson et al., 1999), the protection
observed in animals vaccinated with the recombinant
PLD was postulated to result from antibody-mediated
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neutralization of toxin activity. Included in the
same study was an assessment of the capacity of the
PLD-based proprietary vaccine, Glanvac-31M (a
member of the Glanvac M vaccine family), to protect
against challenge with the UK-derived C. pseudotubercu¬
losis isolate. Statistically significant protection was
again observed with this vaccine, as indicated by a de¬
creased number of infected loci. Glanvac1 M vaccine
appeared to be less successful than the recombinant
PLD vaccine in preventing the spread of the challenge
infection beyond the site of inoculation and into the
superficial lymph nodes; it was conceded, however,
that the immunity produced by the Glanvac1 ^ vac¬
cine was demonstrated by challenge with a heterolo¬
gous bacterial strain. However, the high degree of
sequence conservation between the PLD-encoding
genes from different C. pseudotuberculosis isolates may
well negate the issue of homologous versus heterolo¬
gous challenge.
Combined vaccines. In reviewing CLA vaccine develop¬
ment, Burrell (1983) stated that, despite the capacity of
cell-associated antigens (Cameron etal., 1969) and PLD
(Burrell, 1978b) to give some protection, full protection
required the presence of both. In defence of this, it was
revealed that an alhydrogel-adjuvanted vaccine com¬
posed of formalin-killed whole C. pseudotuberculosis cells,
enriched with formalin-treated, PLD-rich culture
supernate, protected completely against experimental
C. pseudotuberculosis infection and outperformed vac¬
cines consisting ofcell-free toxoided culture supernates
(Burrell, 1983). In contrast, a report of work conducted
during the development of Glanvac'M revealed that
supplementation ofcell-free toxoid vaccine with C. pseu¬
dotuberculosis cells made no difference to the observed
protection (Eggleton etal., 1991b).
A further commercially available CLA vaccine
(Caseous D-T1M; Colorado Serum Co., Denver, CO,
USA) contains clostridial toxoids and a combination
of C. pseudotuberculosis bacterin and toxoid. Piontkowski
and Shivvers (1998) reported that this vaccine gave
some protection to sheep against experimental infec¬
tion, in that it reduced the incidence ofexternal and in¬
ternal CLA lesions.
Fontaine et al. (2006) reported that vaccination of
sheep with a C. pseudotuberculosis bacterin enriched with
recombinant PLD resulted in complete freedom from
infection 3 weeks after experimental homologous chal¬
lenge. It had been reported previously (Simmons etal.,
1998) that C. pseudotuberculosis (even a non-virulent mu¬
tant) was capable of persisting within granulomas in
the draining lymph node, as a result of the inaccessibil¬
ity ofabscesses to the immunological factors required to
clear the infection. Therefore it was suggested that vac¬
cination had enabled clearance of the organism prior to
establishment within the lymph node.
Live vaccines. Pepin et al. (1993) reported that sheep in¬
fected experimentally with C. pseudotuberculosis were
protected against further challenge, despite being un¬
able to clear the original infection. This observation in¬
dicates the possible value ofan attenuated vaccine.
Because PLD is an important virulence factor
(Carne and Onon, 1978), Hodgson etal. (1992) hypothe¬
sized that genetic inactivation of the pld gene might
provide the basis for a live recombinant veterinary vac¬
cine. A mutant derivative ofpldwas constructed in vitro,
by cloning the gene into a suitable plasmid vector
(pEP2), and disrupting it by insertion ofan erythromy-
cin-resistance cassette. Subsequently, the resulting re¬
combinant plasmid (pBTB58) was introduced into
C. pseudotuberculosis by electroporation, and recombina¬
tion between homologous plasmid-borne and chromo¬
somal sequences resulted in replacement of the wild-
type gene by the mutant copy. To ensure the stability of
the mutation, pBTB58 vector sequences were removed
from mutant cells by transformation with the plasmid
pEP3; because pEP3 possesses the same origin of repli¬
cation as that of pBTB58, plasmid segregation resulted
in loss of pBTB58 sequences and retention of pEP3.
Inoculation of sheep with up to 10' colony-forming
units of the PLD-deficient C. pseudotuberculosis strain
(so-called "Toxminus") failed to produce the abscessa-
tion normally associated with wild-type C. pseudotuber¬
culosis. However, at higher doses, transient abscesses
were formed at the inoculation site. Despite this, the
authors concluded that the degree of attenuation was
equivalent to at least a 100-fold reduction in infective
dose. The vaccine potential of the attenuated strain
was determined by challenge ofTbxminus-immunized
sheep with wild-type C. pseudotuberculosis. A degree of
protection against challenge and strong humoral and
cellular immune responses were observed, but these ef¬
fects were lower than those produced by wild-type in¬
fection.
It was later postulated (Hodgson etal., 1994) that the
rationale behind the creation of the Tbxminus mutant
was flawed: while the recombinant strain was attenu¬
ated for virulence and hence useful as a live vaccine
vector, one of the major immunodominant antigens
(PLD) had been removed, thus reducing immune sti¬
mulation. Hodgson et al. (1994) therefore constructed a
mutant derivative of PLD in which the histidineoo ami-
no-acid residue (a constituent of the enzyme's active
site) was substituted for tyrosine, and expression of the
resulting plasmid-borne, mutant pld gene produced a
biologically inactive derivative of PLD. On transfor¬
mation ofToxminus with the inactivated pld construct,
cells were able to secrete an inactive PLD derivative,
albeit at a level lower than that ofwild-type PLD.
In an attempt to avoid inoculation-site reactions and to
provide a convenient means of vaccine administration,
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Hodgson et al. (1994) administered each of two vaccines
(Toxminus andloxminus carrying the inactivated pld)
to sheep via the oral route. Both vaccines induced sig¬
nificant and similar humoral immune responses.
Furthermore, in animals immunizedwith the strain ex¬
pressing the inactivated pld, challenge elicited a rapid
anamnestic response to PLD; this response was quicker
and of greater magnitude than the humoral response
(1) to infection in unvaccinated animals, or (2) in those
receiving Toxminus alone. Despite significant humoral
responses, the protection against challenge conferred
by theloxminus strain was negligible; this contrasted
with a previous report of subcutaneous vaccination
withloxminus (Hodgson etal., 1992). The difference in
protection was attributed to the failure of oral vaccina¬
tion, unlike subcutaneous vaccination, to stimulate a
significant Thl immune response, IgGl having been
identified as the dominant IgG isotype. Despite the
failure of Toxminus alone, immunization with Toxmi¬
nus expressing the mutant pld gene resulted in signifi¬
cant protection against challenge, confirming the
earlier observations that antibodies against PLD pro¬
tected against CLA (Jolly, 1965; Nairn etal., 1977; Bur-
rell, 1978a; Eggleton etal., 1991b, c).
Continued efforts to produce an effective live vaccine
vector led to attempts to express a range of foreign anti¬
gens in theToxminus strain, under the control ofseveral
different promoters (Moore et al., 1999). In the course of
this work, loxminus-based systems were developed to
enable antigens to be expressed, intracellularly or in se¬
creted form, as native or fusion proteins, either consti-
tutively or by controlled induction. Furthermore, genes
were successfully expressed from plasmids, or following
integration into theTbxminus chromosome. In addition
to derivatives of C. pseudotuberculosis pld, genes from
other pathogenic organisms, including Mycobacterium
leprae, Taenia ovis, Babesia bovis, Dichelobacter nodosus and
Anaplasma marginale, were successfully expressed. Sub¬
sequently, it was revealed that subcutaneous immuni¬
zation of sheep withToxminus expressing inactive pld,
orA marginale or D. nodosus antigens, resulted in the in¬
duction of a significant humoral immune response; the
same was not true, however, for 77 ovis or B. bovis anti¬
gens.
Other reports of attempts to create live vaccine vec¬
tors against CLA have been generally less successful
than those discussed above. Disruption of the aroQ
gene, encoding 3-dehydroquinase (an essential enzyme
in aromatic amino-acid biosynthesis), led to the crea¬
tion of attenuated mutants of two strains of C. pseudotu¬
berculosis, one possessing and one lacking PLD. Both
strains were cleared from the liver and spleen of mice
within 8 days of intraperitoneal inoculation (Simmons
et al., 1997). In contrast, complementation of the chro¬
mosomal aroQ^mutation, by introduction of a plasmid
encoding the wild-type aroQ_gene, was sufficient to re¬
store the virulence of the mutant strains to some extent,
but not to the level shown by the wild-type parent
strain. Protection studies with one of the attenuated
mutants revealed that high doses induced a degree of
protection against wild-type challenge, in addition to
the stimulation of INF-y production by murine spleno-
cytes. INF-)' plays a role in macrophage activation, and
the suppression of C. pseudotuberculosis growth and lesion
development is largely due to the bactericidal action of
activated macrophages (Hard, 1970). Therefore, the
vaccine potential of the attenuated strains was evident;
it was observed, however, that both were effectively
cleared from INF-y-deficient mice, suggesting that the
attenuation allowed clearance by some other, unde¬
fined route. This, in turn, was considered useful, given
that vaccination would be unlikely to cause infection,
even in immunocompromised animals (Simmons
etal., 1997).
Despite the encouraging initial results in mice, trials
in sheep proved disappointing in respect of the protec¬
tion against CLA offered by the AroQ_ mutants (Sim¬
mons et al., 1998). Consistent with previous results,
both mutants showed reduced ability to persist within
lymph nodes and to produce local reactions at the in¬
oculation site. However, both failed to stimulate detect¬
able production of specific INF-y-secreting
lymphocytes and induced only low concentrations of
anti-C.pseudotuberculosis IgG. Not surprisingly, these im¬
mune responses did not protect sheep from infection.
DNA vaccines.With the advent ofDNAvaccination tech¬
nologies, there have been reports of the successful im¬
munization of numerous species against various
micro-organisms (Donnelly et al., 1995), but such re¬
ports in respect of farm livestock have been relatively
few in number (Van Drunen Littel-van den Hurk et
al., 2000). In general, DNA vaccines would seem to have
been less successful than conventional or sub-unit pro¬
tein vaccines in protecting against infection, probably
due to a weak and short-lived immune response
(Rothel etal., 1997; Schrijver^ifl/., 1997).
In an effort to improve the efficacy ofDNA vaccina¬
tion against intracellular pathogens, fusion of antigen-
encoding genes to those encoding specific "effector" mo¬
lecules has been attempted. One such effector molecule
is the cytotoxic T lymphocyte antigen-4 (CTLA-4)
(Brunet et al., 1987), which assists in directing secreted
vaccine antigens to lymph nodes and antigen-presenting
cells (APCs) (Boyle et al., 1998; Drew et al., 2001). CTLA-
4, a repressor ofT-lymphocyte proliferation, is expressed
on the surface of activated Tcells. In its dimeric form it
competes with CD28 for binding to the CD80
and CD86 (B7 domains) on antigen-presenting cells
(Linsley etal., 1991; Thompson and Allison, 1997). A trun¬
cated derivative ofCTLA-4 (designated CTLA-4-HIg)
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was created, composed of the C-terminal end of the ex¬
tracellular domain fused to the hinge CH2 and CH3
domains ofhuman IgGl (HIg); this derivative was able
to dimerize as a result of the IgG hinge domains. Sub¬
sequently, chimeric proteins, consisting of antigen-
encoding sequences fused to CTLA-4-HIg, were found
to be specifically targeted to APCs (Boyle etal., 1998). In
a later study it was shown, in vaccinated mice, that the
antibody response to a T. ovis 45W antigen-CTLA-4-
Hlg fusion construct was 30 times higher than that
achieved with non-targeted DNAvaccination. Further¬
more, the kinetics of the antibody response to the
targeted construct were faster than achieved with non-
targeted DNA or with an adjuvanted protein vaccine;
unfortunately, vaccination of outbred sheep with the
fusion vaccine failed to enhance immune responses
(Drew etal., 2001).
In the only report of the development of a DNA vac¬
cine against C. pseudotuberculosis infection, De Rose et al.
(2002) fused the sequence encoding the extracellular
domain of bovine CTLA-4 (Parsons et al., 1996) with
that encoding the CH2 and CH3 domains of human
IgGl (Boyle et al., 1998) and that of a genetically inacti¬
vated derivative of PLD (APLD) (Tachedjian et al.,
1995), to generate the construct boCTLA-4-Ig-APLD.
In an attempt to determine the optimal route of immu¬
nization, the DNA vaccine was administered either in¬
tramuscularly in the left thigh, subcutaneously in
the groin, or via gene gun delivery into the skin of the
lower rear flank. Subsequently, antibody responses and
resistance to experimental challenge with C. pseudotu¬
berculosis were examined. Before challenge, only intra¬
muscular vaccination resulted in a significant (albeit
minimal) increase in serum anti-APLD IgG concentra¬
tions. After challenge, antibody concentrations in ani¬
mals vaccinated by the gene gun or subcutaneous
method were not significantly higher than in non-vac¬
cinated animals; however, IgG concentrations in intra¬
muscularly vaccinated animals increased dramatically
after challenge, suggesting a strong anamnestic re¬
sponse. Furthermore, sterile immunity (i.e., absolute
protection from infection) was observed in 45% ofani¬
mals vaccinated intramuscularly, which was similar to
the results of a previous study (Hodgson et al., 1999) of
vaccinationwith APLD protein. IgG2 titres in animals
vaccinated intramuscularly were significantly ele¬
vated, suggesting that aThl immune response was re¬
sponsible for the observed protection against infection.
Identification of immunodominant antigens. In attempts to
develop more refined CLAvaccines, PLD has been the
main focus ofresearch. This was due, in part, to the per¬
ceived importance of the toxin in the dissemination of
C. pseudotuberculosis within the infected host (Carne and
Onon, 1978) and to the observation that anti-PLD anti¬
bodies assist in clearance of C. pseudotuberculosis from
experimentally infected animals (Eggleton et al.,
1991a). It is also probable that, in the absence ofa C. pseu¬
dotuberculosis genome sequence and of information on
other virulence determinants, PLD was favoured for in¬
clusion in novel vaccines. However, as discussed above,
C. pseudotuberculosis cell-associated antigens also contri¬
bute to protection against CLA (Brogden et al., 1990;
Hodgson et al., 1992), and have even been suggested
to be essential for the induction of optimal immunity
(Cameron etal., 1969; Cameron, 1972; Burrell, 1983).
In an investigation of immunodominant C. pseudotu¬
berculosis antigens (Muckle et al., 1992), the presence of
seven immunodominant proteins in whole-cell lysates
of C. pseudotuberculosis was investigated with immune
sera from goats with CLA. Of these seven proteins,
three were consistently detected by all sera. Sodium
chloride extracts of C. pseudotuberculosis contained all
three immunodominant antigens, suggesting that they
were loosely associated with the bacterial cell wall.
Subsequent purification and functional analysis of the
most strongly immunoreactive protein identified it as
PLD; however, the identity of the two remaining anti¬
gens remained undetermined.
In a later study, Walker et al. (1994) adopted a novel
approach to the identification of immunodominant
C. pseudotuberculosis antigens based on B lymphocytes
derived from infected loci in sheep. Such antibody-se¬
creting cells (ASCs) had previously been shown to pro¬
duce antibodies of highly restricted specificity
(Meeusen and Brandon, 2006). After experimental in¬
fection of sheep with C. pseudotuberculosis in the right
hock, bacteria drained to popliteal lymph nodes, from
which site ASCs were subsequently obtained. The po¬
pliteal lymph nodes were dissected and mononuclear
leucocytes were isolated. These leucocytes were cul¬
tured in the presence of mitogens, and the culture
supernates were referred to as ASC probes. Immuno-
blots of C. pseudotuberculosis whole-cell lysates were per¬
formed with the ASC probes. A previously undescribed
ca 40 kDa antigen was consistently and strongly recog¬
nized by the probes derived from all experimentally in¬
fected animals. The 40 kDa antigen, which was present
in C. pseudotuberculosis culture supernate, was subse¬
quently purified by chromatography. Immunization of
sheep with 100 pg of the purified antigen (later found to
be a serine protease designated CP40 [Wilson et al.,
1995]), resulted in ca 79% protection against experi¬
mental C. pseudotuberculosis infection. Vaccination with
5 pg of the antigen, although not inducing complete
protection, significantly reduced the number of lung le¬
sions in infected sheep.
The results obtained through use ofASC probes were
significant, since they revealed that the CP40 antigen,
which was found in all C. pseudotuberculosis strains exam¬
ined, was one of the earliest products to be recognized
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by the host during infection (Walker et al., 1994). There
was no obvious relation between CP40 antibody titres
and the amount ofantigen administered or incidence of
lung lesions, implying that cell-mediated immunity
was the main protective mechanism.
Caseous Lymphadenitis in the United
Kingdom
Although it is generally accepted that CLA is a rela¬
tively new arrival to the UK, there exists a tantalizing
report by Heath and Batty (1952) concerning the isola¬
tion of an "unusual diphtheroid" bacterium from three
Swaledale sheep from the same flock in southwest
Cumberland. Based on colony and cell morphology
and biochemical tests, these isolates corresponded al¬
most exactly to a previous description by Morse (1949)
ofC.pseudotuberculosis (at that time C. ovis). Realizing the
potential implications, Heath and Batty consulted two
other authorities. One considered that the organism,
although a member of the genus Corynebacterium, was
not C. pseudotuberculosis because it was non-pathogenic
for guinea-pigs, did not "attack" urea and probably con¬
tained metachromatic granules. The other observed
that the organism was not virulent for sheep but other¬
wise resembled C. pseudotuberculosis. In concluding their
report, Heath and Batty (1952) stated that the organism
might be a different variety of the same species (i.e., C.
pseudotuberculosis) and that it was worthy of record in
view of the extremely rare isolation of Corynebacteria
(other than C. pyogenes) from British sheep.
Given the inconclusive nature of the report referred
to above, and the absence of any further literature per¬
taining to C. pseudotuberculosis infections in the UK, the
currently accepted first cases of infection in live ani¬
mals in this country are those confirmed in January
1990 by workers at Cambridge University (Lloyd et
al., 1990). The diagnosis was made in two dairy goats
from a farm in the south of England, these animals
being part of a group of 20 Boer goats originally im¬
ported from the then West Germany in 1987 (Robins,
1991). C. pseudotuberculosis infection, although not a noti¬
fiable disease at that time, was still of interest to the UK
State Veterinary Service. The farm on which the af¬
fected goats were kept was therefore placed under im¬
mediate movement restrictions and the tracing of
prior movements of the batch of imported goats led to
the confirmation ofCLA in herds on a further five pre¬
mises. The goats on each of these premises were either
slaughtered or placed under movement restrictions. In
addition, a group of in-contact sheep was slaughtered,
but the animals showed no lesions ofCLA at necropsy.
In June 1991, superficial abscesses were noted in a
number of sheep during a routine examination of a
flock in Dorset. Bacteriological investigations led to
confirmation of C. pseudotuberculosis infection. Once
again sheep movements related to the affected flock
were traced and as a result the infection was confirmed
in a further seven sheep flocks. During the subsequent
investigations no link to recently imported animals
could be established. The affected flocks, found in var¬
ious parts of southern England, were composed of
purely indigenous animals. Consequently, after consid¬
ering the extent of infection and the fact that CLA was
present within most countries of the European Com¬
munity, the UK Government decided that no further
actionwould be taken in relation to the disease in either
sheep or goats. All existing movement restrictions on
affected goat herds and sheep flocks were therefore
lifted (Robins, 1991).
In the immediate aftermath of these events, diag¬
noses of CLA in both sheep and goats as recorded on
the nationalVeterinary Investigation Diagnosis Analy¬
sis (VIDA) database remained in low single figures
(Fig. 8). The first case ofovine CLA in Scotland was re¬
ported in the Roxburghshire area of the Borders
(Anon, 1996) and this coincided with increased publi¬
city for the disease in the veterinary and farming press.
According to VIDA statistics, the incidence subse¬
quently rose sharply, reaching a peak of 62 diagnoses
in 1998 and a further peak of 85 diagnoses in 2005
(VIDA, 1995, 2003, 2006, 2007). Cases" of ovine CLA
were also reported in Northern Ireland (Malone et al.,
2006) and in the Irish Republic (O'Doherty etal., 2000),
affecting animals imported from Scotland and Eng¬
land, respectively.
During the late 1990s, concerns were expressed over
the potential under-reporting of new outbreaks in the
UK (Baird, 1997; Rizvi et al., 1997; Smith et al., 1997;
Winter, 1997; Binns et al., 2002). The disease was often
stated to be a particular problem of flocks from the
"terminal sire breeds". In addition, there was a percep¬
tion that infection was particularly prevalent amongst
the rams in these flocks. Reports from England and
Scotland identified outbreaks in which up to 60% of
adult males showed clinical signs of CLA, while fe¬
males showed a much lower prevalence (Scott et al.,
1997; Watson and Preece, 2001; Anon, 2006). Specula¬
tion on the reasons for this difference has focussed on
particular management systems applied to breeding
males.
The risks to sheep farming presented by a high
CLA prevalence in rams of the terminal sire breeds
have been identified by a number of authors (Watson
and Preece, 2001; Binns et al., 2002; Baird, 2003; Baird
et al., 2004). More recently, the disease has been diag¬
nosed in breeds associated with hill and upland set¬
tings, several outbreaks being reported in rams from
North Country Cheviot flocks in the north of Scotland
(Anon, 2004).
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Fig. 8. Recorded outbreaks ofCLA in GB sheep flocks from 1991 to 2006: Source'. Veterinary Investigation Diagnosis Analysis (VIDA) data¬
base.
Future Direction
Debate continues over the best methods of controlling
CLA in the UK. Many in the farming community ad¬
vocate the licensing of a proprietary vaccine. Vaccina¬
tion is the main strategy in many other countries where
CLA is endemic. However, recent research would sug¬
gest that simply licensing pre-existing proprietary vac¬
cines will not provide the solution that many in the
farming community might expect (Fontaine et al.,
2006). Other vaccines may in the future provide en¬
hanced protection, but much further work is required.
It is the authors'opinion that accurate serodiagnosis,
together with segregation or culling of infected ani¬
mals, offers a method for the complete eradication of
CLA. In the absence ofeither this approach or the use
of vaccination, there would seem little to prevent the
eventual spread of CLA to all parts of the sheep indus¬
try in the UK, providing an object lesson in how a dis¬
ease may spread from a point source to an endemic
state. Improvements in serodiagnosis and vaccination
will require continued effort to clarify the mechanisms
by which C. pseudotuberculosis interacts with its host,
causes disease, and often persists throughout life.
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G. Baird, B. Synge, D. Dercksen
CASEOUS lymphadenitis (cla) is a chronic, suppurative dis¬
ease caused by infection with the bacterium Corynebacterium
pseudotuberculosis, which affects several animal species but
is rare in human beings (Peel and others 1997). The disease
is common in sheep and goats in many parts of the world
(Pepin and others 1994), but was believed to be absent
from Great Britain until 1990 (Lloyd and others 1990).
Examination of laboratory data indicates that outbreaks in
British sheep flocks reached a peak in 1998, before falling in
recent years (vida 2002). However, such data are subject to
several important sources of bias and there is a need to estab¬
lish more robust estimates of the prevalence of cla infection
in Great Britain.
There is currently concern that cla is most common
within the terminal sire breeds, suggesting a potential for fur¬
ther spread within the wider sheep industry. Experience in
Britain indicates that a disproportionate number of rams are
affected by the disease (Baird 2000, Binns and others 2002),
possibly as a result ofmanagement practices which favour the
spread of infection among adult males. Rams are also a
frequent vector of disease between otherwise closed flocks
(Watson and Preece 2001). A study of cla prevalence within
rams of the terminal sire breeds is therefore a logical starting
point in any consideration of the current disease situation
within Great Britain.
Sheep flocks that have membership of the Maedi-Visna
Accreditation Scheme, one of the sheep and goat health
schemes operated by the Scottish Agricultural College (sac),
are blood tested biennially to confirm freedom from maedi-
visna virus infection. At each flock test all active rams over
18 months of age must be blood sampled. Since the majority
of the 3000 flocks within the accreditation scheme come from
the terminal sire sector, a serological survey of samples from
member flocks provides a cross-section of that part of the
British sheep industry.
A double antibody sandwich elisa has been developed to
detect antibodies to the Cpseudotuberculosis exotoxin, phos-
pholipase D. The calculated diagnostic specificity of this elisa
in sheep is 99±1 per cent and the sensitivity is 79±5 per cent
(Dercksen and others 2000), making it well suited for use as
a tool in disease prevalence studies.
For a period of nine months during 2000, serum samples
were collected from flocks within the sheep and goat health
schemes. A total of 2538 samples from rams in 745 flocks were
then tested blind using the elisa,with results expressed as net
extinction values. Values below 100 were considered negative,
values of 100 to 200 as inconclusive and values above 200 as
positive. In cases in which an inconclusive result was obtained
by elisa, furtherWestern blot analysis was performed, with
six clear, visible bands being taken as a positive result.
In total, 244 sera gave positive elisa net extinction values
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FIG 1: Results of a survey in 2000 showing regions or counties
of Great Britain with sheep flocks containing rams
seropositive for caseous lymphadenitis (blue shading)
FIG 2: Recorded breed of flocks containing caseous
lymphadenitis antibody-positive rams from a serological
survey in 2000 (total 134). Flockswithin the 'mixed breed'
category are composed of sheep from two or more pure
breeds. Those flocks in the 'Suff/Char/Tex' category are
composed of sheep from two or more of the Texel, Charollais
and Suffolk breeds only
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gave an overall apparent prevalence of seropositive animals
within the sample group of 9-93 per cent (95 per cent confi¬
dence limits 8-76 per cent and 111 per cent, 99 per cent con¬
fidence limits 8-39 per cent and 11-4 per cent). Eighteen per
cent of the total flocks sampled (134 of 745 flocks) had one
or more f.lisa-positive animals; 48 (36 per cent) of these had
more than one positive animal, while on 10 occasions five or
more positive animals were detected within the same flock.
While acknowledging the limitations inherent in the sam¬
pling method, this study suggests that cla is well established
within the main terminal sire breeds in Great Britain and that
the infection is present in most parts of the country (Fig 1).
In fact, the rather low test sensitivity recorded for the elisa
suggests that the true flock seroprevalence may actually be
higher than the 18 per cent calculated here. Flocks from a
wide range of sheep breeds appear to be affected by the dis¬
ease (Fig 2); however, the temptation to over-interpret the
data should be avoided. For example, it is noted that more
than 60 per cent of the seropositive flocks are composed of
sheep from the Texel,Charollais and Suffolk breeds. This find¬
ing has less significance than might at first appear, as these
breeds account for a similar percentage of the Maedi-Visna
Accreditation Scheme membership.
The findings of this study are broadly in line with the small
number of published reports of uk outbreaks and with anec¬
dotal evidence from veterinary practitioners, farmers and
contract shearers. The results are of significance in terms of
disease control and provide the basis for a larger-scale preva¬
lence study, within both the terminal sire sector and the wider
sheep industry in Great Britain.
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S. A. Wani, M. A. Bhat, I. Samanta,
Y. Nishikawa, A. S. Buchh
ENTEROHAEMORRHAGIC Escherichia coli (ehec) are a
group of verocytotoxin-producing E coli (vtec) that cause
bloody diarrhoea, haemorrhagic colitis, haemolytic uraemic
syndrome and thrombocytic purpura in human beings. The
pathogenicity of these bacteria ismainly mediated by shiga tox¬
ins (Stxl,Stx2 and their variants) and the products of the locus
ofenterocyte effacement (lee). The lee contains the eaeA gene
encoding intimin, a bacterial outermembrane protein involved
in the intimate adhesion of bacteria to enterocytes and the pro¬
duction of characteristic attaching and effacing lesions (Paton
and Paton 2002). In addition, the ehec harbour a large plas-
mid, which carriers a marker gene, hylA, encoding a haemolysin
termed enterohaemolysin (Schmidt and others 1995).
The first reports ofStx production by £ coli strains isolated
from calves with diarrhoea were published by Kashiwazaki
and others (1980) and Wilson and Bettelheim (1980). The
association between diarrhoea in calves and vtec was later
confirmed by Hall and others (1985) and Mohammad and
others (1985), and several other studies suggested that the
strains which produce Stxl only and possess the eae gene were
more involved in calf diarrhoea (Mainil and others 1993,
Orden and others 1998). Stx-producing £co/i have been asso¬
ciated with diarrhoea in one- to eight-week-old calves, with a
peak between four and five weeks of age, although newborn
and older calves have also been affected (China and others
1998). Similarly, vtec have been detected in calves with diar¬
rhoea under 16 weeks of age in Germany (Wieler and others
1996) and less than three months of age in Spain (Blanco and
others 1996). In India, however, there have been no reports of
vtec in animals with diarrhoea and few reports of the isola¬
tion and molecular characterisation of vtec from human
beings with bloody and watery diarrhoea (Gupta and others
1992, Khan and others 2002a). Chattopadhyay and others
(2001) were first to report the isolation of vtec from non-
diarrhoeic animal sources in India. Similarly, Khan and oth¬
ers (2002b), while investigating the prevalence and genetic
profiling of non-ol57 vtec in Calcutta, detected stxl and stx2
in 18 per cent of normal cow stool samples. To the authors'
knowledge, this is the first report of an association of ehec
0116 with an outbreak of diarrhoea in calves.
An outbreak of bloody diarrhoea occurred in one- to 16-
week-old crossbred calves in an organised dairy farm in
Kashmir, India. The outbreak began in the third week of July
2002 and continued for one week. Seven of 10 calves were
affected, presenting with diarrhoea for four to five days and
voiding blood-tinged, liquid, malodorous faeces. Other signs
included lethargy and dehydration. All the affected calves
recovered. Faecal samples from the affected calves were
screened for rotavirus by a sandwich elisa and rna-poly-
acrylamide gel electrophoresis (page), followed by silver stain¬
ing (Wani and others 2004), and were screened for salmonella
and £ coli as described byWani and Gupta (1986) and Wani
and others (2004). The E coli isolates were serogrouped by the
National Salmonella and Escherichia Centre, Kasauli, India.
£ coli strains were subjected to multiplex pcr for the detec¬
tion of sfxl, stxl, eaeA and ehec hlyA genes. To extract bac¬
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Control of caseous lymphadenitis in six sheep
flocks using clinical examination and regular
ELISA testing
G. J. Baird, F. E. Malone
In an effort to control the spread of caseous lymphadenitis (CLA) infection, flocks of affected
sheep on six holdings were tested serologically at regular intervals using an antibody ELISA
with a mean (sd) specificity of 99 (1) per cent and a sensitivity of 79 (5) per cent. Western
blot assays to detect antibodies to the phospholipase D (PLD) exotoxin of Corynebacterium
pseudotuberculosis were used as a further test when ELISA results were inconclusive. Owners
were advised to remove from the flock any sheep that demonstrated clinical signs of CLA or
tested positive for PLD by ELISA or western blot. Of the six trial flocks, one was dispersed after
only two blood tests, and in another the recommendations for CLA control were not followed
and infected animals were retained within the flock. In the remaining four flocks, the testing
regimen and other advice enabled the disease to be controlled to such an extent that the
appearance of new clinical cases of CLA was effectively halted. This remained the case for up
to five years after the end of the trial. In two of these flocks, a small number of seropositive
animals were detected at the last flock test). However, on the other two holdings all sheep
were seronegative in the final two flock tests, consistent with the complete eradication of
infection.
CASEOUS lymphadenitis (CLA) of sheep, which is caused by
Corynebacterium pseudotuberculosis, has been a significant disease in
much of the sheep-rearingworld formore than a century. The chronic
and often subclinical nature of the infection makes the condition dif¬
ficult to control (Baird and Fontaine 2007). As a consequence, disease
prevalence has remained high in many regions, leading to significant
economic losses associated with poor production and carcase con¬
demnations at slaughter and meat inspection (Pepin and others 1994,
Williamson 2001).
C pseudotuberculosis was first introduced into the UK in the late
1980s (Robins 1991), and since then the infection has spread widely
within the sheep and goat populations (Binns and others 2002, Baird
2003, Baird and others 2004, Baird and Fontaine 2007). In the UK,
CLA infections most often cause abscessation of the superficial lymph
nodes of the head and neck; the lymph nodes of the limbs and torso are
less commonly affected. These lesions are generally recognised as firm,
discrete swellings beneath the skin. The visceral form of the disease
is also commonly found in the UK. In one study of infected flocks in
Northern Ireland, lesions were present in the lungs of one-third of CLA-
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affected sheep (Malone and others 2006). In the same study, internal
CLA lesions only (involving the lungs and/or internal lymph nodes)
were present in almost one-quarter of CLA-affected sheep.
In vitro, C pseudotuberculosis is sensitive to a range of antibiotics
(Muckle and Gyles 1982, Judson and Songer 1991). However, in vivo,
clinical CLA is generally refractory to antibiotic therapy. This resist¬
ance is believed to be due to the intracellular nature of the organism
during much of the process of pathogenesis and to the fibrous wall and
thick, dry contents of the CLA abscess (Williamson 2001). Surgical
treatment of external lesions and prolonged antibiotic treatment have
been suggested as alternatives to culling in cases in particularly valu¬
able sheep (Davis 1990); however, the long-term effectiveness of sur¬
gical intervention (Gezon and others 1991) and antibiotic treatment
(Rizvi and others 1997) is generally poor.
CLA remains a common disease of sheep and goats in many
parts of the world. In countries where proprietary vaccines are widely
available, a significant degree of control can be established in infected
flocks through planned and regular vaccination. Even under these cir¬
cumstances, although disease prevalence may be greatly reduced, total
eradication of the condition is not achieved.
Although the production of autogenous vaccines against CLA is
allowed in the UK, proprietary vaccines, which are used to control
CLA in other parts of the world, are not licensed for use. Moreover,
recent research suggests that simply licensing pre-existing propri¬
etary vaccines for use in the UK might not provide the complete
solution that advocates of this approach expect (Fontaine and oth¬
ers 2006). Novel vaccines may provide enhanced protection in
the future, but much further work is required. Thus, other meth¬
ods of controlling and eradicating the disease must be considered
seriously.
To date, control of the disease has relied on the physical exami¬
nation of newly purchased sheep before their introduction into
naive flocks and the culling of clinically affected sheep from flocks
in which CLA is known to be present. However, the high level of
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TABLE 1: Results of serial serological examinations for caseous lymphadenitis in six sheep flocks
Round Total number of
Flock EtISA result 1 2 3 4 5 6 7 8 9 seropositive sheep













B Number (%) positive 17(10.8) 7(5.3) 4(4.2) 1 (0.9) 1 (1.0) 0 0 30
Number (%)negative 135 (85.4) 113(86.3) 89 (93.7) 99 (88.4) 86 (89.6) 94 (100) 62 (100)
Number (%) inconclusive 6(3.8) 11(8.4) 2(2.1) 12(10.7) 9 (9.4) 0 0
Total sheep 158 131 95 112 96 94 62
C Number (%) positive 68 (63.0) 12(34.3) 5(8.5) 18 (37.5) 22 (44.0) 19 (26.4) 15(21.4) 0 0 159
Number (%)negative 30 (27.8) 23 (65.7) 54(91.5) 29 (60.4) 27 (54.0) 52(72.2) 55 (78.6) 94 (98.9) 41(100)
Number (%) inconclusive 10 (9.3) 0 0 1(2.1) 1 (2.0) 1(1.4) 0 1(1.1) 0
Total sheep 108 35 59 48 50 72 70 95 41
0 Number (%) positive 17 (28.8) 9(17.6) 16(35.6) 14(66.7) 13(59.1) 56
Number (%)negative 39 (66.1) 42 (82.4) 23(51.1) 4(19.0) 9 (40.9)
Number (%) inconclusive 3(5.1) 0 6(13.3) 3(14.3) 0
Total sheep 59 51 45 21 22
E Number (%) positive 5(7.8) 1 (1.7) 2(2.9) 0 2(2.9)* 10
Number (%)negative 59 (92.2) 51 (89.5) 63 (92.6) 80 (98.8) 62 (91.2)
Number (%) inconclusive 0 5(8.8) 3(4.4) 1 (1.2) 4(5.9)
Total sheep 64 57 68 81 68
F Number (%) positive 0 2(9.1) 0 0 2 (9.1)* 4
Number (%)negative 21 (91.3) 19(86.4) 23 (100) 22 (100) 19 (86.4)
Number (%) inconclusive 2(8.7) 1 (4.5) 0 0 1 (4.5)
Total sheep 23 22 23 22 22
*
No lesions detected on examination of animals after culling
subclinical infection means that efforts to detect carrier sheep and
to remove sheep showing external signs of disease cannot totally
control the disease.
Essential to the bacterium's ability to establish itself and spread
through the body is the phospholipase D (PLD) exotoxin, a sphingo-
myelin-specific enzyme that catalyses the dissociation of sphingo¬
myelin into ceramide phosphate and choline (Bernheimer and
others 1980). Although a number of significant biological activities
have been attributed to PLD; the most important in terms of patho¬
genesis is the damage that it causes to mammalian cell membranes
(Pepin and others 1994). This activity allows C pseudotuberculosis to
resist destruction within phagocytic cells (Yozwiak and Songer 1993)
and promotes carriage of the bacterium from the original site of infec¬
tion within local tissue fluids (Batey 1986).
The role of PLD in ovine and caprine infections has made it the
principal component of the proprietary CLA vaccines available around
the world, and the detection of antibodies to PLD is the basis of spe¬
cific serological tests for CLA. These assays have been explored as a
means of controlling the disease in sheep through the identification
and removal of infected carrier sheep. Most promising in recent years
has been the development of an EL1SA for diagnosis of the disease.
Initially, the antigens used in CLA-diagnostic ELISAs were prepa¬
rations of C pseudotuberculosis cell wall or exotoxin derived from culture
supernatants (Maki and others 1985, Sutherland and others 1987,
Kuria and Holstad 1989, Ellis and others 1990, Sting and others
1998). In the majority of these assays, the test sensitivity was good,
but specificity was relatively poor as a result of cross-reactions with
extraneous protein molecules within the antigen preparations. The
developers of more recent ELISAs have claimed specificity and sen¬
sitivity levels sufficient to allow their use as diagnostic tools in the
field. Improvements include the use of purer sources of PLD antigen,
such as that derived by recombinant technology from Escherichia coli
containing a plasmid bearing the pld gene (Menzies and others 1994).
Menzies and others (1994) reported a test sensitivity of 86.3 per cent
and a specificity of 82.1 per cent. Another ELISA method has been
reported to have a test specificity of 100 per cent, a sensitivity of detec¬
tion of total antibody of 71 per cent (95 per cent confidence interval
[CI] 63 to 78 per cent), and a sensitivity of detection of IgG antibody
to C pseudotuberculosis of 83 per cent (95 per cent CI 76 to 89 per cent)
(Binns and others 2007). The sensitivity of the IgG antibody assay
was believed to be higher because of the greater affinity of IgG class
antibodies compared with the IgM antibodies also detected by the
total antibody ELISA.
The ELISA that comes closest to the requirements of a diagnos¬
tic test was developed in the Netherlands (ter Laak and others 1992)
and was later refined to improve specificity and sensitivity (Dercksen
and others 2000). This assay is an indirect double antibody sandwich
ELISA that uses PLD exotoxin purified from the supernatant of C
pseudotuberculosis cultures and polyclonal rabbit anti-PLD serum as a
capture antibody. The improved method is calculated to have a spe¬
cificity of mean (sd) 99 (1) per cent and a sensitivity of 79 (5) per cent
in sheep. The high specificity of this ELISA and moderate sensitivity
make the test suitable for a test-and-cull scheme.
The ELISA method originally described by ter Laak and others
(1992) and improved by Dercksen and others (2000) has been used in
an established disease eradication and control scheme in the Dutch
dairy goat industry. Dercksen and others (2000) reported a specificity
of 98 (2) per cent and sensitivity of 94 (3) per cent for the improved
ELISA in goats. A scheme for the eradication of CLA and subsequent
accreditation of freedom from disease has been available to goat pro¬
ducers in the Netherlands for a number of years (Dercksen and oth¬
ers 1996). By 1996, 46 herds and 11,000 goats had been accredited,
and trade in stock was then established between members. By 2007,
the membership of the scheme had risen to 605 herds, representing
approximately 220,000 accredited goats.
A similar health scheme using the earlier version of the ELISA test
was proposed for the control and eradication of CLA in the smaller
Dutch sheep industry (Schreuder and others 1994), although prob¬
lems of test sensitivity in some flocks led to its closure (Dercksen and
others 2000). The test was subsequently modified and the sensitivity
in sheep was improved by Dercksen and others (2000). However, no
further attempts have been made to establish a CLA health scheme in
what is a relatively small Dutch industry.
Materials and methods
Sheep and management
Sheep from six flocks were clinically examined and samples of blood
were taken for testing using an ELISA for CLA at regular intervals over
a four-year period. Three of the flocks were located in Scotland, one
was in England and two were in Northern Ireland.
Farm A was a mixed enterprise on approximately 22 ha farm¬
ing a small herd of pedigree Charolais cattle and a flock of pedigree
Suffolk sheep flock (flock A). At the start of the study, the trial flock
was approximately 50 breeding ewes, and its management was
closed apart from the periodic purchase or hiring of rams. A labora¬
tory diagnosis of CLA was made for the first time in February 1997.
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FIG 2: Seroprevalence of caseous lymphadenitis in flock D during
the eradication trial
The source of the CLA infection was considered to be a shearling
ram purchased during the autumn of 1996. After a period in the
trial, towards the end of 1999, the flock owner decided to cease
active farming. A dispersal sale of the entire Suffolk sheep flock took
place shortly after.
Farm B had a suckler cattle herd, a commercial sheep flock and
a pedigree Suffolk sheep flock (flock B), the latter supplying rams
for home use and for sale. A diagnosis of CLA was made within the
Suffolk flock for the first time in March 1997. The source of the CLA
infection was believed to be a shearling ram that had been leased for
a period of six months to flock A. On its return to flock B, this ram
and other in-contact rams developed clinical signs of CLA, and the
diagnosis was confirmed by cultures. In the year 2000, stock numbers
on the farm were reduced, with a flock of approximately 60 breeding
Suffolk ewes being retained.
Farm C had a pedigree Suffolk flock of approximately 75 breed¬
ing ewes (flock C) and a small livery stable for horses and ponies on
approximately 10 ha. CLA was diagnosed for the first time within
this flock in 1999. During the process of establishing the Suffolk
flock, breeding sheep had been purchased from a number of sources,
and it is believed that this is how the infection entered the farm. After
the initial bacteriological diagnosis of CLA infection, the flock was
managed under essentially closed conditions.
Farm D had a small pedigree charollais sheep flock (flock D) of
approximately 20 breeding ewes, as part of a much larger farming
enterprise. The flock produced rams for use in the larger commercial
flock, and any additional sheep were sold for breeding. The first diag¬
nosis of CLA was made in 1997, and the infection was believed to
have entered the flock through breeding stock purchased within the
previous few years.
Farm E had a flock of approximately 60 breeding pedigree Suffolk
ewes (flock E) on a smallholding with no other livestock. The first
diagnosis of CLA was made in January 1999. The affected sheep had
been purchased in November 1998.
Farm F had a charollais sheep flock of 25 breeding ewes (flock F).
Although this flockwas on the same holding, it was managed at sepa¬
rate premises from a commercial flock of approximately 190 cross¬
bred ewes. The first cases of CLA were diagnosed in July 1999 and
involved two shearling rams, both of which had been born on the
farm. A further five cases were confirmed in rams between August
and November 1999. It was believed that CLA had entered the flock
with sheep purchased during the previous two years.
At the start of the study, the flock owners were given specific advice
on management changes likely to reduce the spread of CLA infection
within their flocks. This advice included the immediate isolation of sus¬
pected clinical cases pending bacteriological confirmation by removing the
suspect animals from the Hock and keeping them in an area where nose-
to-nose contact was not possible. Treatment of housing and pens that had
held sheep known to be infected, by means of steam cleaning and use of a
disinfectant solution from the Defra-approved list (Defra 2009), was also
recommended. Guidance was given on hygienic measures to be taken
during procedures likely to cause damage to the skin, such as castration,
shearing and tattooing. Finally any sheep already diagnosed with CLA
had to be culled ormanaged separately for the duration of the trial.
Clinical examinations
Each sheep flock was visited at intervals of approximately six months
during the trial period of three to four years. The regulations relating
to the foot-and-mouth disease epizootic of 2001 meant that no farm
visits could take place between February and November to the hold¬
ings that were in the trial during that year.
All trial sheep were individually identified through ear marks
or tags and examined for clinical signs of CLA. This examination
involved palpation and visual inspection of the superficial lymph
nodes of the head, neck and body. Any sheep with enlarged or
abscessed lymph nodes were isolated, and, where possible, samples of
purulent discharge were taken for bacterial culture. At each visit, every
sheep over six months of age was clinically examined in this way,
after which it was blood sampled.
Blood samples were taken from sheep on farm A twice during
1999. The trial was then discontinued with the sale of the flock. Blood
samples were taken from sheep on farm B on seven occasions between
May 1999 and June 2003, on farm C on eight occasions between July
1999 and May 2003, on farm D on five occasions between July 1999
and August 2003, on farm E on five occasions between February 2000
and July 2003, and on farm F on five occasions betweenMay 2000 and
August 2003.
Serology
Sera were examined blind at the Dutch Central Veterinary Institute
(ID-DLO), Lelystad, the Netherlands, using the refined ELISA meth¬
od described by Dercksen and others (2000). On the basis of the
ELISA results, samples were designated as negative, inconclusive or
positive. When the ELISA test reaction was inconclusive, a western
blot technique was applied to the sera. The western blot result was
taken as positive when at least two bands were clearly visible on
the test membrane at 31 kDa and 68 kDa. If the western blot gave a
negative result (no bands) or an unconvincing result (one or two very
weak bands), the sample was classified as inconclusive. All sheep
classified as seronegative or inconclusive were retained within the
flock and re-sampled at the next flock test. It was recommended
that all sheep considered to be seropositive by ELISA orWestern blot
should be culled immediately or removed from the flock and man¬
aged separately.
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TABLE 2: Site of caseous lymphadenitis (CLA) lesions in 28 sheep
examined postmortem
Number (%) of sheep
Lesion site with CIA lesions
Lungs 13(46)
Parotid lymph node 10(36)
Bronchomediastinal lymph node 8(29)
Prescapular lymph node 3(11)
Submandibular lymph node 2(7)
liver 2(7)
Prefemoral lymph node 1(4)
Summary of the distribution of CLA lesions
Internal CLA lesions only (lungs and/or visceral lymph nodes) 14 (50)
CLA lesions in superficial lymph nodes only 8(29)
Both internal and superficial CLA lesions present 6(11)
Pathology
During the trial, any sheep identified as CLA-positive on the basis
of clinical examination or serology were either isolated from the rest
of the trial flock or culled. A proportion of the sheep that were clini¬
cally affected and ELISA-positive were examined postmortem.Where
flock management allowed, a proportion of the ELISA-negative cull
sheep were also examined postmortem. A standard operating proce¬
dure was adopted to ensure consistency. Postmortem examinations
were carried out by the authors. Sheep from flocks A; B; C andD were
examined at the Scottish Agricultural College Veterinary Services
Disease Surveillance Centre, St Boswells. Sheep from flocks E and F
were examined at the Agri-Food and Biosciences Institute, Veterinary
Sciences Division, Omagh. Each sheep was condition scored, and
a general external examination of the carcase was performed, with
particular reference to any enlarged superficial lymph nodes or puru¬
lent sinus discharges. A detailed postmortem examination was then
undertaken, once again with particular reference to the lymph nodes
and to the lungs.
Any suspect lesions, all prescapular, submandibular parotid and
retropharyngeal lymph nodes and a portion of bronchomediastinal
lymph nodes were cultured and examined as described by Cowan
and Steel (1993). Tissues that showed no gross lesions of CLA were
dipped in 40 per cent alcohol and flamed to remove any surface con¬
taminating organisms. They were stomached in nutrient broth, before
plating out on to blood agar. Plates were incubated aerobically at 37°C
and inspected at 24 and 48 hours. If C pseudotuberculosis was present,
visible growth tended to be limited at 24 hours, with colonies reach¬
ing a diameter of 1 to 2 mm at 48 hours. Presumptive identification
of recovered bacteria was made on the basis of colony morphology,
catalase activity and microscopic examination after Gram staining.
A definitive identification of the organism was made using the API
Coryne identification system (bioMerieux).
Results
Clinical examinations
Before the first round of clinical examinations, 11 sheep in flockA had
clinical signs consistent with CLA and were removed from the flock,
and four sheep in flock B, one sheep in flock C, three sheep in flock
D, five sheep in flock E and seven sheep in flock F were confirmed as
clinically and bacteriologically positive for CLA. At the first round of
testing, a further three sheep in flock B, 30 sheep in flock C and one
sheep in flock D had clinical signs consistent with CLA. No further
clinical cases of CLA were detected in flocks A, B, C, E or F during
subsequent rounds of testing. However, the owner of flock D contin¬
ued to report visible evidence of disease throughout this period
Contact with the owner of flock B confirmed that the flock
remained clear of clinical evidence of CLA until it was sold in 2005,
and contact with the owners of flocks C, D, E and F as recently as
July 2009 confirmed that those flocks also remained free of clinical
disease.
Serology
The results of the serological examinations are summarised in Table
1. In all four flocks where testing was completed and management
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advice on the control of infection was followed (flocks B, C, E and
F), the serological incidence of infection declined. In flocks B and C,
seroprevalence reduced to such an extent that at the final two flock
tests no seropositive sheep were detected. At the final test, two sheep
were seropositive in flocks E and F. These four animals were exam¬
ined after culling, and no CLA lesions were found. The decline in
seroprevalence in flock C during the trial is shown in Fig 1. In com¬
parison, the owners of flockD failed to follow advice on the removal
of seropositive sheep, and as a result seroprevalence and incidence of
clinical signs increased during the trial. The seroprevalence in flockD
is shown in Fig 2.
Pathology
A total of 88 postmortem examinations were performed on sheep of
known serological status from the six trial flocks. Of these, 28 carcases
were found to have gross evidence of abscessation, subsequently con¬
firmed as CLA by bacteriology. CLA lesions were most commonly
seen in the lungs (13 cases), parotid lymph nodes (10 cases), broncho¬
mediastinal lymph nodes (eight cases) and prescapular lymph nodes
(three cases) (Table 2). Of the 13 sheep with lung abscesses, seven also
had lesions in at least one other superficial or visceral lymph node site
orwithin the parenchyma of the liver.
Discussion
Since the arrival ofC pseudotuberculosis in the UK, the prevalence ofCLA
in the sheep industry has risen inexorably. The proprietary vaccines
used widely to control CLA in other parts of the world have not been
licensed for use inmany European countries, including the UK. Farmers
concerned about the spread of infection between andwithin flocks have
therefore had to rely on clinical examination to identify affected sheep.
The development of an ELISA method for detecting antibodies
to the PLD exotoxin of C pseudotuberculosis (ter Laak and others 1992)
led to the establishment of a CLA health scheme within the Dutch
dairy goat sector (Dercksen and others 1996). This scheme established
a means for owners of infected goat herds to eradicate CLA, with the
ultimate aim of CLA-free accreditation for their herd.
Although serological testing has been used as a research tool in a
number of other countries, blood tests have not been widely used to
control and eradicate disease. The present study has shown that the
regular use of an ELISA to test and remove positive sheep, in associa¬
tion with clinical inspections and changes in farm management, can
gready reduce the incidence of CLA in affected flocks.
The proportion of sheep with gross lesions that showed only the
internal or visceral form of CLA was somewhat higher (50 per cent)
than in previous reports from the UK, which report that between one-
quarter and one-third of sheep were affected in this way (Malone and
others 2006, Baird and Fontaine 2007). Almost half of the visceral
lesions identified in the present study were located within the lung
parenchyma. Sheep with such pulmonary lesions have been identified
by several authors as the principal source of infection for other sheep
(Ellis and others 1987, Pepin and others 1994). The first mathematical
model of C pseudotuberculosis infection indicated that, whereas trans¬
mission from superficial lesions predominates during the early spread
of infection within a naive population, transmission from respiratory
abscesses dominates the endemic phase of disease (O'Reilly and oth¬
ers 2008). This indicates that CLA management based purely on the
removal of visibly affected sheep is unlikely to be successful. Thus,
using serology to identify infected sheep offers the opportunity for
enhanced disease control.
The most significant effects of the strategy were seen in trial flock
C, where at the start of the study the seroprevalence was greater than
60 per cent and approximately 40 per cent of all adult sheep showed
clinical signs of disease. Although seven rounds of testing over three
years were required to remove all seropositive sheep from the flock,
the two final tests, which took place six months apart, failed to iden¬
tify any antibody-positive sheep, and no further clinical cases of CLA
were detected by the owner during the next five years. Although clini¬
cal inspection alone cannot detect animals with the internal form of
the disease, the absence of external signs of CLA for this length of
time, in the view of the authors, constitutes effective eradication of
disease. In future, postmortem examinations of fallen stock or abat-
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toir examinations of cull sheep may be suitable methods of disease
monitoring in flocks that have adopted CLA eradication by regular
ELISA testing.
The present study indicates that effective control of CLA may be
achievable in flocks with a high prevalence through the use of serol¬
ogy and management changes. However, it also makes clear that a
reduction in disease prevalence is not possible when owners are insuf¬
ficiently motivated to make the required changes in management or
are unwilling to remove clinically or serologically positive sheep. This
was indicated in trial flockD, where advice on the control of infection
and cullingwas not followed and the clinical and serological incidence
of CLA increased during the study.
This trial was fully funded; flock owners were not required to
pay for any testing or veterinary visits, and they received payment for
animals that were culled and submitted for postmortem examination.
This would not be the case for a test-and-cull programme operated
commercially. Thus, it seems likely that the owners of CLA-affected
flocks of high value and small size would be most likely to consider
such a scheme. The scheme may appear less attractive to the own¬
ers of larger flocks, where the costs of testing, culling and sourcing
replacements would be correspondingly greater.
In recent years, work in the UK has led to the development of a
commercially available CLA ELISA test for sheep. This assay has sim¬
ilar levels of sensitivity and specificity to those reported for the ELISA
used in the present trial. The introduction of the UK-derived test has
prompted interest in the use of serology to control the spread of CLA
within the UK sheep industry. In 2005, the CLA Monitoring Scheme
incorporated the UK-developed serodiagnostic ELISA and western blot
analysis based on the recombinant PLD antigen, to encourage presale
testing of sheep (Anon 2005).
CLA eradication by means of ELISA testing may be hindered
by the development of a vaccine against CLA. Although no fully
licensed vaccine is available, vaccination against CLA is allowed in the
UKwith the authorisation of the Veterinary Medicines Directorate
(VMD). With the agreement of the VMD, an autogenous C pseudo¬
tuberculosis vaccine may be prepared. Alternatively, on receipt of a spe¬
cial treatment certificate, a proprietary CLA vaccine may be imported
into the UK. Furthermore, anecdotal evidence suggests that unauthor¬
ised importation and use of proprietary vaccines may be occurring.
This is significant because the use of CLA vaccines containing PLD
antigen has been shown to produce seroconversion detectable as posi¬
tive titres in the ELISA test (Fontaine and others 2006). For this reason,
the use of vaccination is incompatible with a test-and-cull programme
as described here.
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Abstract
Using a virulent United Kingdom Corynebacteriuin pseudotuberculosis isolate, an ovine experimental model of caseous lymphadenitis was
developed, in which the manifestation of disease was equivalent to the naturally observed infection in this country. Subsequently, the capacity of
several experimental vaccines to protect against experimental challenge was determined. Sheep were immunised with a recombinant derivative
of phospholipase D, deriving from the virulent UK isolate, a formalin-killed bacterin of the same strain, or a bacterin supplemented with
recombinant phospholipase D. Following homologous experimental challenge, the phospholipase D and bacterin vaccines were observed to
confer statistically significant protection against infection, and appeared to restrict dissemination of challenge bacteria beyond the inoculation
site in the majority of animals. More importantly, the combined vaccine succeeded in providing absolute protection against infection, whereby
challenge bacteria were eradicated from all vaccinates. In addition to the experimental vaccines, a commercially available CLA vaccine,
unlicensed for use in the European Union, was assessed for its capacity to protect against heterologous challenge. The vaccine conferred
significant protection, although the dissemination of infection beyond the inoculation site was not restricted as it had been with the previous
vaccines. However, no animals immunised with this vaccine manifested infection within the lungs; thus, a potentially important route of disease
transmission was eliminated. The results of this study provide information pertinent to the development of an effective caseous lymphadenitis
vaccination strategy in the UK.
© 2006 Elsevier Ltd. All rights reserved.
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1. Introduction
The facultatively intracellular bacterium, Corynebac¬
terium pseudotuberculosis, is the causative agent of the
chronic, suppurative disease of sheep and goats known as
caseous lymphadenitis (CLA). The disease, which causes
significant economic losses to the sheep industries world¬
wide [1-4], is characterised by the formation of encap¬
* Corresponding author. Tel.: +44 131 445 511 1; fax: +44 131 445 6111.
E-mail address: Michael.Fontaine@Moredun.ac.uk (M.C. Fontaine).
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sulated abscesses containing thick, caseous pus, most fre¬
quently within superficial lymph nodes, but also within
internal lymph nodes and organs. Until recently, CLA was
apparently absent from the United Kingdom; the first doc¬
umented case of the disease in this country was reported
in 1990 [5], following the importation of infected Boer
goats in 1987 [6]. Subsequently, following the first sheep
outbreak in 1991, CLA has become increasingly prevalent
within the terminal sire breeds, where at least as many as
18% of flocks are thought to be infected [7], In addition,
through the sale of infected rams, the disease is threat-
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ening to become widely established within commercial
flocks.
The potential to vaccinate sheep against infection with C.
pseudotuberculosis has been the focus of research attention
for many years now. Bacterin vaccines, or those comprised
of cellular components have been shown to offer a degree of
protection against experimental infection [8-12], In addition,
they have also shown some success when used to vacci¬
nate against naturally acquired infection in sheep and goats
[13,14],
Significantly, some of the earliest investigations into vac¬
cination against C. pseudotuberculosis infection reported the
capacity of the potent C. pseudotuberculosis exotoxin to
induce protective immunity in guinea pigs [15]; however,
despite these encouraging results, the general consensus was
initially held that the chronic nature of C. pseudotuberculosis
infections in sheep, compared to the relatively acute manifes¬
tation in guinea pigs, rendered exotoxin vaccines unsuitable
for use against CLA [16,17]. Later work revealed that C. pseu¬
dotuberculosis exotoxin, now characterised as phospholipase
D (PLD) [16], did in fact offer protection against infection in
sheep [18]; subsequently, significant efforts have been made
to produce effective CLA vaccines based on this antigen.
The majority of studies have employed formalin-inactivated
toxoid vaccines derived from PLD-rich C. pseudotubercu¬
losis culture supernatants, and these have conferred vary¬
ing levels of protective immunity in both sheep and goats
[18-22],
At this time, there is no commercially available CLA vac¬
cine licensed for use in the UK. Permission may be sought
by veterinary practitioners for the use of so-called autoge¬
nous vaccines, which are adjuvanted bacterins derived from
C. pseudotuberculosis isolates from flock outbreaks, intended
only for immunisation of animals on the holdings from which
the vaccine isolates derived; however, the protective capac¬
ity of these relatively crude preparations has been purely
anecdotal. In light of these facts, there currently exists no
information pertaining to the capacity to vaccinate against
CLA in the UK. Interestingly, the clinical manifestation of
the disease in this country has been suggested to be more
similar to that of CLA in goats than that of sheep elsewhere
in the world [23]; however, whether this is due to differences
between C. pseudotuberculosis isolates, the susceptibility of
UK sheep breeds or other differences in the pathogenesis of
CLA infections in this country, is open to debate. We have
assessed the capacity of a C. pseudotuberculosis bacterin to
protect sheep against homologous challenge with a virulent
UK isolate of C. pseudotuberculosis. In addition, we have
assessed the capacity of a recombinant derivative of PLD
and a recombinant PLD-supplemented C. pseudotuberculo¬
sis bacterin to protect against equivalent challenge. Finally,
we have also investigated the capacity for a commercial vac¬
cine preparation, not licensed for use in this country, to protect
against heterologous challenge with a UK C. pseudotubercu¬
losis strain.
2. Materials and methods
2.1. Media and culture conditions
C. pseudotuberculosis was propagated on blood agar (BA)
plates derived from Blood Agar Base (Oxoid) and 5% (v/v)
sheep blood, or in Brain Heart Infusion broth (BHI; Oxoid,
Basingstoke, Hampshire, UK), at 37 °C (200x rpm for liq¬
uid cultures) for up to 48 h. Unless otherwise specified,
Escherichia coli strains were routinely cultured at 37 °C
(200x rpm for liquid cultures) in Luna Bertani medium (LB;
Oxoid) containing ampicillin (100p,g/ml), or carbenicillin
(50 p-g/ml) and 10 mM glucose for expression experiments.
2.2. Molecular biological techniques
Unless otherwise specified, all DNA manipulations were
performed according to standard techniques [24], Restric¬
tion endonucleases and other modifying enzymes were pur¬
chased from Promega (Southampton, UK) or Roche (East
Sussex, UK) and used according to the manufacturers' sup¬
plied instructions. Small-scale extraction and purification of
plasmid DNA from E. coli was performed using the QIAquick
Spin Miniprep Kit (QIAGEN, Crawley, West Sussex, UK),
and genomic DNA was extracted from C. pseudotuberculosis
using the NucleoSpin Tissue Kit (BD Biosciences (Clon-
tech), Erembodegen, Belgium). PCR-amplified DNA frag¬
ments were purified using the Strataprep PCR Purification
Kit (Stratagene, La Jolla, CA, USA), and cloned into pPCR-
Script using the PCR-Script Cloning Kit (Stratagene). For
cloning, restriction endonuclease-digested DNA fragments
were electrophoresed through 1.0% (w/v) agarose gels and
purified using the QIAquick Gel Extraction Kit (QIAGEN).
Custom PCR and sequencing primers (Table I) were syn-
thesised to order by Sigma-Genosys (Sigma-Genosys Ltd.,
Haverhill, Suffolk, UK). Automated DNA sequencing was
performed using a MegaBACE sequencing apparatus (Amer-
Table 1
Oligonucleotide primers
Primer name Sequence" Description
pld#01 b 5'-CGCGCCATATGGCGCCTGTTGTGCATAACCCAGC-3' Binds at bp 73-95 of pld
pld#02 5'-GCGCGGGATCCTCACCACGGGTTATCCGC-3' Binds at bp 924-907 of pld
pET(fwd) 5'-GGATAACAATTCCCCTC-3' Binds at bp 5261-5277 of pET-15b
pET(rev) 5'-CTAGTTATTGCTCAGCG-3' Binds at bp 5452-5436 of pET-15b
" Restriction endonuclease cleavage sites underlined; pld#0\b =Nde\ and pld#02 = BainHl.
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sham Biosciences UK Ltd., Buckinghamshire, UK) by the
Functional Genomics Unit of the Moredun Research Insti¬
tute.
2.3. Cloning of the C. pseudotuberculosis pld gene
The pld gene of the virulent UK C. pseudotuberculosis iso¬
late, 3/99-5 [25] was amplified by PCR. The published pld
sequence (GenBank accession #L 16586) was used to design
the primers pld#01b and pld#02, and to facilitate cloning
primers included restriction endonuclease cleavage sites. The
amplified fragment, corresponding to the truncated pld gene
lacking the first 72 bp (encoding the 24 amino acid (aa) secre¬
tion signal sequence), was cloned into pPCR-Script and
the resulting construct was designated pMMF003. To allow
expression of the truncated 3/99-5 pld gene, pMMF003 was
digested with Ndel and BamHl, and the 859 bp fragment was
ligated into pET-15b. Following transformation of E. coli
XL 10-Gold Kan (Stratagene), the desired construct was iden¬
tified and designated pMMF004. DNA sequencing of both
leading and complementary strands was performed using the
primers pET(fwd) and pET(rev), to confirm the identity of
the cloned fragment.
2.4. Expression and purification of recombinant PLD
(rPLD)
Expression of the pld gene in pMMF004 was performed
in E. coli BL21 (DE3) and induced by the addition of IPTG
(1 mM final concentration) to exponentially-growing cultures
(ODfioonm of ~0.6). Induced cultures were incubated for
1 h prior to the addition of rifampicin (150 p,g/ml final con¬
centration). Incubation was continued for a further 3 h, and
then cells were harvested by centrifugation at 6000 x g for
15 min at 4°C. Cell pellets were resuspended in BugBuster
Protein Extraction Reagent (Merck Biosciences (Novagen),
Nottingham, UK) to approximately 5 ml/g of wet cell pel¬
let. Complete protease inhibitor cocktail (Roche) was added
(lx final concentration) to inhibit proteolytic degradation,
then Benzonase enzyme (Novagen) was added (1 p-g/ml final
concentration) and incubation was performed with gentle
rotation on a shaking platform for 40 min at room temper¬
ature. During this incubation, cells were lysed and viscosity
due to nucleic acids was reduced. Subsequently, centrifuga¬
tion was performed at 16,000 x g for 30 min at 4°C to pellet
cell debris, and then cleared supernatants were supplemented
with imidazole to a final concentration of 10 mM.
rPLD was purified by immobilised metal-ion affinity chro¬
matography. Twelve ml EconoPak columns (Bio-Rad, Hemel
Hempstead, Hertfordshire, UK) were loaded with 2 ml (bed
volume) of Ni-CAM HC resin (Sigma-Aldrich Company
Ltd., Irvine, UK), pre-equilibriated with lysis buffer (Column
Buffer (CB) [50 mM Tris-HCl, pH 8.0 and 300 mM NaCl]
supplemented with lOmM imidazole). To each column was
added 5 ml of cell lysate (originating from approximately
500 ml of culture), and the volume was supplemented with a
further 5 ml of lysis buffer. Columns were sealed and incu¬
bated for 16 h at 4 °C on a tube rotator. Subsequently, columns
were drained by gravity flow and washed with 25 x 2 ml
of wash buffer (CB supplemented with 20 mM imidazole).
Finally, column-bound protein was eluted in 5 x2ml of
elution buffer (CB supplemented with 250 mM imidazole).
Eluted proteins were concentrated and buffer exchanged in
lOmM PBS (pH 7.2), supplemented with 0.1% SDS and 1 x
complete protease inhibitors, through 10KMr Amicon Ultra
centrifugal filters (Millipore, Watford, UK) at 3080 x g and
4 °C. The final concentration of rPLD was determined using
the DC Protein Assay (Bio-Rad) and the purity of the prepa¬
ration was estimated by analysis of SDS- and silver-stained
polyacrylamide gels to be in excess of 99%.
2.5. Preparation ofchallenge inoculum
C. pseudotuberculosis 3/99-5 was passaged three times
on BA plates, and then growth was collected using ster¬
ile, cotton-tipped swabs. Bacteria were suspended in PBS,
in polystyrene Universal tubes, by gently rolling swab tips
against the tube sides. Dilutions of the primary suspension
were prepared to give the required cells/ml for subsequent
challenge. Cells/ml were estimated by use of a Densimat
(bioMerieux, Basingstoke, UK), and then quantified accu¬
rately using a Thoma counting chamber.
2.6. Preparation offormalin-killed C.
pseudotuberculosis
For vaccination, C. pseudotuberculosis was cultured on
BA plates, as for Section 2.5. Approximately 1011 cfu were
suspended in 20 ml of PBS in a Universal tube and supple¬
mented with 40% formalin to a final concentration of 0.2%
(v/v). Cells were incubated overnight at 4 °C, and then quan¬
tified using a Thoma counting chamber. Subsequently, cells
were pelleted by centrifugation at 3080 x g for 15 min at
4°C, and resuspended in distilled water to a final concen¬
tration of 1.25 x 1010 cells/ml. To confirm complete killing
100 p.1 aliquots of the bacterial suspension were plated onto
BA plates, incubated at 37 °C and monitored daily for 5 days.
2.7. Experimental challenge and vaccination
For all challenge/vaccination experiments, male, approx¬
imately 1-year-old Suffolk-cross sheep were used. Prior to
undertaking the vaccination study, a dose titration exper¬
iment was performed to determine the minimum cells/ml
required to induce experimental infection manifesting clin¬
ical signs and pathology similar to naturally observed
CLA. Groups of two animals were inoculated with 10",
103, 104 or 108 bacteria, and an unchallenged control
group was also included, administered sterile saline. The
identification of the animals in each challenge group
was 1578N + 1638N, 1630N + 1570N, 1549N + 1531N,
1689N + 1728N, and 1640N + 1603N, respectively. Forchal-
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lenge, a 1 ml inoculum was administered subcutaneously,
2 cm caudal to the base of the left ear of each animal, on
a line passing through the ear to the left eye. Subsequently,
animals were housed in their respective groups for 9 weeks,
during which time blood was collected at regular intervals
for serology. Animals were then sacrificed, a full necropsy
was performed, and samples corresponding to inoculation
site abscesses, lung, liver, spleen and brain tissues, as well
as left- and right-hand-side (LHS and RHS, respectively)
parotid, prescapular, sub-mandibular, retropharyngeal, medi¬
astinal, prefemoral, inguinal and popliteal lymph nodes were
collected for determination of the presence of bacteria. Subse¬
quently, vaccinated animals were challenged with the deter¬
mined optimal bacterial dose, exactly as described above,
following which they were housed in their respective groups
for 3 months until post mortem analysis.
For immunisations, vaccine antigens were formulated in
physiological saline to final volumes of 1 ml, containing
50% (v/v) of a 13 mg/ml colloidal suspension of aluminium
hydroxide (Alhydrogel; Sigma). Groups of six animals were
immunised with either saline (control), 50% Alhydrogel
(control), 50 p,g of rPLD, 5 x 109 formalin-killed C. pseudo¬
tuberculosis whole-cells, or a combination of 50 p,g of rPLD
and 5 x 109 killed whole-cells; the Alhydrogel group was
included to ensure that there was no effect of the adjuvant
on the host resistance to infection. In addition, animals were
immunised with the commercial inactivated-PLD vaccine,
Glanvac-3™ (Commonwealth Serum Laboratories (CSL)
Ltd., Victoria, Australia), currently unlicensed in the UK.
Vaccines were administered subcutaneously to the RHS lat¬
eral neck. A 4-week interval was allowed between the first
and second immunisations, and bacterial challenge was per¬
formed 2 weeks following the second immunisation.
2.8. Post mortem bacteriological analyses
To determine infection with C. pseudotuberculosis, tissue
samples were disrupted in PBS; aliquots were plated onto BA
plates and incubated to allow colony development. Presump¬
tive identification of recovered bacteria as C. pseudotubercu¬
losis was made on the basis of colony morphology, catalase
activity, Gram-stain and appearance by microscopical analy¬
sis. A random selection of samples were also analysed using
the API Coryne test (bioMerieux).
2.9. Serology
Animals' immunological responses to vaccination and/or
infection were determined by measurement of serum anti-C.
pseudotuberculosis and anti-PLD IgG by ELISA. Ninety-six
well microtitre plates were coated with either rPLD (rPLD-
ELISA) or whole C. pseudotuberculosis cells (WC-ELISA)
and blocked with 1 x TBS buffer containing 0.05% (v/v)
Tween 20 (TBST) and 3% (w/v) Top-Block (Sigma). Sub¬
sequently, plates were incubated in the presence of experi¬
mental serum samples, diluted (1/200) in TBST containing
1% Top-Block. Plates were washed with TBST, and bound
anti-C. pseudotuberculosis and anti-rPLD IgG was detected
by use of a horseradish peroxidase-conjugated mouse anti-
sheep/goat IgG monoclonal antibody (Clone GT-34; Sigma)
and 3,3',5,5'-tetramethylbenzidine (TMB) substrate (Sigma).
Colorimetric reactions were stopped and intensified with 2 M
H2SO4, and the absorbance of each sample at 450 nm was
subsequently determined.
2.10. Computational and statistical analyses
Analysis of DNA sequences and design of oligonu¬
cleotide primers was performed using the Clone Manager
Professional Suite (Scientific and Educational Software Ltd.,
Durham, NC, USA). Unless otherwise stated, statistical
analyses were performed using Genstat (8th edition; VSN
International Ltd., Hemel Hempstead, Hertfordshire, UK).
Because of the lack of independence between measurements
made on the same animal, a repeated measures model was
fitted to the ELISA data. The correlation structure was mod¬
elled using a powermodel and the parameters of the statistical
model were estimated using the REML directive in Gen¬
stat. Several analyses were carried out on the necropsy data
to determine differences in the extent and pattern of infec¬
tion in the various tissues. A one-way analysis of variance
(ANOVA) was used to investigate the mean percentage of
tissues infected with C. pseudotuberculosis in the different
groups. An angular transformation of the percentages was
used to stabilise the variances within the groups and mean
differences between groups were assessed using a least sig¬
nificant difference (LSD) approach. Three different patterns
of infection were defined: no tissues infected, infection at the
inoculation site only, and infection at the inoculation site and
at least one other tissue. Animals were classified as having
one of these three pattern types and a Fisher exact test was
implemented, using the R language for statistical comput¬
ing (available from http://www.R-project.org), to determine
whether there was an association between groups and pat¬
tern types. The nature of the association was illustrated using
correspondence analysis.
3. Results
3.1. Optimisation of infection model
In order to determine the optimal dose of C. pseudotu¬
berculosis required to induce a similar disease manifesta¬
tion in experimentally infected animals to that observed in
natural cases of CLA, a dose titration experiment was per¬
formed. Prior to infection, the absence of clinical symptoms
or circulating anti-C. pseudotuberculosis whole-cell and anti-
PLD IgG was confirmed by clinical examination and ELISA
analysis of blood samples taken from experimental candi¬
dates using the rPLD- and WC-ELISAs (Fig. 1); thus, the
absence of natural infection within the flock was ensured.
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Fig. I. Measurement of humoral immune response in sheep challenged with
C. pseudotuberculosis. Levels of IgG (presented as ODasonm values) against
C. pseudotuberculosis whole-cells (top) and PLD (bottom) were determined.
Challenge was performed at week 0, and groups correspond to: control,
1640N (*) and 1603N ( 1 ); 102, 1638N (A) and 1579N (- - A - -
); 103, 1570N (O) and 1630N (- -o ); 104, 1531N ( □ ) and
1549N (□); 108, 1728N (- - O- - - ) and I689N (0).
Bacteriological analysis of tissue samples taken post mortem
was performed, and the sites from which C. pseudotuber¬
culosis was recovered from each animal are presented in
Table 2. In light of the observation that no bacteria were
recovered from either brain, spleen or liver tissue samples or
inguinal, popliteal and prefemoral lymph nodes from any of
Table 2
Recovery of C. pseudotuberculosis from tissues of challenged animals
Dose (cfu/ml) Animal # Tissue samplea,b
Lung LPs. LPa. LR Med IS
Control 1640 — — — — — —
Control 1603 - - - - - -
io2 1579 + - - - - +
io2 1638 + - - - - +
103 1630 + + + + - +
103 1570 + - - + - +
io4 1549 + + - - + +
104 1531 - + + - + +
io8 1689 + + - + + +
108 1728 + + - + + +
" LPs.: left-hand side (LHS) prescapular lymph node; LPa.: LHS parotid
lymph node; LR: LHS retropharyngeal lymph node; Med: mediastinal lymph
node; IS: inoculation site.
b Presence/absence of bacteria denoted by +/—, respectively.
the experimental animals in the current study or in infection
experiments conducted by us previously (unpublished data),
future experiments were refined by eliminating the sampling
of these sites. From the bacteriological data, it was apparent
that as few as 102 cells were capable of causing infection. A
challenge dose of 104 cells was chosen for subsequent exper¬
iments, due to the observation that, with this dose, infection
occurred in multiple lymph nodes and the lungs (i.e. was not
restricted to a specific site).
Serological analysis of the blood samples taken from the
experimental animals during the course of infection was
performed. The levels of anti-C. pseudotuberculosis whole-
cell and anti-PLD IgG of each animal were determined and
are presented in Fig. 1 as the absorbance values at 450 nm,
obtained using either ELISA. As expected, all infected ani¬
mals were observed to have mounted an immunological
response to the challenge bacterium, as determined using the
WC-ELISA; however, there was no evidence that the magni¬
tude of the response was directly associated with the number
of challenge bacteria administered. Results were similar for
anti-PLD IgG determination using the rPLD-ELISA; how¬
ever, it is interesting to note that, despite mounting an immune
response against C. pseudotuberculosis whole cells, one ani¬
mal (1531N) failed to mount any observable response to PLD
during the time-course of the experiment.
3.2. Vaccination and challenge ofexperimental animals
with C. pseudotuberculosis
Prior to vaccination, experimental candidates were
screened by clinical examination and by both ELISAs; all
animals were free from observable signs of infection and
lacked circulating anti-C. pseudotuberculosis whole-cell and
anti-PLD IgG (data not shown). Unfortunately, one animal in
group 3 died unexpectedly in the period between the first and
second immunisations; however, no inoculation site reaction
was observed, and the cause of death was determined not to
be associated with any effects of vaccination.
Prior to experimental challenge, serology was performed
to monitor the response to vaccination in each animal, using
the WC-ELISA and rPLD-ELISA (Fig. 2, top and bottom
panels, respectively). To compare immune responses between
treatment groups, data are presented as average OD45onm val¬
ues (as determined by either ELISA) per group, and standard
errors at each time point are included. As expected, using the
rPLD-ELISA, the highest mean levels of anti-PLD IgG were
observed for the animals immunised with rPLD (rPLD and
rPLD + whole-cell vaccines) and Glanvac™. For the former
groups, anti-PLD IgG mean levels reached a maximum prior
to the booster vaccination; furthermore, given the similar
responses in animals in these groups, the whole-cell compo¬
nent of the rPLD + whole-cell vaccine was not considered to
contribute to the immune response measured using the rPLD-
ELISA. Mean levels of anti-PLD IgG in Glanvac™ vacci¬
nates were consistently less than those observed for rPLD and
rPLD + whole-cell vaccinates, and, rather than peaking, con-
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Fig. 2. Measurement of anti-PLD and anti-C. pseudotuberculosis IgG.
Serum anti-C. pseudotuberculosis whole-cell (top) and anti-PLD (bottom)
IgG levels were calculated for each treatment group, expressed as the mean
and standard error of ODasonm per group. Samples were obtained following
primary and secondary vaccinations (weeks 0 and 4, respectively) and for
3 months following bacterial challenge (at week 6). Treatment groups are
(1) (— O - — ) saline control; (2) ( □ ) Alhydrogel control, (3) (A)
rPLD, (4) (*) killed-whole cells, (5) (—A— ) rPLD + killed-whole cells,
and (6) (O) Glanvac-3.
tinued to rise following the secondary vaccination. Repeated
measures models were fitted to both the whole cell and rPLD
IgG ELISA data. For the rPLD data there was strong evidence
(P< 0.001) of a different pattern in the mean responses over
time, particularly where the levels of anti-PLD IgG in rPLD
and rPLD + whole cell vaccinates were significantly higher
than those of Glanvac™ vaccinates in the weeks immedi¬
ately post-immunisation and pre-challenge. Mean levels of
anti-PLD IgG in animals immunised with formalin-killed
whole-cells were similar to those of non-immunised animals
of the two control groups, confirming the observation that the
immune response measured in rPLD + whole-cell vaccinates
was likely to be a result of the rPLD portion of the vaccine
(Fig. 2).
In contrast to results using the rPLD-ELISA, the WC-
ELISA was able to determine the presence of high mean
levels of anti-C. pseudotuberculosis IgG in killed whole-
cell-vaccinated animals (whole-cell and rPLD + whole-cell
vaccines), while not detecting an immune response in those
animals vaccinated with rPLD or Glanvac™ (Fig. 2). This
was probably due to the fact that PLD is a secretory anti¬
gen, which would have been sparingly present in the killed
whole-cell vaccine, and also in the cell preparations used
in the WC-ELISA. Therefore, given the similarities in IgG
levels between whole-cell and rPLD + whole-cell vaccinates,
the response in animals immunised with rPLD + whole-cell
vaccine can only have been against the whole-cell portion of
the vaccine. As with rPLD and rPLD + whole-cell vaccinates
(using the rPLD-ELISA), mean antibody levels in whole-cell
and rPLD + whole-cell vaccinates reached their maximum
level prior to administering the secondary vaccination. Over¬
all, using the combined results of the two ELISAs, it was
possible to determine that all animals, except for those of
the control groups, had mounted observable immunological
responses to vaccination.
The levels of serum anti-PLD and anti-C. pseudotubercu¬
losis IgG were determined, as for the pre-challenge serum
samples, following bacterial challenge at week 6 (Fig. 2).
After challenge, average anti-PLD IgG levels in the two
control groups increased to their maximum level by week
10 (4 weeks post-challenge). Anti-PLD IgG levels in killed
whole-cell vaccinates remained similar to those of the con¬
trol groups, rising steadily to a maximum level by week
10. Mean anti-PLD IgG levels in rPLD and rPLD + whole-
cell vaccinates remained essentially constant until week 10,
by which point anti-PLD IgG in animals immunised with
Glanvac™ had reached an equivalent level; from that point
on, mean anti-PLD levels in rPLD, rPLD + whole-cell and
Glanvac™ vaccinates declined gradually to coincide with
the anti-PLD levels observed in animals of the control and
whole-cell immunised groups. Mean levels of anti-C. pseudo¬
tuberculosis IgG in the rPLD and rPLD + whole-cell vaccine
groups remained essentially constant from the point of chal¬
lenge. Mean anti-C. pseudotuberculosis IgG levels in the
two control groups and animals immunised with rPLD and
Glanvac™ were similar to each-other, rising slightly after
challenge, but never reaching an equivalent level to that
observed for killed whole-cell vaccinates.
3.3. Post mortem analyses
Bacteriological sampling of tissue samples collected from
vaccinated experimental animals was performed. The num¬
bers of infected sites varied between groups, and to a lesser
extent between individual animals. However, C. pseudotuber¬
culosis was not recovered from the RHS parotid or the LHS
and RHS submandibular lymph nodes of any animal. Data
pertaining to the loci within animals of each treatment group
from which bacteria were isolated is presented in Table 3.
Significantly, no evidence of infection was found within any
of the animals immunised with the rPLD + whole-cell vac¬
cine, including the apparent resolution of inoculation site
abscesses. The observed number of lung lesions varied to
a large extent, both between groups and individual animals.
Therefore, rather than directly comparing the actual numbers
of lung lesions as a means of determining disease severity, a
more robust method of comparing the presence or absence of
lesions was used to determine differences.
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Table 3
Recovery of C. pseudotuberculosis from tissues of vaccinated, challenged animals and percentage of infected tissues by treatment group
Treatment group Group size (n) Tissue sample" Meanb S.E.
IS LPa. LPs. RPs. LR RR Lung Med
Saline 6 6/6 I/6 3/6 1/6 3/6 2/6 1/6 1/6 37.5 6.5
Alhydrogel 6 6/6 2/6 5/6 0/6 4/6 0/6 3/6 1/6 43.7 8.4
rPLD 5 5/5 0/5 0/5 0/5 0/5 0/5 1/5 0/5 15.0 2.5
Whole-cell 6 5/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 10.4 2.1
rPLD + whole-cell 6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 0 0
Glanvac™ 6 5/6 1/6 1/6 0/6 3/6 0/6 0/6 0/6 20.8 7.0
a Abbreviations correspond to: tissues; IS, inoculation site, and lymph nodes; Lpa., LHS parotid; LPs., LHS prescapular; RPs., RHS prescapular; LR, left
retropharyngeal; RR, right retropharyngeal; Med, mediastinal.
b Mean percentage of tissues containing CLA lesions.
An ANOVA was performed to determine whether the
mean percentage of tissues infected with C. pseudotuber¬
culosis varied significantly between the different treatment
groups. Only the eight tissues observed to show infection in
any of the animals were used in the analysis (RHS parotid
excluded). There was strong evidence (P< 0.001) that the
mean percentage of tissues infected was different between
the different treatment groups. The mean percentages and
standard errors on the original scale are shown in Table 3.
The two control groups had similar means and there was no
evidence of an affect of Alhydrogel on the outcome of infec¬
tion. Furthermore, the means of the control groups were both
significantly different to those of the groups of immunised
animals (using an LSD at the 5% level), confirming that all
of the vaccine antigens assessed in the study offered a signif¬
icant level of protection against infection.
In the experimental subjects, the most common sites of
infection were the LHS prescapular and retropharyngeal
lymph nodes, which is consistent with the drainage of chal¬
lenge bacteria from the site of administration to a local
draining lymph node. To determine whether spread of C.
pseudotuberculosis from the inoculation site to other internal
sites was more or less likely within the different treatment
groups, each animal was assigned to one of three different
pattern groups (data not shown), which were determined on
the basis of there being no tissues infected (PI), infection
in the inoculation site but no other tissues (P2), or infection
in the inoculation site and at least one other tissue (P3). A
Fisher exact test indicated that there was very strong evidence
(P< 0.001) that some treatment groups displayed different
patterns of infection to other groups.
The association between treatment group and pattern type
was investigated further using correspondence analysis (data
not shown). The scores of the first and second components
were plotted against each other for treatment groups and pat¬
tern types separately (Fig. 3). It was expected that if a pattern
type (PI, P2 or P3) was associated with a particular treat¬
ment group then the pattern and treatment groups would be
located close to each other on the correspondence plot. It
was observed that PI and rPLD + whole-cell vaccinates were
clearly associated with each other and separated from the
















Fig. 3. A correspondence analysis plot showing treatment groups and pattern
of infection. Treatment groups were saline (Gl), Alhydrogel (G2), rPLD
(G3), formalin-killed whole-cells (G4), rPLD +killed whole-cells (G5) and
Glanvac-3 (G6). Patterns of infection were defined as no tissues infected
(PI), infection in the inoculation site but no other tissues (P2) and infection
in the inoculation site and at least one other tissue (P3). All treatment groups
associate with a particular pattern of infection, with the exception of G6.
second component, P2 and P3 were distinct, with rPLD and
whole-cell vaccinates associated with P2 and control animals
associated with P3. Interestingly, Glanvac™ vaccinates did
not cluster well with any pattern group, but associated most
closely with P3.
4. Discussion
To our knowledge, this is the first study conducted to
investigate the potential for vaccination of sheep in the UK
against CLA. We report here statistically significant lev¬
els of protection against both homologous and heterologous
challenge with a virulent, UK-derived C. pseudotuberculosis
strain, isolated from a natural CLA outbreak. In a homol¬
ogous challenge model, vaccination with either the highly
purified rPLD antigen, or formalin-killed C. pseudotuber-
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culosis cells prevented spread of challenge bacteria beyond
the site of inoculation in the majority of immunised ani¬
mals. More importantly, vaccination with a combination of
rPLD and killed whole-cells resulted in complete protection
against challenge. In addition, vaccination with the commer¬
cial vaccine, Glanvac™, also offered statistically significant
protection against heterologous challenge, although it was
less effective in preventing the dissemination of challenge
bacteria beyond the site of inoculation than the former anti¬
gens.
Experimental infections of sheep with C. pseudotubercu¬
losis, conducted by us previously (unpublished data) and as
part of this study, have revealed a consistent pattern of infec¬
tion which appears to be restricted to the lymph nodes of the
head and neck region and the lungs. This experimental data
is consistent with the observed manifestation of CLA in the
UK [23], which is uncommon in other countries. Interest¬
ingly, there is variation in the extent of lung involvement in
our experimental candidates, which also appears to be con¬
sistent with the manifestation of CLA in the UK, in which
up to 25% of infected animals may suffer from lung lesions
[26]. The experimental infections undertaken in this study
were conducted using the lowest number of bacteria as was
possible to achieve signs of infection consistent with those
observed naturally (104 cells, although 102 cells were found
to cause infection); this has relevance, since excess numbers
of bacteria may overwhelm the host immune response and
mask any protective effects of vaccination.
PLD appears to be an important virulence factor, respon¬
sible for the dissemination of C. pseudotuberculosis from
the primary site of infection [27]. Previous studies have
assessed the capacity of different forms of PLD-based vac¬
cine to protect against CLA [20,21,28,29], and in this study
a highly purified, recombinant 6x histidine-tagged fusion
derivative of PLD, lacking the secretion signal peptide was
used. Despite being prepared under native conditions, the
final rPLD vaccine formulation contained a small amount of
detergent, which abrogated toxin activity (data not shown).
Of the five rPLD-immunised animals remaining at the time
of challenge, dissemination of the challenge bacteria beyond
the site of inoculation was prevented, with the exception of
one animal which also manifested evidence of lung infection.
Several authors have suggested that the protective immu¬
nity induced by vaccination with PLD derives from toxin
neutralisation through the action of anti-PLD antibodies
[19,21,30,31], However, one study reported that a geneti¬
cally inactivated PLD derivative did not confer a level of
protection equivalent to that of Glanvac™ [29]; the latter
vaccine comprising a formalin-inactivated PLD preparation
derived from ultra-filtrated C. pseudotuberculosis culture
supernatants [29,32]. The reason for the difference in pro¬
tective ability was hypothesised to result from the remain¬
ing, approximately 1% [33], PLD activity following toxoid-
ing, which potentially contributed to immunity via another
route [29], Given the high-purity and inactive nature of our
rPLD vaccine, it is most likely that its protective capacity
was as a direct consequence of the stimulation of humoral
immunity, since the alternative route of protection suggested
above would be lacking in the absence of toxin activity, and
PLD-based vaccines have not been shown to stimulate cell-
mediated immunity [29], Significantly, conflicting hypothe¬
ses as to the issue of the route of protection may well have
their origins in the purity of vaccine preparations. Toxoid
vaccines prepared from C. pseudotuberculosis culture super¬
natants routinely contain other, undefined bacterial antigens
[32]; therefore, stimulation of protective immune responses
by these other antigens may well contribute to the overall
protection observed. In support of this, immunoblots using
sera from Glanvac™-vaccinated animals were observed to
intermittently recognise a novel 40kDa C. pseudotubercu¬
losis serine protease [34], suggesting that this protein was
present in some batches of vaccine. The antigen was shown to
be located within C. pseudotuberculosis culture supernatants,
and it is possible, therefore, to hypothesise that it may have
been co-purified along with the toxin component during vac¬
cine preparation.
Previously, it has been observed that the kinetics of the
ovine antibody response to immunisation with PLD tend
to be low until the point of bacterial challenge [35,36].
In the present study, the antibody response to vaccination
with Glanvac™ corresponds to previous observations, in that
mean anti-PLD IgG increased with successive vaccinations,
and increased even further following challenge (Fig. 2). In
contrast, animals vaccinated with rPLD mounted a statisti¬
cally significantly more rapid response, which, on average,
peaked prior to the second immunisation. The reason for the
differences in the speed of the immune response between vac¬
cines is not apparent, but inadvertent measurement of trace
E. coli contaminating proteins in the rPLD preparation was
shown not to contribute to the antibody response measured in
the rPLD-ELISA by repeat testing of selected sera by EL1SA
using an HPLC-purified rPLD preparation (data not shown).
It is possible that the different responses were due to different
relative amounts of rPLD and wild-type PLD in the experi¬
mental and Glanvac™ vaccines, respectively. Alternatively,
it has been reported that native PLD is more immunogenic
than the toxoided form [32], Glanvac™ comprises a fomol-
toxoid while the rPLD antigen described here was inactivated
by the presence of a small amount of detergent. Given that
the two methods of inactivation differed, it is possible that
rPLD remained more immunogenic than PLD in Glanvac™.
Currently in the UK, the only vaccination strategy for
which permission may be sought is for the use of so-called
"autogenous" C. pseudotuberculosis bacterin vaccines. Auto¬
genous vaccines are flock-specific, in that they are prepared
using isolates from defined flock outbreaks, and are permitted
for use only in the single holding from which they originated.
Until now, evidence for the protective capacity of autoge¬
nous CLA vaccines in the UK has been purely anecdotal;
however, we have now demonstrated significant protection
against homologous challenge using a C. pseudotuberculosis
bacterin vaccine. Our results are bolstered by previous stud-
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ies, conducted in other countries, where bacterin vaccines
have been successfully used to protectmice and sheep against
experimental [8,91 and natural [14] infection by C. pseudotu¬
berculosis. According to our results, vaccination with killed
whole-cells was sufficient to prevent the spread of C. pseudo¬
tuberculosis beyond the site of inoculation, and in one animal
even the inoculation locus was found to be sterile. While our
data provides evidence that the use of autogenous vaccines
may be efficacious against CLA, in our laboratory PFGE anal¬
ysis of C. pseudotuberculosis isolates deriving from different
animals of the same flock have revealed the presence of differ¬
ent, albeit related, clones in different animals (unpublished
data). The genome of C. pseudotuberculosis of sheep/goat
origin would appear to be extremely stable, and we have
not observed alterations in genetic structure following mul¬
tiple passages in synthetic media or through sheep ([25] and
unpublished data). Therefore, the reason for the existence of
multiple clones within a flock can only be as a result of the
movement of animals between holdings, such as through nor¬
mal sale/purchase practices. This has important implications
for the success of autogenous vaccination strategies, should
they be found not to confer protection against heterologous
C. pseudotuberculosis strains.
The best CLA vaccine, whether it be formulated using C.
pseudotuberculosis killed whole-cells, toxoided PLD, or a
combination of both, has been the focus of debate for some
years now. Previous studies revealed that the use of whole cell
[ 11,37] and toxoid [ 18] vaccines, while conferring significant
protection, were not capable of inducing complete protection
against experimental infection with C. pseudotuberculosis.
Latterly, Eggleton and co-workers published a report in which
it was stated that the incomplete protection observed with
these early experiments resulted from a lack of a suitable ani¬
mal disease model at that time, and it was reported that the
addition ofwhole-cells to a toxoid vaccine made no difference
to the extent of the observed lesions following experimental
infection [33]. However, in a contrasting study [32], it was
claimed that a combined whole-celi/toxoid vaccine was capa¬
ble of conferring complete protection against experimental
challenge, and that this combination vaccine outperformed
a toxoid vaccine equivalent to that used by Eggleton et al.
[33],
The results of our study would tend to support the find¬
ings of previous authors [11,37], in that neither our rPLD
or whole cell vaccine was sufficient to completely pre¬
vent CLA following experimental challenge. In contrast,
in our hands, immunisation of sheep with a combination
of rPLD and formalin-killed whole-cells resulted in com¬
plete protection against experimental challenge, inasmuch
as no evidence of infection was identified in tissue sam¬
ples from challenged animals. Even the infected sites of
inoculation, which frequently remained as encapsulated, sup¬
purative foci containing live C. pseudotuberculosis cells in
other experimental groups, were able to resolve, and these
observations are consistent with those of a previous study
[32],
The reason for our combined vaccine offering such effec¬
tive protection against challenge is possibly due to stimula¬
tion of a strong antibody-mediated response, combined with
priming of the cell mediated immune system through sub¬
cutaneous vaccination with the killed whole-cells (although
no attempt was made to measure the latter during any
stage of the experiment). Interestingly, both the rPLD and
the formalin-killed whole-cell vaccines prevented dissem¬
ination of challenge bacteria beyond the site of inocula¬
tion to essentially equivalent extents. The protection offered
by rPLD was antibody-mediated; therefore, given that the
magnitude of the humoral response to whole-cell antigens
(following vaccination with either the killed whole-cell vac¬
cine or the combination rPLD + whole-cell vaccine) was
equivalent in scale to that observed against rPLD, it is
also possible that complete protection derived purely as a
result humoral immunity deriving from vaccination with
both antigens. In the absence of neutralising antibody, C.
pseudotuberculosis has been shown to survive killing by
non-activated macrophages of several species [38,39] and
the importance of activated macrophages in the suppression
of C. pseudotuberculosis growth and lesion development
has been shown in a murine model [40,41]. In addition,
murine macrophage killing of C. pseudotuberculosis follow¬
ing opsonisation with hyperimmune ovine serum has been
demonstrated [38] and PLD has been shown to aid bacterial
dissemination through promoting vascular permeability [27].
Taken together, these observations help explain the results of
the combined rPLD/whole cell vaccination, since neutralisa¬
tion of PLD (and other C. pseudotuberculosis proteins) by
serum antibodies in vaccinated animals would presumably
abrogate vascular permeabilisation to some extent (limiting
the spread of the challenge bacterium) in addition to opson-
ising bacteria for killing by non-activated macrophages. Fur¬
thermore, if cellular immunity was involved in the protec¬
tion observed in whole-cell vaccinates, adequate priming of
the cell-mediated immune response would allow activated
macrophages to kill bacteria already restricted to the site of
inoculation by neutralisation of PLD (and other colonisation
factors).
It seems likely that challenge bacteria were killed at the
site of primary infection, soon after administration, since
their dissemination would have resulted in the formation
of granulomas within the draining lymph node and other
sites. This hypothesis is consistent with that of Simmons
and co-workers, who observed that sheep vaccinated sub-
cutaneously with live, attenuated (AroQ-deficient) mutants
of C. pseudotuberculosis remained unable to clear the vac¬
cine strain from the lymph node draining the inoculation site
[42], It was considered likely that the inaccessible location
of the attenuated mutants within the granulomas allowed
their persistence through exclusion of immunological fac¬
tors.
The data presented here is the first scientific investiga¬
tion of the capacity for Glanvac™ to protect against the UK
form of CLA. We have measured protection against disease
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through its use, and, although the protection observed was
lower than with the other experimental vaccines tested, it is
of relevance that it was the only vaccine tested for its capacity
to protect against heterologous challenge. Unfortunately, for
this reason it is not possible to directly compare the protective
capacity ofGlanvac™ with ourrPLD vaccine. It is interesting
to note that, although the overall prevalence of infected loci
was reduced within Glanvac™ immunised animals, there
was only one animal which appeared free from infection.
The remaining animals manifested infections of either the
inoculation site, or several distinct loci. Therefore, there is
the suggestion that this vaccine was not sufficient to prevent
the dissemination of C. pseudotuberculosis beyond the pri¬
mary site of infection, which is in contrast to observations
of the rPLD and killed whole-cell vaccines. Interestingly, no
lung lesions were identified in Glanvac™-vaccinated ani¬
mals. An aerosol route of C. pseudotuberculosis transmission
has previously been postulated [43], and it is therefore pos¬
sible that, despite not completely preventing infection, the
eradication of a potential route of disease transmission could
have a significant impact on the spread of infection to other
animals. This hypothesis is consistent with the findings of an
Australian study, in which Glanvac™-vaccinated sheep with
CLA were observed to have 96% fewer lung abscesses com¬
pared with unvaccinated infected sheep [44]; in that study,
77% of disease transmission occurred around the fourth and
fifth shearings in the absence of any obvious discharging
abscesses, implying spread from discharging lung abscesses.
In light of these facts, it would appear that there is some
justification for the use of the Glanvac™ range of vac¬
cines against CLA in the UK; however, it is also entirely
possible that a more effective alternative could be devel¬
oped.
One question that remains to be answered is whether the
difference in protection between Glanvac™ and our experi¬
mental vaccines was simply due to issues with the heterolo¬
gous versus homologous challenge models, or due to the fact
that Glanvac™ was simply outperformed by our experimen¬
tal vaccines. This is relevant, since a single vaccine, if chosen
wisely, might have the capacity to protect against infection by
a variety of different isolates, irrespective of their geographi¬
cal origin. Clearly, protection against heterologous challenge
by our experimental vaccines needs to be determined, and
future experiments are planned to address this. In conclusion,
the data we have presented here contributes significantly to
the existing knowledge regarding the potential for vaccina¬
tion against CLA in the UK, and provides a firm platform
from which to embark on future studies.
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